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Introduction  |  11
The number of patients needing renal replacement therapy is increasing. In the United 
States the incidence of end stage renal disease (ESRD) increased from approximately 
73,035 to 116,395 patients in the period 1995-2009 and is still increasing 1-2. In the 
Netherlands in the same period, the number of newly diagnosed patients with ESRD 
increased from approximately 1280 to 1900 patients [Source: www.renine.nl]. 
In the nineties of the last century it was recognized that early detection of renal function 
loss and adequate addressing and treatment of (potentially) damaging factors such as 
poor lifestyle (high BMI, smoking), hypertension and poor glycemic control was needed 
in an effort to try to curb the increase in the number of patients developing ESRD. A 
system classifying renal function loss in different stages would aid in the comprehension 
of the course, treatment and eventual prevention of progressive renal function loss and 
its complications over time 3-8. Until then, patients were often diagnosed late, and in part 
presented themselves at a moment they already developed symptoms as a consequence 
of severe renal function loss 8-10. Moreover, it was acknowledged that not only patients 
with ESRD but also patients with moderate renal function loss were at increased risk for 
cardiovascular morbidity and mortality, especially those aged <65 years 11-12. Depending 
on the degree of renal function loss, those patients have a 1.5 to 20 fold increased risk for 
developing cardiovascular disease compared with patients without renal function loss 13. 
These findings sparked the introduction of the term chronic kidney disease (CKD) and 
the development of a classification system with well described definitions. 
Primary care physicians have an important task in the early detection of CKD as well 
as the assessment of cardiovascular risk factors. Moreover, decisions regarding drug-
dose adjustments of renally excreted drugs and the eventual initiation of therapies 
to prevent kidney failure progression may be initiated by primary care physicians 14. 
However, primary care physicians were mostly uninformed about renal function loss and 
insufficiently trained in the interpretation of serum creatinine measurements before the 
new classification system was proposed 8. To raise awareness for CKD and to be able to 
recognize CKD adequately worldwide, a clear definition and classification was needed. 
Assessment of glomerular filtration rate
Before the introduction of formulas to estimate GFR in clinical practice, the most 
commonly used measure of overall GFR was the serum creatinine concentration. 
Creatinine is a substance produced in the muscles by the non-enzymatic dehydration 
of creatine. The first time creatinine was proposed as a marker of GFR originates from 
1926, when the renal clearance of exogenously administered creatinine was evaluated 15. 
Eight years later, the actual measurement of endogenous serum creatinine was realised 
16. However, the drawback of using serum creatinine as a measure of renal function is the 








































12  |  Chapter 1
concentration is not only determined by glomerular filtration, but also dependent on 
many other factors (see table 1). These factors, together with the variation coefficient 
of the assay, and the interperson variability of creatinine production, filtration and 
secretion results in the conclusion that up to 50% or more of GFR must be lost before 
serum creatinine values rise above the upper limit of normal 8,18. An example of the 
weakness of serum creatinine as a marker of GFR is illustrated by the elderly. In the 
elderly, muscle mass is usually decreased. When GFR remains unchanged, the decreased 
creatinine production should lead to lower serum creatinine levels. In the elderly, there is 
usually evidence of progressive decrease of GFR. As a result serum creatinine values will 
actually rise to pseudonormal values and be comparable to values in younger persons 
with a larger muscle mass. Thus, creatinine levels considered normal in a 20-year old 
may represent major renal function loss in a frail elderly person. 
The GFR can be reliably measured by calculating the renal clearance of a substance that 
is not bound to plasma proteins, freely filtered, not metabolized, and not reabsorbed or 
secreted by the renal tubules. 
Inulin fulfills the prerequisites mentioned above, and is considered the golden standard 
technique for the measurement of GFR 19-20. Radioactive markers such as 125I-Iothalamate 
and 99mTc-DTPA, provide good alternatives to inulin for measuring GFR. Although 
these techniques are accurate measures of GFR they are cumbersome, invasive and 
costly and therefore not suitable for use in daily practice. 
A good alternative in daily practice is the creatinine clearance (CCR). The CCR is 
calculated from the amount of creatinine excreted by the kidneys in 24 hours and the 
concomitant serum creatinine concentration. The CCR will always provide higher values 
than true GFR (10-40%), since – as already stated - creatinine is partly eliminated by 
tubular secretion 21-23. Therefore, the CCR is considered by many as an imperfect marker 
of glomerular filtration rate, especially in renal diseases 24. Moreover, the accuracy 
of the 24-hour CCR is strongly dependent on the accuracy of the urine collection, 
especially when urine is collected only once 8. To improve the accuracy of this method it 
is recommended to perform a 24-hour urine collection 2-3 times. 
The limitations of the abovementioned techniques have stimulated the introduction 
of formulas for estimating GFR and CCR. These formulas use serum creatinine 
concentration and take into account several variables influencing the creatinine 
production (depending on the formula incorporating age, gender, weight and race). In 
the past decades various formulas have been developed and have become an integral part 
of daily clinical practice: the Cockcroft-Gault (CG) formula (1976) 25, the Modification 
of Diet in Renal Disease (MDRD) formula (1999/2002) 18,26 and the Chronic Kidney 









































Introduction  |  13
important to know the background of these formulas and their pitfalls to allow correct 
interpretation of their results. Most of these renal function prediction equations have 
been developed in populations with specific characteristics, which hamper their use in 
patients that differ from the population these formulas were developed in. Moreover, 
these formulas may show substantial variability depending on the technique used to 
measure serum creatinine 28-32. 
Table 1. Factors affecting the serum creatinine concentration 33-36
- Production 
o Increased creatinine production 
	 Increased muscle mass (bodybuilding, great physical effort)
	 Muscle decay (rhabdomyolysis)
	 Meat consumption (stewed meat)
	 Exogenous creatinine sources (creatinine supplements)
o Decreased creatinine production
	 Decreased muscle mass, e.g. inactivity, amputation, malnutrition
- Excretion 
o Decreased or blocked tubular creatinine excretion





•	 Diabetic ketoacidosis 
•	 Increased glucose
•	 Increased serumalbumin 






	 The enzymatic assay has less interferences than the Jaffe. Possible 









































14  |  Chapter 1
GFR prediction equations
The CG formula is a formula that has been developed to estimate the CCR 25. Apart 
from age, gender and creatinine, it also contains weight as a variable, since this was 
considered a crude estimate of muscle mass and therefore also of creatinine ‘production’. 
This equation was developed in a cohort of 249 non-obese male patients with a weight 
within the 10% range of fat-free body mass. Moreover, the majority of participants had 
a normal renal function, and the Cockcroft-Gault formula is therefore especially reliable 
in patients with a CCR >60 ml/min. The correction factor applied for women (0.85) was 
based on an educated guess 25. 
The MDRD has been developed in a training cohort of 1070 and a validation cohort of 
558 patients with severe renal function loss (mean GFR 39.8 ml/min), overt proteinuria 
(>1 g/day urinary protein loss) and all participants were younger than 70 years 18,26. 
The body weight was ≥ 80% and ≤ 160% of their standard body weight. The MDRD is 
indexed for a body surface area of 1.73m2 (which approximates the BSA of a non-
overweight average-sized person). This formula gives inaccurate results when used for 
people with a normal or slightly reduced eGFR (eGFR >60 ml/min/1.73m2) 31-32,37-39. In 
an attempt to provide better estimates of GFR particularly for values exceeding 60 ml/
min/1.73m2, the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-
EPI) was developed and validated. This formula was developed in a population with a 
mean GFR of 68 ml/min/1.73m2 and a mean BMI of 28 kg/m2. This formula showed 
to be somewhat more precise and accurate than the MDRD study at higher GFR 
values leading to less misclassification of CKD 27, although its estimate still may show a 
considerable deviation from the true value in individual cases 40. 
Estimated GFR values are usually applied in guidelines and clinical decisions regarding 
pharmacovigilance, and referral policies from primary care to nephrology departments 
also are often made based on these estimates. 
CKD-staging: the K/DOQI guidelines 
The K/DOQI guidelines are based on such GFR estimates 8. The GFR estimated by 
the MDRD formula became one of the two components in the classification scheme of 
CKD, as developed by the National Kidney Foundation in 2002 18,26. These so-called 
Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines provided a definition 
of CKD and introduced a uniform staging system (table 1) 8. The second component 
was the presence of kidney damage as defined by persistent proteinuria (defined as 
albuminuria >30 mg/g of urinary creatinine), renal haematuria, or abnormalities in 
kidney imaging. The diagnosis CKD is made when kidney damage is present according 
to this definition. In addition, an eGFR value below 60 ml/min/1.73m2 during ≥ 3 months 









































Introduction  |  15
Since care pathways have been developed for patients with various CKD stages, a 
proper estimation of GFR is pivotal for good patient care. Since an eGFR <60 ml/
min/1.73m2 apparently is deemed sufficient for the diagnosis of CKD, accuracy of the 
formulas around this threshold value is of utmost importance. Application of the K/
DOQI classification and using MDRD eGFR to the Dutch population, resulted in a 
high prevalence of CKD in The Netherlands (table 2) 4. 
However, there are still many open ends when using GFR estimating equations in 
daily (clinical) practice; the use of the formulas may give biased results when used in 
populations that differ from the population in which these formulas originally were 
developed. Moreover, we need more insight in the differences between the various 
formulas, the use of threshold values of eGFR in relation to age, the implications of 
variations in creatinine assays on the prediction formulas, and the role of eGFR on 
pharmacovigilance. 
Stage Description GFR (ml/min/1.73m2) Prevalence in the 
Netherlands (%) 41
1 Normal GFR with evidence of 
chronic kidney damage *
≥90 * 1.3
2 Mildly decreased GFR with 
evidence of chronic kidney 
damage *
60-89 * 3.8
3 Moderately decreased GFR 
with/without evidence of kidney 
damage
30-59 5.3
4 Severely decreased GFR with/
without evidence of kidney 
damage
15-29 0.04
5 Kidney failure <15 or dialysis <0.04
Table 2 Kidney disease outcomes quality initiative stages 8. *Other evidence of chronic kidney 
damage may be: persistent microalbuminuria; persistent proteinuria; persistent haematuria (after 
exclusion of other causes such as urological disease); structural abnormalities of the kidneys 
demonstrated on ultrasound scanning or other radiological tests (e.g. polycystic kidney disease, 
reflux nephropathy); or biopsy-proven chronic glomerulonephritis. 
The importance of accurate creatinine measurements 
Both Jaffe as well as enzymatic assays are used for routine assessments of creatinine 
in plasma, serum and urine 42-46. In the assays for serum and urine creatinine, several 
substances may (and quite often will) interfere. The Jaffe techniques are among the oldest 
techniques to measure creatinine and are still often used as a routine method to assess 
creatinine. Originally the Jaffe reaction is a chemical reaction in which creatinine under 








































16  |  Chapter 1
orange colored complex that can be detected and quantified 45. Since its development, 
several more recent versions of Jaffe assays minimized analytical interferences (such 
as glucose, uric acid, protein, and ketoacids) by adjusting temperature, calibrator set 
points, and assay constituents 47-49. The later developed enzymatic technique, which was 
less sensitive to analytical interferences, is based on the enzymatic reaction of creatinine 
with creatinine iminohydrolase 50-52. This results among others in the formation of 
ammonia which is quantified by reaction with bromphenol blue. Also for the enzymatic 
assay, newer and more accurate versions have been developed over time 53-55.
Since the use of formulas to estimate renal function in clinical practice has increased, 
and the early identification and advices for management of patients with CKD is based 
on these estimates, focus has been on the consequences of the use of different creatinine 
measurement procedures among laboratories 56. Obviously, formulas that are developed 
in one laboratory can only be reliably used in other laboratories if  the assays used in 
these laboratories report similar values. This was initially not considered. However, 
some years after the introduction of the MDRD formula, developed from data from the 
Modification of Diet in Renal Disease Study, it became evident that there was an error 
when serum creatinine assays were not calibrated with the kinetic Jaffe method as used 
in the core laboratory in which the formula was developed and validated 57-59. Especially 
in the physiologic range, which is important to identify patients with “silent kidney” 
disease, the calibration bias resulted in larger uncertainty in GFR estimates 41. 
Also in trueness verification studies a significant interlaboratory variation was observed 
and led to the decision that calibration traceability to higher-order reference methods 
(Isotope-Dilution Mass-Spectrometry (IDMS)) was needed to realize comparable 
biochemical measurement results in order to produce more accurate renal function 
estimates 60. Independent of the method used (enzymatic or Jaffe) or the laboratory that 
performed the creatinine measurements, this should lead to a better comparability. As 
a consequence, the MDRD was re-expressed using enzymatic creatinine measurements, 
and a coefficient appropriate for the new serum creatinine values was applied 30. 
Since 1998, it is legally mandatory in the European Union to have calibration traceability 
in clinical laboratory measurements to higher-order standards (the European in vitro 
diagnostics (IVD) directive 98/79/EC) 61-62. Since the development of NIST SRM 967 
in 2006, a matrix-based IDMS targeted creatinine standard, all essential elements 
(i.e. methods, laboratories, and materials) needed to complete the creatinine reference 
system are in place, as defined by the international Joint Committee on Traceability 
in Laboratory Medicine (www.bipm.org) 63-64. Since then, the values assigned by in 









































Introduction  |  17
measurement procedures have to be methodologically traceable to higher-order reference 
measurement materials, regardless of the method applied. 
In this thesis, different aspects of the use of formulas for estimating GFR in different 
populations and the impact hereof on referral policies and CKD staging are evaluated. 
More specifically, our aims were (1) to evaluate the performance of the MDRD and 
the CKD-EPI equation in a diabetes population and in an obese population, (2) to 
evaluate whether and how eGFR and albuminuria relate to mortality in a subgroup of 
elderly patients with T2DM, (3) to assess the consequences of applying age related cut-
off  values for renal function on the referral policy from primary to secondary care, (4) 
to evaluate the role of different techniques to measure creatinine (in plasma and urine) 
on both renal function prediction equations and CCR. In addition, we addressed (5) to 
evaluate the problem of medication errors in a community based population, and how 
a medication alert system warning for impaired renal function can improve medication 
safety. 
Outline of the thesis
Several patient- and screening-related factors need to be taken into account when aiming 
for accurate detection and classification of patients with renal function loss. In chapter 
two, classification of CKD is addressed in a cross-sectional analysis of outpatients of 
the Maxima Medical Centre Eindhoven with type 2 diabetes mellitus (T2DM) and a 
known 24-hour CCR. In these patients the performance of the MDRD and the more 
recently developed CKD-EPI formula was compared. The performance of estimation 
equations in patients with T2DM was further explored in chapter three which focused on 
the influence of (over)weight on the performance of renal function estimating equations. 
Since overweight and obesity are prevalent in T2DM and formulas to estimate renal 
function were originally developed in rather lean populations, this may induce problems 
in renal function estimation using formulas. Unlike the MDRD and the CKD-EPI, body 
weight is included as a variable in the CG. Since excess body weight in an overweight and 
obese population usually comprises adipose tissue and not muscle mass, this formula is 
thought to overestimate renal function, especially in patients with a body mass index BMI 
>30 kg/m2. Therefore, we evaluated the influence of (over)weight on the performance of 
the MDRD and CKD-EPI equations versus the CG (in the same cohort as was used in 
chapter two), as well as the implications of using different formulas to estimate renal 
function on the (mis)classification of chronic kidney disease in this patient group. 
Besides patient-related factors, also differences in the assay techniques of creatinine 
might influence the results of renal function equations and thereby classification of 








































18  |  Chapter 1
five we evaluated the implications of accurate serum creatinine measurements on kidney 
disease staging. In chapter four we discussed this subject from a theoretical point of view, 
using data from the annual external quality assessment program of the external quality 
assessment organization in the Netherlands. In chapter five the variability between 
creatinine assays in both plasma and urine and the influence hereof on GFR estimating 
equations or when calculating the CCR in a real-life population was evaluated. 
Although it is well-recognized that CKD is associated with a burden of complications 
mainly due to cardiovascular comorbidity, the classification and the impact of CKD 
on cardiovascular morbidity and mortality in different age-groups is still under debate. 
Age-related cut-off  values were suggested, since previous studies have shown that 
classic cardiovascular risk factors (such as a diminished renal function) possibly have 
a diminished effect or different consequences when assessed in elderly. In chapter six 
we therefore analyzed the relation between eGFR, albuminuria and mortality in older 
patients with T2DM. 
Quite a few CKD guidelines classify patients independent of their age. However, some 
guidelines take a different approach, and introduced age-related cut-off  values for 
referral. In chapter seven the impact of age-related cut-off  values as proposed by the 
Dutch ‘Landelijke Transmurale Afspraak Chronische Nierschade’ on referral patterns 
was compared with the staging system used in the K/DOQI guidelines in which no age-
related cut-off  values are applied. 
Although the MDRD has not been developed in elderly patients and moderate reduction 
in eGFR (MDRD 45-60 ml/min/1.73m2) are regularly found in elderly people, the K/
DOQI guidelines recommend further diagnostics and treatment when the MDRD 
is <60 ml/min/1.73m2. Whether and to what extent renal function loss in the elderly 
population is pathologic or physiologic is still debated. Although elderly patients may 
have a diminished renal function that has no consequences for their life expectancy, 
medication use in elderly patients (especially those with polypharmacy) should be 
reviewed regularly for potential adverse drug events. Therefore, in chapter eight we 
addressed the problem of increased susceptibility for medication errors in CKD. In this 
chapter medication errors in patients with an eGFR ≤40 ml/min/1.73m2 were evaluated 
in a community based population from a preventive perspective. Finally, in chapter nine 
the different studies in this thesis are discussed. Moreover, some recommendations and 
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Background and objectives Equations to estimate the glomerular filtration rate (GFR) 
are routinely used to assess renal function. Due to systematic underestimation and 
limited precision of the current prediction equations, a new prediction equation was 
presented: the chronic kidney disease collaboration equation (CKD-EPI). We compared 
the performance of the CKD-EPI and the Modification of Diet in Renal Disease 
equation (MDRD) and evaluated the implications hereof on chronic kidney disease 
(CKD) staging in diabetic patients. 
Methods This cross-sectional study included 844 diabetic patients with a wide range 
of age: 18-92 years. Serum creatinine was measured by a traceable enzymatic method 
and was used to calculate the MDRD and the CKD-EPI. The performance of both 
renal function estimating equations was examined, by means of the correlation, bias and 
precision, using the creatinineclearance as a reference method. 
Results Correlation between the MDRD, CKD-EPI and the creatinineclearance was 
0.75 respectively 0.76. The bias of the MDRD and the CKD-EPI compared with the 
CCR are -22 (± 26) ml/min/1.73m2 and -20 (± 26) ml/min/1.73m2, respectively (p <0.01 
for both). When using the CKD-EPI 17.1% of the women was categorized in lower 
CKD stages as compared with the MDRD. A higher proportion of diabetic patients <65 
years were diagnosed with stage 3-5 CKD when using the MDRD; 12.9% versus 10.7%.
Conclusions The MDRD and CKD-EPI are equally imprecise. The CKD-EPI equation 
gives higher estimates of GFR in young diabetics than the MDRD, leading to a lower 
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Introduction
Renal function testing is routinely performed in various patient populations with a 
wide range of renal function. Impaired renal function is an independent risk factor 
for (premature) cardiovascular disease 1. Several traditional (diabetes mellitus (DM) 
and hypertension) and non-traditional (among others endothelial dysfunction and 
oxidative stress) risk factors seem to play an attributable role, but exact mechanisms and 
interactions remain to be elucidated 1. Currently, the glomerular filtration rate (GFR) is 
considered to be the best overall indicator of renal function 2. 
Gold standards for assessing GFR, such as renal inulin clearance or isotopic methods 
are cumbersome and costly and therefore reserved for research settings 3-4. A less costly 
and less complex method to measure renal function is the 24-hour creatinine clearance 
(CCR). This is the most frequently applied method to assess renal function in daily 
practice, although collecting 24-hour urine samples is time consuming, and the reliability 
of the outcome is highly dependent on the accuracy of the urine collection 5. 
Several prediction formulae for estimating renal function have been developed. 
The four-variable Modification of Diet in Renal Disease equation (MDRD), is the 
prediction formula that is most frequently used 2,6. Its advantages and disadvantages 
have been extensively debated 7-8. One of its major disadvantages are its imprecision 
and its systematic underestimation of GFR, in patients with normal to high normal 
serum creatinine levels, and the underestimation in women and young people 7,9. To 
overcome the aforementioned disadvantages, a new prediction equation, the Chronic 
Kidney Disease Epidemiology Collaboration equation (CKD-EPI) was developed 10. 
This formula was developed in a population with predominantly young and middle aged 
people (87% ≤65 years) with an average GFR of 68 ml/min/1.73m2; 43% was female 10. 
Potential complementary covariates such as renal transplant, diabetes and weight were 
considered, but the final equation used the same variables as the MDRD equation 11. 
Therefore, it is not clear whether the CKD-EPI can be applied in all populations. Since 
an accurate estimate of renal function is important and renal function is frequently 
assessed in diabetic patients, we wanted to evaluate the performance of the CKD-EPI 
and the MDRD equations in a large, anthropometrically diverse cohort of diabetic 
patients.
Materials and methods
This retrospective observational cross-sectional study was conducted at the diabetes 
outpatient clinic of the Maxima Medical Centre in Eindhoven, The Netherlands. A total 
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type 1 or type 2 DM, were collected. An anonymous database was created, using data 
from the “Chipsoft Electronisch Zorg Informatie Systeem” [Chipsoft Electronic Care 
Information System] (CS-EZIS), the computerized medical record system used at the 
Maxima Medical Centre. Data collected included 24-hour urinary creatinine (mmol/L), 
serum creatinine (μmol/L), HbA1c (mmol/mol), weight (kg), height (centimeters), age 
(years), and gender; all data being collected on the same day, except for the 24-hour urine 
collection, which was collected in the 24 hours previous to the other measurements. The 
body mass index (BMI) of each patient was calculated (BMI = weight (kilograms) / 
height (metres)2) and added to the database. Ultimately 916 patients remained eligible for 
inclusion. Two subjects younger than 18 years old and three subjects with a CCR >250 
ml/min were excluded, since the MDRD has not been validated in these patient groups. 
In 176 cases, subjects had collected two 24-hour urine portions during the indicated 
period. In these cases the mean of the two 24-hour creatinineclearances was used.
Medication details and information on co-morbidities were also not available. Since no 
information on race was available, all patients were considered to be Caucasian. No 
formal approval from the Medical Ethics Committee was required, as our data included 
only anonymous patient characteristics and laboratory data.
Renal function measurements and definitions
The serum creatinine concentration was measured by an enzymatic technique (Modular 
PA, Roche), and validated by isotope dilution mass spectrometry (IDMS). Renal 
function was estimated by two different eGFR equations, the MDRD and the CKD-
EPI (table 1). 24-hour CCR corrected for body surface area (BSA) was calculated (table 
1). The Dubois formula was used to calculate the BSA 12.
Equation Gender Serumcreatinine 
(µmol/L)
eGFR (ml/min/1.73m2
CKD-EPI Female ≤62 144 x (IDMS creatinine/88.4/0.7)-0.329 x (0.993)age
Female >62 144 x (IDMS creatinine/88.4/0.7)-1.209 x (0.993)age
Male ≤80 141 x (IDMS creatinine/88.4/0.9)-0.411 x (0.993)age
Male >80 141 x (IDMS creatinine/88.4/0.9)-1.209 x (0.993)age
MDRD Female All 175 x (IDMS creatinine/88.4)-1.154 x age-0.203 x 0.742
Male All 175 x (IDMS creatinine/88.4)-1.154 x age-0.203
Creatinineclearance 
BSA corrected
All All (urine creatinine [mmol/L] x 1000/serum creatinine 
[μmol/L]) x (24-hour volume urine [ml]/1440) x 
(1.73m2/BSA)
Table 1. Renal function prediction equations. CKD-EPI: chronic kidney disease epidemiology 
equation; MDRD: modification of diet in renal disease formula; BSA: body surface area; IDMS: 
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Statistical analysis
Analyses were performed using SPSS 16.0 (SPSS, Chicago, IL). Q-Q plots and histograms 
were used to assess normality. Continuous variables are represented as mean (± standard 
deviation) for the normally distributed values and as a median (interquartile range) for 
the non-normally distributed variables. 
Spearman’s coefficient of correlation was calculated to determine the correlation between 
the CCR and the eGFR calculated by the MDRD and the CKD-EPI formulas. Bland-
Altman plots were created; showing the mean of two measurement methods (i.e. CCR 
and the MDRD / CKD-EPI) against the absolute difference between these two methods. 
The Krippendorff  coefficient, an aggregate measure for method concordance, was 
calculated (see textbox; 1 meaning perfect concordance and -1 meaning perfect 
discordance between two methods), since neither maximum correlation nor agreement 
in accuracy and precision alone will suffice to prove concordance and thus sufficient 
reproducibility among methods; this requires μ1=μ2, σ1
2=σ2 
2 and ρ=+1 (μ1 being the 
population mean of the CCR, μ2 being the population mean of the MDRD or the 
CKD-EPI, σ1 and σ2 being the standard deviation of μ1 and μ2 respectively, ρ being the 
Pearson correlation coefficient between the CCR and the MDRD or the CKD-EPI. The 
Krippendorff  coefficient corresponds to the Bland Altman plot in a similar way as ρ 
corresponds to the simple scattergram 13, see textbox.
The bias and precision (see textbox) of both formulas were determined. Ultimately 
we evaluated the classification of patients according to the CKD-EPI or the MDRD 
equation compared to when the CCR is used to classify patients. Moreover, the 
prevalence of stage III-V CKD in this diabetic population was evaluated per age group.
Textbox
Bias: Mean difference between the GFR estimating formula and the  
 creatinineclearance corrected for BSA
Precision: Standard deviation of the bias
Krippendorff  coefficient:  K= (2 x σ1 x σ2 x ρ) / (2 x σ1 x σ2 + (σ1 - σ2)2 + (µ1 - µ2))2
Results
The patient characteristics are presented in table 2. Age ranged from 18-92 years with 
53.6% of the population aged under 65 years. The population represented a wide range 
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Characteristic All
n (%) 916
Sex, male (%) 55.3
Age (year) 63 [53, 72]
HbA1c (mmol/mol) 50 [42, 60]
BMI (kg/m2) 28 [25, 32]
Creatinine (µmol/L) 79 [67, 97]
Creatinine clearance (ml/min/1.73m2) 96 [70, 123]
MDRD (ml/min/1.73m2) 77 ± 25
CKD-EPI (ml/min/1.73m2) 79 ± 24
Table 2. Demographic and clinical characteristics. Data are presented as number (%) or median 
[interquartile range]. 
The correlation and Krippendorff coefficient 
The correlation was 0.75 and 0.76 between the MDRD respectively the CKD-EPI and 
the CCR. Figure 1 shows the Bland-Altman plots that evaluate the extend of agreement 
between the CCR and both GFR estimating equations. 
Krippendorff’s coefficient, demonstrating the method concordance between both GFR 
prediction equations and the CCR, was almost equally large for the MDRD and the 
CKD-EPI: 0.54 respectively 0.57.
Figuur 1. Bland-Altman plots comparing the creatinineclearance and the estimated glomerular 
filtration rate, calculated by the Modification of Diet in Renal Disease formula or the Chronic 
Kidney disease Epidemiology Collaboration equation. The upper and the lower horizontal line 
represent the upper (2 SD) and lower (2 SD) limits of agreement, respectively. The horizontal 
line in the middle represents the mean difference between the creatinineclearance and the GFR 
estimating equations. 
Bias and precision
The results for the bias and the precision are presented in table 3. The bias of the MDRD 
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respectively (p <0.01 for both). Both the MDRD and the CKD-EPI showed a large bias 
and imprecision in all CCR categories which was most prominent in people with a CCR 
>90 ml/min/1.73m2: -53.4 (± 35.2) and -51.4 (± 34.8) ml/min/1.73m2 for the MDRD and 




n Bias Precision  Bias Precision
>90 521 -53.4 35.2 -51.4 34.8
60-90 248 -19.0 18.6 -16.4 18.6
45-59.9 85 -9.4 15.2 -8.5 16.5
30-44.9 44 0.9 20.4 1.2 20.0
<30 18 8.4 21.3 8.7 24.0
All 916 -36.2 35.7 -34.2 35.3
Table 3. Precision of eGFR prediction equations. Precision (ml/min/1.73m2), defined as the 
standard deviation of the mean difference between the estimated glomerular filtration rate 
(estimated by the modification of diet in renal disease formula (MDRD) and the chronic kidney 
disease epidemiology collaboration equation (CKD-EPI)) and the creatinine clearance, is shown 
per creatinine clearance stage. CI=confidence interval.
eGFR prediction formulae and staging
Figure 2 represents the eGFR values for both formulas by age category for male (A) and 
female (B) patients. For both the CKD-EPI and the MDRD a steep decline was observed 
with aging. When compared with the MDRD, the CKD-EPI gave higher estimates of 
GFR at young age (≤65 years). In older age, the MDRD and CKD-EPI gave a similar 
estimation of GFR. 
Figure 2. A Men: The dashed lines represent the 5th percentile, the median and the 95th percentile 
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Figure 2. B The dashed lines represent the 5th percentile, the median and the 95th percentile of the 
CKD-EPI. The black line represents the 5th percentile, the median and the 95th percentile of the 
MDRD.
The influence on CKD staging using the CKD-EPI or MDRD formula are illustrated 
in table 4a and 4b, for men and women respectively. Smaller stages than in the KDOQI 
guidelines are used, to provide a more detailed insight. These tables clearly demonstrate 
that the CKD-EPI provides higher eGFR values than the MDRD, specifically at higher 
levels of eGFR and in women (along the total range of renal function). 26.4% of the 
women were categorized in a lower CKD stage using the CKD-EPI.
MDRD CKD-EPI
(ml/min/1.73m2) <30 30-44 45-59 60-74 75-89 >90 Total
<30 10 10
30-44 1 34 35
45-59 2 56 6 64
60-74 81 27 108
75-89 74 40 114
>90 13 163 176
Total 11 36 56 87 114 203 507
Table 4a (male). Estimated GFR stage for males using the chronic kidney disease epidemiology 
collaboration equation (CKD-EPI) or the modification of diet in renal disease formula (MDRD). 
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MDRD CKD-EPI
(ml/min/1.73m2) <30 30-44 45-59 60-74 75-89 >90 Total
<30 12 2 14
30-44 30 11 41
45-59 1 51 12 64
60-74 60 38 98
75-89 50 45 95
>90 5 92 97
Total 12 33 62 72 93 137 409
Table 4b (female). Estimated GFR stage for females using the chronic kidney disease epidemiology 
collaboration equation (CKD-EPI) or the modification of diet in renal disease formula (MDRD). 
Numbers represent absolute numbers. Blank cells have no observations.
Figure 3 presents the consequence of the introduction of the CKD-EPI on the prevalence 
of stage III-V CKD. A decline in the number of young people (<65 years) diagnosed 
with stage III-V is observed, from 12.6 to 10.7%. In the elderly patient category, the 
numbers of diagnosed patients remains similar using the CKD-EPI or the MDRD. 
Figure 3. Prevalence of chronic kidney disease (CKD) stage III-V (eGFR <60 ml/min/1.73m2) in 
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Discussion
In this study, we evaluated the performance of the CKD-EPI as a new method of renal 
function estimation in diabetic patients. When using the CCR as the comparator and 
using correlation, bias and precision as tools to evaluate the performance of formulas 
estimating renal function, the CKD-EPI did not show any additional value compared 
with the MDRD for use in clinical practice. Bias was comparably high for both MDRD 
and CKD-EPI and both prediction equations had an equal lack of precision; a lack of 
precision that increased with deteriorating renal function.
The CKD-EPI was developed to overcome the deficiencies of the MDRD equation, 
such as the lower accuracy when the GFR is >60 ml/min/1.73m2, and underestimation 
of eGFR in women and healthy young white men. The proposal of Levey et al. to 
replace the MDRD with the CKD-EPI formula for routine clinical testing because of 
its superior accuracy can be disputed, among others in the group of diabetic patients 
14. Although the CKD-EPI performed better than the MDRD in the validation data 
set when the GFR was >60 ml/min/1.73m2, its precision remained limited 10. As this 
imprecision was seen in all groups of the validation data set, transplant status, diabetes, 
and weight were selected as predictor variable 11. The performance of the CKD-EPI 
did not improve significantly as a result of these attempts to improve the precision of 
the formula. In spite of these findings, this formula is also recommended to be used in 
diabetic patients. This lack of precision and the presence of bias has consequences for 
the correct classification of CKD 14-15. 
The performance of the CKD-EPI compared with the MDRD has been sparsely 
assessed in diabetic patients. 16-17. In these two recent studies, in which diabetic patients 
with a good renal function or an impaired renal function, respectively, were assessed 
(mean measured GFR 102 ± 24 ml/min/1.73m2 using 51CR-EDTA 16 and 55.4 ± 29 ml/
min/1.73m2 using inulin 17), it was demonstrated that the CKD-EPI had a substantial 
larger bias than the MDRD 16-17. The first study, evaluating the consequences of the 
bias and imprecision on CKD staging, found that 16% of the study population was 
misclassified as having CKD 16. Unfortunately, the authors of the first study 16 did not 
mention the characteristics of the subgroup that was misclassified. 
From studies in the general population with middle-aged people it was shown that using 
the CKD-EPI equation to estimate GFR reduces the number of patients categorized in 
CKD stage III-V (eGFR <60 ml/min/1.73m2) 17-18. People who had an MDRD-eGFR 
<60 ml/min/1.73m2 but were reclassified to ‘normal’ (no CKD) using the CKD-EPI, had 
a cardiovascular risk profile similar to the population without evidence of CKD and 
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who were reclassified were more often white, women and younger. Those who remained 
in stage 3a (eGFR <60 and ≥ 45 ml/min/1.73m2) had a significantly greater burden of 
diabetes, higher fasting plasma glucose, and higher HbA1c levels.
Based on the results of our study, it can be suggested that the CKD-EPI might lead to 
underdiagnosing of kidney disease in younger subjects; overall 19.8% is categorised in 
a lower stage when the CKD-EPI is used. Although the number of patients included 
in this study is small, there is a trend for young and especially female patients to be 
re-categorised in a lower CKD stage when the CKD-EPI is used to estimate GFR. 
Differences in estimated GFR using the CKD-EPI or MDRD were largest in the age 
category <65 years. The fact that the bias of the CKD-EPI and the MDRD is influenced 
by age was found previously in a group of potential kidney donors and adult patients 
who underwent a GFR measurement for clinical reasons, using 125I-iothalamate 19. It was 
shown that absolute bias was larger in the younger patient group 19. 
From previous studies we know that younger people (18-64 years) have an increased 
risk of mortality and end stage renal disease at similar levels of GFR (estimated by the 
MDRD) 20. Such a finding in relatively young persons requires further evaluation of the 
patient. The sooner these people are diagnosed as having a reduced renal function, the 
sooner they can be treated.
Apart from creatinine-based renal function prediction equations, cystatin C is increasingly 
mentioned as a biomarker that can be used in formulas to predict GFR. Various studies 
found cystatin C to be a better predictor of GFR than creatinine although other studies 
found no difference 21-23. Particularly in patients with muscle loss and in populations 
where rapid detection of small changes in GFR are important, cystatin C may provide 
a more accurate estimate of kidney function than serum creatinine 21. In patients with 
DM cystatin C appears to be more sensitive than creatinine for the detection of a mild 
reduction in kidney function 24. However, whether cystatin C improves medical decision 
making, leading to more favorable patient outcomes remains to be evaluated in future 
research 25. 
Strengths and limitations
This is one of the few studies evaluating the effect of the CKD-EPI on the classification 
of CKD in a cohort of patients with diabetes. Recent studies have emphasized the 
importance of careful calibration of serum creatinine measurements 26. The fact that 
a traceable enzymatic serum creatinine technique was used in this study, increases the 
validity of the study results. 
Unfortunately, as we did not have a gold standard to measure GFR, 24-hour CCR 
was used as measurement. However, since the CCR is still frequently used to asses 
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is clinically relevant. We did not have data on urinary protein excretion. Therefore we 
cannot make inferences about the presence of chronic kidney disease (CKD) other than 
CKD stage III-V in our population. Moreover serum creatinine concentrations were 
measured only once in the majority of people, so we cannot speculate on chronicity of 
CKD in this population. Still, estimated GFR based on a single creatinine measurement 
offers reasonable accuracy for identifying CKD stage III or higher. 
Conclusion
The classification of CKD in diabetic patients and the related risk of complications (i.e. 
cardiovascular morbidity and mortality, acute kidney injury, end stage renal disease) can 
be facilitated by GFR estimations, as long as one recognizes that the precision of both the 
MDRD and the CKD-EPI equations is limited. Compared with the MDRD equation, 
the CKD-EPI equation gives higher estimates of GFR in young diabetic people, leading 
to a lower prevalence of CKD on population level. Moreover, the performance of the 
CKD-EPI equation in diabetic patients has to be determined in a study in which a gold 










































eGFR in patients with diabetes  |  35
References
1. Nanayakkara PWB, Gaillard CAJM. Vascular disease and chronic renal failure: new insights. The 
Netherlands Journal of Medicine 2010;68:5-13.
2. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate 
from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:461-70. 
3. Smith HW. The Kidney: Structure and Function in Health and Disease. New York: Oxford University 
Press; 1951.
4. Gaspari F, Perico N, Remuzzi G. Application of newer clearance techniques for the determination 
of glomerular filtration rate. Curr Opin Nephrol Hypertens. 1998;7:675-680.
5. Shemesh O, Golbetz H, Kriss JP, et al. Limitations of creatinine as a filtration marker in 
glomerulopathic patients. Kidney Int. 1985;28:830-838.
6. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: 
Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39 (2 Suppl 1):S1–S266. 
7. Glassock RJ, Winearls C. An epidemic of chronic kidney disease: fact or fiction? Nephrol Dial 
Transplant. 2008;23:1117-1121.
8. Eknoyan G. Chronic kidney disease definition and classification: the quest for refinements. Kidney 
Int. 2007;72:183-185.
9. Stevens LA, Coresh J, Feldman HI, et al. Evaluation of the modification of diet in renal disease 
study equation in a large diverse population. J Am Soc Nephrol. 2007;18:2749-2757.
10. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann 
Intern Med. 2009;150:604-612.
11. Stevens LA, Schmid CH, Zhang YL, et al. Development and validation of GFR estimating equations 
using diabetes, transplant and weight. Nephrol Dial Transplant. 2010;25:449-457. 
12. Dubois D, Dubois EF. A formula to estimate the approximate surface area if height and weight be 
known. Arch Intern Med. 1916;17: 863-871.
13. Krummenauer F, Doll G. Statistical methods for the comparison of measurements derived from 
orthodontic imaging. European Journal of Orthodontics. 2000;22:257-269. 
14. Delanaye P, Cavalier E, Mariat C, et al. MDRD or CKD-EPI study equations for estimating 
prevalence of stage 3 CKD in epidemiological studies: which difference? Is this difference relevant? 
BMC Nephrology. 2010;11:8.
15. Botev R, Mallié JP, Couchoud C, et al. Estimating glomerular filtration rate: Cockcroft-Gault and 
Modification of Diet in Renal Disease formulas compared to renal inulin clearance. Clin J Am Soc 
Nephrol. 2009;4:899-906.
16. Camargo EG, Soares AA, Detanico AB, et al. The Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation is less accurate in patients with Type 2 diabetes when compared 
with healthy individuals. Diabetic Medicine. 2011;28:90-95.
17. Rognant N, Lemoine S, Laville M, et al. Performance of the Chronic Kidney Disease Epidemiology 
Collaboration equation to estimate glomerular filtration rate in diabetic patients. Diab Care 2011 
may 3 [epub ahead of print].
18. Matsushita K, Selvin E, Bash LD, et al. Risk implications of the new CKD Epidemiology 
Collaboration (CKD-EPI) equations compared with the MDRD study equation for estimated GFR: 
The atherosclerosis risk in communities (ARIC) study. Am J Kidney Dis. 2010;55:648-659. 
19. Michels WM, Grootendorst DC, Verduijn M, et al. Performance of the Cockcroft-Gault, MDRD, and 
new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol 2010;5:1003-
1009.
20.  O’Hare AM, Choi AI, Bertenthal D, et al. Age affects outcomes in chronic kidney disease. J Am Soc 
Nephrol. 2007;18:258-265. 
21. Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimator of glomerular filtration rate? Clin 
Chem 2002;48:699-707.
22. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a 








































36  |  Chapter 2
Chapter 3
The Cockcroft-Gault: a better predictor of renal function 
in an overweight and obese diabetic population
23. Herget-Rosenthal S, Trabold S, Pietruck F, et al. Cystatin C: efficacy as screening test for reduced 
glomerular filtration rate. Am J Nephrol 2000;20:97-102. 
24. Perlemoine C, Beauvieux MC, Rigalleau V, et al. Interest of cystatin C in screening diabetic patients 
for early impairment of renal function. Metabolism 2003;52:1258-1264.
25. Madero M, Sarnak MJ. Association of Cystatin C with adverse outcomes. Curr Opin Nephrol 
Hypertens 2009;18:258-263.
26. Myers GL, Miller WG, Coresh J, et al; National Kidney Disease Education Program Laboratory 
working group. Recommendations for improving serum creatinine measurement: a report from 
the laboratory working group of the National Kidney Disease Education Program. Clin Chem. 
2006;52:5-18.
I. Drion, H. Joosten, L. Santing, S.J. Logtenberg, K.H. Groenier, 
A.G. Lieverse, N. Kleefstra, H.J.G. Bilo
Obes Facts 2011;4 (5):393-399
Chapter 3
The Cockcroft-Gault: a better predictor of renal function 
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Background and objectives The performance of the Cockcroft-Gault (CG) equation, 
the Modification of Diet in Renal Disease (MDRD) formula and the Chronic Kidney 
Disease Epidemiology Collaboration equation (CKD-EPI) was evaluated in body mass 
index (BMI) categories. 
Methods In this retrospective cohort study in diabetic patients, creatinine clearance 
was measured by collecting 24-hour urines. Renal function was estimated by using the 
CG, MDRD and CKD-EPI. The performance of the equations was evaluated using 
correlation, Krippendorff’s coefficient, bias, precision and accuracy.
Results The bias of the MDRD and CKD-EPI increased from respectively -13.9 ml/
min/1.73m2 and -14.0 ml/min/1.73m2 (BMI <25 kg/m2); to -31.7 ml/min/1.73m2 and -29.6 
ml/min/1.73m2 (BMI >30 kg/m2). Bias of the CG decreased from -13.4 ml/min (BMI 
<25 kg/m2) to -3.2 ml/min (BMI >30 kg/m2). With an accepted 30% dispersion, CG had 
the largest accuracy in the overweight and obese group (76.9% and 76.8%, respectively). 
The MDRD and CKD-EPI had an accuracy of 45.8% and 34.0% (overweight group), 
respectively, and 51.9% and 37.3% (obese group), respectively.
Discussion All renal function prediction equations are biased when used in overweight 
or obese diabetic populations with a preserved renal function. The CG provides the 
best estimate of kidney function. The limitations of renal function prediction equations 
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Introduction 
Because of the worldwide increasing prevalence of obesity and its associated problems 
such as diabetes mellitus (DM) and hypertension 1-3, the number of patients with 
complications such as renal function loss will also increase. Diagnosing renal dysfunction 
at an early stage is advocated, since early changes in lifestyle and pharmacological 
interventions can prevent or slow down further progression of renal damage 4-6. To 
facilitate early recognition of chronic kidney disease (CKD), the Kidney Disease 
Outcome Quality Initiative (KDOQI) guidelines were introduced 7. These guidelines 
classify CKD based on structural abnormalities, persisting albuminuria and / or 
haematuria of glomerular origin and an estimated glomerular filtration rate (eGFR) 8-9. 
Increased urinary excretion of albumin is an early and sensitive marker of CKD due to 
DM and hypertension. Numerous studies have shown a strong independent association 
between the level of urinary protein excretion and the risk of cardiovascular mortality 
in populations with DM 8,10-11. Besides albuminuria, eGFR remains the cornerstone for 
assessment and staging of CKD. Since the use of serum creatinine alone as a measure for 
renal function is too inaccurate, and inulin, radioactive tracer elements or 24-hour urine 
collections are either expensive or cumbersome in daily practice, different formulae have 
been developed in the past decades to estimate the GFR or creatinine clearance (CCR). 
There is considerable debate regarding the indiscriminate use and the interchangeable 
results of the 4-variable Modification of Diet in Renal Disease (MDRD) equation 12, the 
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation 13 and the 
Cockcroft-Gault (CG) equation 14 in overweight and obese patients 15-20. 
The MDRD, based on GFR measurements using 125I-Iothalamate, was developed in a 
relatively young population (subjects <70 years of age) with known renal disease (mean 
GFR 39.8 ml/min/1.73m2) and overt proteinuria (>1 gram per day urinary protein loss). 
The body weight of these subjects was ≥80% and ≤160% of their standard body weight. 
The MDRD is considered to be reliable in subjects with a GFR ≤60 ml/min/1.73m2, and 
is indexed for a body surface area (BSA) of 1.73m2 (which approximates the BSA of a 
non-overweight average-sized person) 12. 
The CKD-EPI was developed in an attempt to get a better estimate of GFR in values 
exceeding 60 ml/min/1.73m2. It was developed in a population with a mean GFR of 68 
ml/min/1.73m2 (indexed for BSA) and a mean BMI of 28 kg/m2 13.
The CG is an equation to estimate CCR that was developed in a cohort of largely non-
obese male subjects with a wide age range, a weight within the 10%-range of the fat-free 
body mass and a normal renal function 14. Therefore, a CG estimate is considered to be 
especially reliable in CCR levels >60 ml/min. Unlike the MDRD and the CKD-EPI, 








































40  |  Chapter 3
therefore also of creatinine ‘production’. Since excess body weight in an overweight and 
obese population usually comprises adipose tissue and not muscle mass, this formula is 
thought to have considerable limitations in this patient category.
Theoretically, the CG will virtually always provide higher results than the MDRD, 
since the CG equation not only represents the glomerular function but also the tubular 
function. Furthermore, most adults will have a larger BSA than the standard BSA of 
1.73m2, which is used in the MDRD and CKD-EPI. This means that these differences 
may lead to misunderstandings, and incorrect interpretation of results. Therefore, we 
aimed to investigate the influence of (over)weight on the performance of the MDRD 
and CKD-EPI equations versus the CG equation in diabetic patients, and to analyze the 
effect on the (mis)classification of chronic kidney disease (CKD). 
Methods
Study population
The data for this retrospective, observational, cross-sectional study were collected from 
May 2005 until December 2006 at the outpatient clinic of the Maxima Medical Center 
in Eindhoven, the Netherlands. During that period, 1097 24-hour creatinineclearances 
of adult patients with DM were collected. An anonymous database was created with 
data abstracted from the ‘Chipsoft Electronisch Zorg Informatie Systeem’ (CS-EZIS), 
the computerized medical record system of the Maxima Medical Center. The database 
thus contained data regarding the 24-hour urinary creatinine, serum creatinine, HbA1c, 
weight, length, age and sex of each of these patients. In addition, BMI and BSA (BSA = 
0.20247 * height (m)0.725 * weight (kg)0.425) 15 were calculated and added to the database. 
The patients were divided into three groups, based on their BMI according to the WHO 
classification: a normal weight group (BMI of 18-24.9 kg/m2), an overweight group (BMI 
of 25-29.9 kg/m2) and an obese group ((BMI ≥30 kg/m2) http://www.who.int/mediacentre/
factsheets/fs311/en/index.html; accessed 25th May 2011). 
Thirteen patients with a CCR of more than 250 ml/min and two patients who were 
younger than 18 years old were excluded, as the eGFR prediction equations are not 
validated in this patient group. In cases in which more than one 24-hour urine sample was 
performed (n=236) in the indicated period, the most recent sample was used. Ultimately, 
the database contained complete data for 844 patients. 
The population is a mixture of type 1 diabetes mellitus (T1DM) and type 2 diabetes 
mellitus (T2DM) patients. The exact numbers of each type are unknown. 
Permission from the Medical Ethics Committee was not required, as our data only 
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Renal function measurement
The enzymatic Roche Modular P method, validated by isotope dilution mass spectrometry 
(IDMS), was used to measure serum and urinary creatinine. The 4 variable-MDRD and 
the CKD-EPI were used to estimate GFR (for formulae, see box). CCR was estimated 
by using the CG equation. In this study, measured CCR was used as a reference value for 
the renal function. This value was based on a 24-hour urine collection, and calculated 
using the formula UxV/P (see box), to calculate the 24-hour CCR.
In order to make a better comparison between the estimations of the MDRD and CKD-
EPI on the one hand versus the CCR and CG on the other hand, the results of the 
MDRD and CKD-EPI were recalculated for the individual BSA (using the DuBois 
formula 15 as mentioned above) of each patient (designated as MDRD-BSA and CKD-
EPI-BSA, respectively).
Box. Prediction equations
*k is 0.7 for females and 0.9 for males, a is -0.329 for females and -0.411 for males, min indicates 
the minimum of serum creatinine/k or 1, and max indicates the maximum of serum creatinine/k 
or 1
Statistical analysis
Data analysis was performed using SPSS version 16.0 (SPPS Inc., Chicago, IL, USA). 
Demographic data were stratified according to BMI categories, and presented as median 
(interquartile range, IQR) or mean (standard deviation, SD), depending on whether 
data were skewed or not. Student’s t-test, the Chi-square test or ANOVA was used to 
compare the demographic characteristics and the values of the renal function prediction 
equations between the BMI categories. The accuracy of the renal function prediction 
formulae for the different BMI categories was compared using the McNemar test.
Creatinine clearance
U (creatinine concentration in urine; μmol/ml) * V (Urine volume; ml/min)/ P (creatinine 
concentration in plasma in (μmol/ml).
Cockroft-Gault equation (ml/min): 
1.23 * (140-age)/serum creatinine) * weight (* 0.85 for women). 
4-variable MDRD equation (ml/min/1.73m2): 
175 * (serum creatinine (μmol/L)/88.4)-1.154 * age (years)-0.203 (* 0.742 for women).
CKD-EPI (ml/min/1.73m2):
141 * min (serum creatinine (mg/dl)/k,1)a * max (serum creatinine (mg/dl)/k,1)-1.209 * 0.993age 
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The performance of the GFR prediction equations, the GFR prediction equations 
corrected for BSA and the CG were compared by calculating correlation, Krippendorf’s 
coefficient 16, bias, precision (the SD of the bias) and accuracy for each BMI category. 
Spearman’s coefficient of correlation was calculated for each BMI category to determine 
the correlation between the CCR and the results of the MDRD, the MDRD-BSA, the 
CKD-EPI, the CKD-EPI-BSA and the CG. The Krippendorff  coefficient was used as 
an aggregate measure for method concordance. A Krippendorff  coefficient of 1 shows 
a perfect concordance between two methods and a Krippendorff  coefficient of -1 shows 
a perfect discordance 16.
Bias was defined as the mean difference between the renal function prediction equations 
and CCR, whereas precision was defined as the SD of this difference. Accuracy (a 
combination of bias and precision), and the percentage of patients who had an estimated 
kidney function within 30% and 50% limits of the CCR, were calculated. 
Results
Population characteristics and design
The patient characteristics of this study are presented in table 1. The mean (SD) CCR 
of the overall study population was 112 (45) ml/min. The mean renal function of the 
overall population estimated with the MDRD, MDRD-BSA, CKD-EPI, CKD-EPI-
BSA and CG was 76 (25) ml/min/1.73m2, 87 (31) ml/min, 78 (24) ml/min/1.73m2, 90 (30) 
ml/min and 99 (42) ml/min respectively. The total study population was equally divided 
between the BMI categories, and included subjects across a wide range of ages (20-92 
years of age), with BMI scores ranging between 15-58 kg/m2. The CCR values ranged 
between 11-250 ml/min. Although non-significant, there were considerable differences 
in sex distribution between the BMI categories. No significant differences in age and 
HbA1c were observed between the BMI categories.
After calculating the results of the GFR prediction equations and the CG equation 
for each BMI category, only the MDRD result was significantly different between the 
normal group (BMI <25 kg/m2) and the overweight group (BMI 25-30 kg/m2) (p<0.04). 
Between the normal and obese group significant differences were found for the CCR 
value (p<0.01), MDRD-BSA (p<0.01) and CG result (p<0.001). However, when the 
GFR prediction equations were not corrected for BSA, no significant differences were 
















































n (%) 243 (29) 295 (35) 306 (36)
Age (in years)* 65 [48-73] 63 [54-71] 63 [56-72]
Sex (men, in %) 57 65 44
Weight (kg)* 70 [63-76] 80 [74-90] 97 [89-109]
BMI (kg/m2)* 23 [22-24] 27 [26-29] 33 [31-37]
HbA1c (%)* 6.7 [6.0-7.4] 6.6 [5.9-7.4] 6.9 [6.1-7.6]
Serum creatinine (µmol/L)* 78 [66-93] 83 [71-103] 78 [66-98]
BSA (m2) 1.83 (0.18) 1.95 (0.18) 2.10 (0.21)
Creatinine clearance (ml/min) 104 (41) 109 (42) 121 (51)
CG (ml/min) 85 (34) 91 (34) 116 (49)
CKD-EPI (ml/min/1.73m2) 82 (24) 77 (24) 77 (23)
CKD-EPI-BSA (ml/min) 87 (28) 87 (29) 94 (31)
MDRD (ml/min/1.73m2) 82 (28) 77 (29) 79 (30)
MDRD-BSA (ml/min) 85 (29) 84 (29) 92 (34)
Table 1. Patient characteristics. Data are represented as mean (standard deviation). *Data are 
represented as median [interquartile range]. BMI: body mass index, BSA: body surface area, 
CG: Cockcroft-Gault equation, CKD-EPI: chronic kidney disease epidemiology collaboration 
equation, CKD-EPI-BSA: chronic kidney disease epidemiology collaboration equation corrected 
for body surface area, MDRD: Modification of Diet in Renal Disease (the 4-variable MDRD 
is used in this study), MDRD-BSA: Modification of Diet in Renal Disease corrected for body 
surface area.
Correlation and Krippendorff’s coefficient
Both GFR estimates, also after a correction for BSA, and the CG result were correlated 
with the CCR value of each BMI category (see table 2). Overall, the Spearman correlation 
coefficient was 0.73 for the MDRD, 0.80 for the MDRD-BSA, 0.74 for the CKD-EPI, 
0.81 for the CKD-EPI-BSA, and 0.78 for the CG equation. If  no correction for BSA 
takes place, the correlation between the CG and the CCR proves to be superior to the 
GFR prediction equations in all BMI categories, except for the MDRD equation in the 
normal weight category (as might be expected). When GFR formulae are corrected for 
BSA, the correlation between the CKD-EPI-BSA and MDRD-BSA results is stronger 
than between the CG result and CCR in all BMI categories. Because correlation alone 
is insufficient to prove the concordance among methods, the Krippendorff  coefficient 
was calculated (see table 2). The best concordance was found between the CG result and 
CCR within all BMI categories. The CKD-EPI result had the worst concordance with 



















































BMI <25 kg/m2 0.82 (0.71) 0.75 (0.58) 0.80 (0.66) 0.76 (0.55) 0.82 (0.68)
BMI 25-30 kg/m2 0.81 (0.71) 0.78 (0.52) 0.82 (0.62) 0.79 (0.47) 0.82 (0.65)
BMI ≥ 30 kg/ m2 0.75 (0.75) 0.72 (0.42) 0.77 (0.58) 0.72 (0.33) 0.78 (0.57)
Table 2. Correlation and Krippendorff’s coefficient for CG and eGFR values per BMI category.
Data are presented as Spearman’s correlation coefficient (Krippendorff’s coefficient). CG = 
Cockcroft-Gault equation; MDRD = Modification of Diet in Renal Disease; MDRD-BSA 
= MDRD corrected for body surface area; CKD-EPI = chronic kidney disease epidemiology 
collaboration equations; CKD-EPI-BSA = CKD-EPI corrected for body surface area; BMI = 
body mass index. 
Bias and precision
All prediction equations had a negative bias in the various BMI categories. The bias 
varied widely, as can be seen in figure 1 The higher the BMI, the greater the mean bias 
for both the MDRD and the CKD-EPI equation (see figure 1). When the MDRD and 
the CKD-EPI were corrected for BSA, the results were similar. However, the mean bias 
for these two equations did not increase as much in the higher BMI categories (see figure 
1). For the CG equation, a decreasing trend in bias was observed with increasing BMI, 
from -18.7 ml/min in BMI <25 kg/m2 to -4.0 ml/min in BMI >30 kg/m2 (p<0.001). 
No significant differences in performance were found between the CKD-EPI and the 
MDRD equations in the normal weight and overweight group (p=0.88 and p=0.50, 
respectively). In the obese patient group the MDRD performed significantly better than 
the CKD-EPI (p=0.01). 
The precision of all these formulas varied widely in all BMI categories (see table 3).
Accuracy
In table 3, the accuracy of the various renal function estimates is presented for each BMI 
category. The CG had the best accuracy (>70.4%) in all BMI categories. The CKD-
EPI equation had a better accuracy than the MDRD equation in all BMI categories 
(when a dispersion of 30% was tolerated), although the difference in accuracy was only 
significant in the overweight group (<0.01); accuracy decreased with increasing BMI. 
However, when the GFR prediction equations were corrected for BSA, the MDRD-BSA 
performed significantly better in all BMI categories than the CKD-EPI-BSA (p<0.01), 
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MDRD (ml/min/1.73m²)MDRD-B (ml/min)CKD-EPI (ml/min/1.73m²)CKD-EPI-B (ml/min)CG (ml/min)
BMI <25 (normal) -22,1 -18,7 -22,2 -16,7 -18,7
BMI 25-30 (overweight)-32,6 -25,1 -32,1 -22,2 -17,9
BMI >30 (obese) -41,4 -29 -43,3 -26,4 -4
BMI <24.9 BMI 25-29.9 BMI ≥30
MDRD-A -22,1 -32,6 -41,4
MDRD-B -18,7 -25,1 -29
CKD-EPI -22,2 -32,1 -43,3
CKD-EPI-B -16,7 -22,2 -26,4

























MDRD (ml/min/1.73m²) MDRD-B (ml/min) CKD-EPI (ml/min/1.73m²) CKD-EPI-B (ml/min) CG (ml/min)
Figure 1 Mean bias per BMI category. Mean bias (ml/min/1.73m2) of each renal function 
prediction equation stratified according to BMI category (kg/m2). Bias is defined as mean 
difference between the (estimated) renal function using equations and the creatinine clearance. 
MDRD = Modification of Diet in Renal Disease; MDRD-B = MDRD corrected for body surface 
area; CKD-EPI = chronic kidney disease epidemiology collaboration equations; CKD-EPI-B = 
CKD-EPI corrected for body surface area; CG = Cockcroft-Gault equation. 
Discussion
This study shows that the CG is a better predictor of renal function than the MDRD 
and the CKD-EPI in diabetic patients, especially when patients are overweight or obese, 
at least when CCR is used as a reference value. The MDRD and CKD-EPI equations 
provided less accurate results for overweight and obese patients. Even though the renal 
function in the studied population was good (mean CCR 112 ml/min), the recently 
developed CKD-EPI did not perform significantly better than the MDRD. When the 
MDRD and CKD-EPI were corrected for BSA, bias and accuracy improved. Even 
so, the CG outperformed the GFR prediction equations in the overweight and obese 
patient group. 
The limitations of creatinine-based prediction equations in overweight and obese 
populations have been discussed in literature before 17-22. A condition frequently 
encountered in obese patients and patients with diabetes is renal hyperfiltration. The 
suggested underlying mechanism is that progressive obesity alters renal hemodynamics, 
leading to an increase in GFR of each single nephron, since the number of nephrons 
will not increase with increasing body fat 23. Ultimately, nephrons will function near to 
or on maximum capacity, i.e. hyperfiltration. Correcting GFR for BSA obscures this 
problem, as was shown in a cohort of 81 obese patients (BMI 41 ± 9 kg/m2) with a 
mean GFR of 101 ± 24 ml/min (measured by Cr-EDTA) and a mean indexed GFR of 
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used as a reference, the MDRD formula underestimated (mean difference: -11 ± 20 ml/
min) respectively overestimated (mean difference: 14 ± 18 ml/min/1.73m2) the measured 
GFR. The observed underestimation of the GFR using the MDRD can be expected 
based on previous literature; however, the overestimation when using an indexed GFR is 
remarkable and suggests that back-correction for BSA is needed 24.
Although overweight and obesity have almost reached epidemic forms nowadays ‘the 
Caring for Australians with Renal Impairment (CARI) guidelines’ are the only guidelines 
to mention the influence of weight on the GFR prediction equations 25. These guidelines 
are also the only ones warning for the unreliable prediction results of the MDRD 
equation in an overweight and obese population 25. The influence of weight on renal 
function equations should however, be considered, especially since many laboratories 
have started to use automated reporting of the MDRD estimates. More importantly, 
clinical decisions are based on these renal function estimates. 
The observation in our study that the CG equation had the least bias in overweight 
and obese subjects is supported by previous publications 17-18. In a population of newly 
diagnosed T2DM patients with a mean isotopic GFR of 115 ml/min/1.73m2, the CG 
equation had the most pronounced bias in lean subjects (mean -20.6 ml/min/1.73m2, CI 
-23.9 to -17.3); a bias that diminished with increasing body weight (-5.6 ml/min/1.73m2 
in an obese population). Contrarily, the bias of the MDRD increased (from -21.3 ml/
min/1.73m2 in the normal weight group to -28.9 ml/min/1.73m2 in the obese group), and 
the accuracy decreased [19]. The fact that we found more pronounced results compared 
with the study of Chudleigh et al. might be due to the use of CCR values instead of 51Cr-
EDTA values as a reference for renal function.
Verhave et al. studied the performance of the CG and MDRD equations in a diverse 
cohort of outpatients with serum creatinine levels of less than 1.5 mg/dL (<133 µmol/L) 17. 
In their study, a rather similar trend for the CG was found, except that in the obese 
population an overestimation of + 10.1 ml/min was found. This is in contrast to our 
study, in which we found a small underestimation. Also in contrast with our findings, 
the investigators found that the MDRD equation underestimated the GFR to a certain 
extent (approximately -12.4 ml/min/1.73m2), irrespective of BMI 17. It is possible that their 
results slightly differ from our results because of differences in creatinine measurement. 
In our study, the creatinine was calibrated to IDMS. 
The influence of weight on the CKD-EPI has not yet been evaluated in a cohort of 
diabetic subjects. In a recently published study performed among potential kidney 
donors (mean CCR 78.2 ml/min/1.73m2), the researchers found that the CKD-EPI and 
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Many of the above mentioned studies, comparing the performance of the CG and 
the MDRD, use an indexed CG equation (often the standard BSA of 1.73m2). In our 
opinion, this is incorrect. Since weight is one of the clinical variables included in the CG 
equation, a correction for BSA will result in a double correction for weight. This double 
correction may well have influenced the performance of the equation in these studies. 
Moreover, a correction to a standard BSA of 1.73m2 may result in a worse performance 
of the MDRD and CKD-EPI equations. In patients with a normal BMI, the impact of a 
correction to a standard BSA of 1.73m2 is rather small, since 1.73m2 is approximately the 
BSA of a non-overweight person. However, such a correction will lead to considerable 
underestimation of renal function in obese patients, since a lot of obese people have 
a BSA which grossly exceeds 1.73m2. When we corrected the values in our study to 
a standard BSA of 1.73m2, the MDRD and CKD-EPI equations did indeed perform 
worse. But when we corrected the data to the actual BSA of participants, the performance 
of both the MDRD equation and CKD-EPI equation improved considerably. 
Another reason why the MDRD equation in our study performed worse than the other 
equations might be that the average renal function in the study population was good 
and the MDRD equation has only been validated in a population with impaired renal 
function (MDRD <60 ml/min/1.73m2). 
Finally, the CCR is not a true reflection of GFR. Still, the CCR is a common way 
to measure renal function in daily practice; contrarily to various isotopic clearance 
techniques or other clearance methods that are reserved for research purposes. 
Unfortunately, details concerning duration of DM, blood glucose lowering treatment 
and the presence of albuminuria are not available for this population due to the method 
of data collection. The inclusion of such data would have allowed the analysis to be 
more complete
Conclusion
In this study, performed among diabetic patients in various weight categories, the CG 
was the best predictor of renal function compared with the 4-variable MDRD and 
CKD-EPI when used in an overweight or obese population. The recently developed 
CKD-EPI equation has no additional value over the existing prediction equations. 
When the existing prediction equations are used in clinical practice, their disadvantages 
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Background and objectives Non-equivalence in serum creatinine (SCr) measurements 
across Dutch laboratories and the consequences hereof on chronic kidney disease 
(CKD) staging were examined. 
Methods National data from the Dutch annual external quality organization of 2009 
were used. 144 participating laboratories examined 11 pairs of commutable, value-
assigned SCr specimens in the range 52-262 µmol/L, using Jaffe or enzymatic techniques. 
Regression equations were created for each participating laboratory (by regressing 
values as measured by participating laboratories on the target values of the samples sent 
by the external quality organization); area under the curves were examined and used to 
rank laboratories. The 10th and 90th percentile regression equation were selected for each 
technique separately. To evaluate the impact of the variability in SCr measurements 
and its eventual clinical consequences in a real patient population, we used a cohort 
of 82424 patients aged 19-106 years. The SCr measurements of these 82424 patients 
were introduced in the 10th and 90th percentile regression equations. The newly calculated 
SCr values were used to calculate an estimated glomerular filtration rate (eGFR) using 
the 4-variable Isotope Dilution Mass Spectrometry traceable Modification of Diet in 
Renal Disease formula. Differences in CKD staging were examined, comparing the 
stratification outcomes for Jaffe and enzymatic SCr techniques. 
Results Jaffe techniques overestimated SCr: 21%, 12%, 10% for SCr target values 52, 
73 and 94 μmol/L, respectively. For enzymatic assay these values were 0%, -1%, -2%, 
respectively. eGFR using the MDRD formula and SCr measured by Jaffe techniques, 
staged patients in a lower CKD category. Downgrading to a lower CKD stage occurred 
in 1-42%, 2-37% and 12-78.9% of patients for the 10th and 90th percentile laboratories 
respectively in CKD categories 45-60, 60-90 and >90 ml/min/1.73m2. Using enzymatic 
techniques, downgrading occurred only in 2-4% of patients. 
Discussion Enzymatic techniques lead to less variability in SCr measurements than Jaffe 
techniques, and therefore result in more accurate staging of CKD. Therefore the specific 
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Introduction
Serum creatinine (SCr) based prediction equations are frequently used in screening and 
clinical settings in order to estimate the glomerular filtration rate (GFR). The current 
variability in SCr measurements affects all estimating equations for GFR, including 
the MDRD equation. Many automated routine methods for SCr measurement exceed 
the desirable imprecision criterion of ≤ 2.2%; therefore, reduction of analytical bias 
≤ 3.4% in creatinine assays by standardization of calibration is needed 1. It is important 
to notice that standardization of calibration does not correct for analytical interferences 
(nonspecificity bias). The bias and nonspecificity problems associated with some of the 
routine methods must be addressed.
Chronic kidney disease (CKD) staging directly relies on these estimated GFR values. 
Using accurate SCr measurements is essential, since systematic errors cause unreliable 
renal function estimates, leading to incorrect drug dose adjustments, misclassifications 
in CKD staging and incomparability of patient data 2-5. 
Since significant interlaboratory variation was observed worldwide, it was internationally 
confirmed that calibration traceability to higher-order reference methods was needed to 
realize comparable biochemical measurement results 2,6-7. 
Therefore, the European in vitro diagnostics (IVD) directive 98/79/EC, and the laboratory 
working group of the National Kidney Disease Education Program recommend that in 
order to improve standardization, clinical laboratory measurements should be traceable 
to internationally recognized and certified reference materials 8-10. Since the development 
of NIST SRM 967 in 2006, a matrix-based IDMS targeted creatinine standard, all 
essential elements (i.e. methods, laboratories, and materials) needed to complete the 
creatinine reference system are in place, according to ISO 17511 11. Since the complete 
traceability is in place in vitro diagnostic manufacturers of creatinine assays in Europe 
are legally obliged to make their products metrologically traceable, regardless of the 
method applied. 
In this study we examine the degree of variability and interchangeability of SCr 
measurements across all clinical chemistry laboratories in 2009 in the Netherlands, in 
order to evaluate the situation after global restandardization, using data from the annual 
national external quality control program of the Dutch external quality assessment (EQA) 
organization for clinical chemistry laboratories (Stichting Kwaliteitsbewaking Medische 
Laboratoriumdiagnostiek, SKML). Subsequently, we investigate in a theoretical model, 
the impact of the variability in SCr measurements between laboratories on estimates 
of GFR using the 4-variable IDMS-traceable MDRD formula and the consequences 
hereof on CKD staging of patients, when the data from the SKML are extrapolated to 








































54  |  Chapter 4
Methods
In this cross-sectional study, we evaluate the effect of different SCr assays on SCr levels 
and CKD classification. EQA data are derived from the 2009 EQA program of the 
SKML. Annually, the SKML creates 11 pairs of frozen commutable, value assigned 
serum samples spiked with crystalline creatinine, aliquoted in 1 ml vials. A commutable 
material reflects the characteristics and properties of native patient samples 2,12. Value-
assignment was performed by a joint committee on traceability in laboratory medicine 
(JCTLM)-endorsed reference laboratory. Each of the 144 laboratories participating in 
the EQA program in the Netherlands annually receives a set containing 11 pairs of these 
commutable samples from the SKML and store them intermittently at -80°C. The 11 
pairs of EQA-samples cover SCr values in the entire measuring range: 52-73-94-115-
136-157-178-199-220-241-262 µmol/L and form a linear sequence; thus each laboratory 
received and analyzed, the range mentioned before in twofold over the year. The target 
values for the SCr levels are established by a JCTLM listed reference laboratory (Bonn, 
Germany) using an Isotope Dilution Gas Chromatography/Mass Spectrometry (ID-
GC/MS) method 13-14. 
Every other week all routine laboratories thawed one of the EQA samples and 
measured the SCr concentration applying their routine SCr methods according to 
the manufacturer’s instructions. 91 (63%) versus 48 (33%) of the laboratories used a 
Jaffe or enzymatic method to measure SCr, respectively. 62 (68%) laboratories using a 
Jaffe technique applied a modified kinetic Jaffe method; 29 (32%) used a compensated 
Jaffe method. Few laboratories used dry chemistry to measure SCr; since this group of 
laboratories was too small to draw conclusions from (n=5), this group was excluded 
from further analyses. Companies and instruments included Abbott (Abott Park, Il, 
USA; Aeroset, Architect), Beckman (Brea, Ca, USA; Synchron, Unicel, LX20, Lxi725), 
Siemens Healthcare diagnostics (The Netherlands; ADVIA 1650, 1800, 2400), Roche 
Diagnostics (Mannheim, Germany; Integra, Hitachi, Modular, Cobas, Cobas Integra) 
and Olympus (Tokyo, Japan; AU 400, 600). In total, 39 different instrument method 
combinations were used to measure SCr. 
Data of the SCr measurements as measured by the participating laboratories were 
reported centrally to the SKML and collected in an completely anonymous database. 
Variability SCr extrapolated in cohort
To investigate the impact of the variability in SCr measurements as found in the national 
EQA database and the eventual clinical consequences hereof in a real patient population, 
we used an unselected cohort of 82424 patients whose SCr had been measured in 2009 
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described before 15. In short, 45.3% of the population was male, age varied from 19-106 
years and 38.7% was older than 65 years old. SCr in this cohort was measured using an 
enzymatic technique (modular P Analyzer, creatinine plus assay; Roche Diagnostics, 
Mannheim, Germany). In order to obtain SCr reference values that are traceable to the 
reference data from the EQA program for each patient, we requested the results from 
the 2009 EQA program from the clinical chemistry department, Isala clinics Zwolle. 
Based on these results we created a regression equation for the Zwolle laboratory 
(the exact procedure is extensively described in the statistical analyses section), using 
inverse regression. Subsequently SCr values as measured in the Zwolle population were 
introduced in this regression equation in order to calculate the SCr values traceable to 
the results of the EQA program for each of the 82424 patients. The GFR using these 
IDMS-traceable SCr values was estimated using the 4-variable IDMS-traceable MDRD 
formula 16-17. 
Statistical analysis
We used SPSS version 16.0 (SAS Institute, Cary, NC, USA) and STATA version 11 
(StataCorp, College Station, Texas USA) for statistical analyses. All SCr measurements 
of the laboratories participating in the EQA program were inspected for outliers 
(truncated at ± 3 standard deviation (SD)); 3 laboratories were removed from the dataset 
because more than 50% of the measurements of these 3 laboratories deviated more than 
3 SD from the other laboratories. The target reference values from the linearity sequence 
of the EQA program served as the reference method against which routine methods to 
measure SCr from participating laboratories were compared, by means of relative and 
absolute bias. The results were displayed in box and whisker plots for each method group. 
Relative bias is defined as the mean percentage difference [(measured SCr-target value 
SCr)/target value SCr] x 100; absolute bias is defined as the mean difference between SCr 
values measured by individual laboratories and SCr target values; precision is defined as 
the SD of the absolute bias. 
We extrapolated the impact of the non-equivalence in SCr measures (as derived from the 
laboratories participating in the EQA program), to our patient cohort of 82424 patients. 
In order to do so, SCr values as measured by laboratories participating in the quality 
assessment program were regressed on the target values of the samples sent by the 
SKML, so-called inverse regression, for each of the participating laboratories separately. 
Regression equations for each of the participating laboratories, (n=47 for Jaffe and n= 
39 for enzymatic), who had not changed their technique to measure SCr in 2009, were 
created. For each of these regression equations (thus for each of the laboratories fulfilling 
the criteria mentioned above), we calculated an area under the curve (AUC) in the range 
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of SCr provide eGFR’s around the threshold value of 60 ml/min/1.73m2, sufficient to 
classify patients as having CKD stage 3. Subsequently, the AUC’s of all the participating 
laboratories were ranked in ascending order for the Jaffe and the enzymatic technique 
separately, in order to establish a 10th and 90th percentile regression equation for each of 
the techniques. Then, SCr values from our cohort of 82424 patients were inserted in the 
10th and 90th percentile regression equations (for the Jaffe technique and the enzymatic 
technique as appropriate). These ‘newly calculated’ SCr values were introduced in the 
appropriate MDRD equations, thus providing 10th and 90th percentile eGFR values. To 
get an impression from the clinical implications of the variation in SCr values on CKD 
staging, we classified the patients according to the K/DOQI guidelines and evaluated the 
differences in CKD staging when SCr values were measured by Jaffe or the enzymatic 
methods 18. 
Ethical statement
No permission was required from the Medical Ethics Committee as our data only 
included lab result information, which had been obtained from a laboratory database. 
No personal patient information was included. Permission to use the national 2009 EQA-
data was obtained from the SKML. The laboratories in the dataset were anonymous. 
Results
The relative and absolute bias for both Jaffe and enzymatic techniques are shown 
in figures 1 to 4. The enzymatic method to measure SCr produced the least biased 
results, which were not significantly different from the target values, whereas the Jaffe 
technique produced the most biased and imprecise results, which differed significantly 
from the reference values. The Jaffe technique especially tended to overestimate SCr 
at low concentrations: 21%, 12%, 10% for the SCr target values 52, 73 and 94 μmol/L, 
respectively. The enzymatic method had a small bias that was constant over the entire 
range of SCr values. The precision for Jaffe / enzymatic (per reference value) is: 10 / 3 (52 
μmol/L), 10 / 3 (73 μmol/L), 7 / 3 (94 μmol/L), 13 / 4 (115 μmol/L), 7 / 5 (136 μmol/L), 
8 / 4 (157 μmol/L), 8 / 5 (178 μmol/L), 9 / 5 (199 μmol/L), 10 / 6 (220 μmol/L), 11 / 5 (241 
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Figure 1. Box and whisker plot showing the percentual bias of the Jaffe technique. Interpretation 
of the vertical axis e.g. 1.1 means a percentual bias of 10%. The box represents the 25th, 50th and 
75th percentile; the whiskers represent the 5th and 95th percentile. The extremes, defined as values 
more than three times the interquartile range, are the signs above and underneath the whiskers. 
The grey line represents the 0% bias line.
Figure 2. Box and whisker plot showing the percentual bias of the enzymatic technique. 
Interpretation of the vertical axis e.g. 1.1 means a percentual bias of 10%. The box represents 
the 25th, 50th and 75th percentile; the whiskers represent the 5th and 95th percentile. The extremes, 
defined as values more than three times the interquartile range, are the signs above and underneath 
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Figure 3. Box and whisker plot showing the absolute bias (mmol/L) for the Jaffe technique. The box 
represents the 25th, 50th and 75th percentile; the whiskers represent the 5th and 95th percentile. The 
extremes, defined as values more than three times the interquartile range, are the signs above and 
underneath the whiskers. The grey line represents the 0 µmol/L bias line.
Figure 4. Box and whisker plot showing the absolute bias (mmol/L) for the enzymatic technique. 
The box represents the 25th, 50th and 75th percentile; the whiskers represent the 5th and 95th 
percentile. The extremes, defined as values more than three times the interquartile range, are the 
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The impact of the variability in SCr measurements on CKD staging is illustrated in tables 
1 and 2. From the tables we can conclude that the differences between the 10th and 90th 
percentile laboratory are large when a Jaffe technique is used. Downgrading to a lower 
CKD class was observed using the Jaffe assay for CKD stages: 45-60 ml/min/1.73m2 
(1.1%, 41.9%); 60-90 ml/min/1.73m2 (1.8, 36.7%) and >90 ml/min/1.73m2 (12.3%, 78.9%), 
for the 10th and 90th percentile values respectively. When an enzymatic technique was 
used, the variability resulted in both upward and downward reclassification of CKD 
stage. Downward reclassification occurred in 2.1-4.1% of patients, whereas upgrading 
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Discussion
The present study shows that interlaboratory non-equivalence in SCr assays in the 
Netherlands was still substantial in 2009, notwithstanding the recent international 
creatinine restandardization effort. The high variability was largely explained by the 
ongoing use of Jaffe assays for measuring SCr. Compared with the enzymatic assays, 
the Jaffe assays had a significantly larger bias, especially for SCr levels in the lower 
range (reference value range 52-115 µmol/L). Although relative bias decreased when 
SCr reference values were higher, imprecision remained high. It was of course to be 
expected that Jaffe methods lead to a positive bias when compared with the ID-/GC-
MS method, and that adjustment for this bias would occur when using the appropriate 
MDRD equation. This has caused the downgrading of patients to a lower CKD category 
relevantly more often when a Jaffe technique instead of an enzymatic technique was 
used, especially in categories >45 ml/min/1.73m2 (up to 79%). In contrast, the use of an 
enzymatic technique more often resulted in upgrading of the CKD stage, which may be 
explained by the differences in bias: the Jaffe technique provided higher values of SCr, 
whereas the enzymatic technique provided slightly lower values. 
Ever since SCr is assessed in clinical practice its accuracy has been debated 1,7,19. Although, 
SCr measurements are routinely performed, it is one of the most variable laboratory 
tests 20. The increasing use of eGFR in clinical practice has renewed the interest on the 
shortcomings of the SCr methodology 1,21-24. Since SCr is the most important variable in 
the renal function estimation equations, calibration of the creatinine assays is necessary 
to reduce bias in these formulas. This even lead to a modification of the factor used in 
the MDRD-equation (from 186 to 175 for IDMS traceable creatinine). However, the 
way this calibration was obtained has been regularly criticized in literature, due to the 
fact that the formulas were modified after having recalibrated the Jaffe creatinine to an 
IDMS traceable enzymatic method, having deleted the intercepts since these were not 
statistically significant.
The substantial bias and between laboratory variance as we found in our study, has 
been shown in various other studies in which data from proficiency testing (PT) and 
EQA scheme programs were evaluated 7,25-26. A European trueness verification study 
of SCr also showed large interlaboratory variability before the matrix-based SRM 967 
standard was available 7. In our study we would have expected a significantly reduced 
interlaboratory CV due to global restandardization on SRM 967. However, despite the 
European IVD directive with stricter regulations, no improvements compared with earlier 
studies, in which a method group SD of 2.6-11 µmol/L and a median CV of 5% at a SCr 
concentration of 74 µmol/L, had been reached 27. The failure to realize amelioration 
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not correct for analytical non-specificity problems, as is the case with the Jaffe method 
28-29. These non-specificity problems concern the measurement of many endogenous 
and exogenous interfering substances such as protein, glucose and ketones when 
SCr is measured using a Jaffe method 28-31. Despite many attempts to improve the 
performance characteristics of the Jaffe reaction, non-specificity remained 7. This leads 
to overestimation of the true SCr concentration. Calibration traceability cannot solve 
this problem nor substitute for improvement of suboptimal routine methods. 
Although the enzymatic assay to measure SCr is not free of interference from various 
substances, it has a better specificity than the Jaffe technique 28. This was recently 
confirmed in a multicentre study evaluating IDMS-traceable enzymatic creatinine 
assays. It showed that the majority of enzymatic methods reached the acceptable total 
analytical error of 8% for SCr values as low as 36 µmol/L, when adequately calibrated 
against IDMS, improving the traceability and standardization of creatinine 32. 
Moreover, upgrading in CKD stage as we observed when enzymatic assays were used in 
the MDRD formula may be less relevant in routine clinical practice than the downgrading 
to a lower CKD stage as occurs when a Jaffe assay was used to measure SCr. E.g. a patient 
whose eGFR is 57 ml/min/1.73m2 (CKD stage 3a) or 62 ml/min/1.73m2 (CKD stage 
2) when a Jaffe respectively an enzymatic assay is used to examine SCr, probably have 
similar risks regarding end-stage renal disease, all-cause and cardiovascular mortality. 
From studies comparing the prognosis associated with the two most commonly used 
equations to estimate GFR (the MDRD and the Chronic Kidney Disease Epidemiology 
collaboration equation, CKD-EPI) during a long follow-up (≥7.5 years) we know that 
individuals reclassified from CKD stage 3a (eGFR 45-60 ml/min/1.73m2) to no CKD 
had lower mortality risk than those not reclassified. Moreover, these participants had an 
equal risk to those classified as no CKD by both formulas 33-34. 
Based on the large batch of evidence in literature showing that alkaline picrate methods 
are inferior methods to measure creatinine, it is time for laboratories to substitute the 
alkaline picrate method by enzymatic methods. Moreover, if  an increasing number 
of laboratories apply enzymatic techniques, the number of vendors of commercial 
enzymatic assays will increase, leading to more competition, which will ultimately 
reduce the costs of these assays. To bring this in a broader perspective, more accurate 
and precise measurements of SCr will lead to a reduction of the source of error in GFR 
estimates and thus errors in the staging of renal failure. Considering the number of 
patients that are misclassified in this study when using an alkaline picrate technique, 
clinical laboratories should also consider the implications for overall health costs, since 
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Although this study is a theoretical analysis, it is one of the few illustrating the 
consequences of variations in SCr measurements on GFR estimation and CKD staging 
for the individual patient. Since the majority of Dutch laboratories is included and we 
have a large heterogeneous cohort of patients in which we tested our model, we are able 
to give a good reflection of the consequences it might have for daily clinical practice. 
Moreover, we have studied creatinine values on 11 different levels against a strong 
reference method; and the samples used, were all recent instead of remote samples, 
which are frequently used in other studies. Selection bias may have occurred, since 
laboratories with too few analyses in the external quality control program were excluded 
for further analysis in our patient cohort. Moreover, we applied the MDRD formula in a 
patient cohort with an age range from 19-106 years. This may have introduced bias since, 
the MDRD has only been validated for patients from 19-70 years, and underestimates 
the GFR in patients >70 years. However, in clinical practice, laboratories automatically 
report eGFR’s each time a creatinine is measured, also in patients older than 70 years, 
and clinical decision making is often based on these estimates.
Conclusions
In conclusion, accurate and precise measurements of SCr are required for a more 
reliable estimation of GFR as support for reliable clinical decision making. Enzymatic 
techniques measure SCr with substantially less variability than Jaffe techniques as 
compared with ID-MS reference values. This leads to more reliable estimation of GFR 
and CKD staging. To allow improvement of reliability of eGFR, specific enzymatic 
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Background and objectives This study examines the variability between various assays for 
measuring creatinine in urine, plasma and peritoneal fluid and the effects hereof on the 
estimated glomerular filtration rate (eGFR) and creatinine clearance (CCR). 
Methods This cross-sectional study measured the creatinine concentration in the plasma, 
urine and peritoneal dialysis fluid of 181 patients, using a compensated Jaffe assay, 
enzymatic assay and liquid chromatography mass spectrometry (LCMS) technique. The 
CCR and eGFR were calculated. Scatterplots, Bland-Altman plots and a concordance 
correlation coefficient (Lin’s coefficient) were used to assess (concordance) correlation 
coefficient, bias and precision. 
Results Mean age is 58 (± 15) years, 53% (n=96) is male, median plasma creatinine levels 
in the non-dialysis group are: 103, 84 and 89 µmol/L for the Jaffe, enzymatic and LCMS 
assay respectively; median urine creatinine levels are 4.1, 4.6 and 5.7 mmol/L respectively. 
Lin’s coefficient for the CCR is 0.466 and 0.715 when creatinine is measured using a Jaffe 
and a enzymatic technique respectively. Bias (precision) for creatinine measurements in 
urine in the non-dialysis group is -1.24 (1.82) mmol/L and -0.75 (1.88) mmol/L for Jaffe 
and enzymatic respectively. 
Discussion Both Jaffe and enzymatic assays provide biased results for creatinine 
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Introduction
Formulas based on plasma creatinine (PCr) are regularly used to estimate the glomerular 
filtration rate (GFR) 1-3. These formulas have replaced the old technique of calculating 
the creatinine clearance (CCR). Still, despite the mainly practical constraints of its 
use, the CCR is regularly used in daily practice as a (surrogate) marker of the GFR, 
especially when other renal function estimates are either uncertain or need confirmation. 
Moreover, the CCR still has an important role in (pre-)dialysis patients, for example to 
help to decide the right moment for initiating renal function replacement therapy and 
to assess residual renal function and the adequacy of both hemodialysis and peritoneal 
dialysis. 
Furthermore, since the 24-hour creatinine excretion rate is considered to be relatively 
constant and independent of 24-hour urinary volume, urinary excretion of biomarkers 
is often expressed after adjustment for urine creatinine concentration to correct for 
sampling errors. Since the introduction of creatinine based formulas for estimating 
GFR in clinical practice, many authors have stipulated the substantial variability in 
PCr measurements, which lead to unreliable estimation of the glomerular filtration 
rate when using formulas 4-7. In order to make techniques for PCr measurement more 
reliable and results comparable, the European in vitro diagnostics directive has stressed 
the importance of standardization of PCr measurements to internationally recognized 
and certified reference materials 8-9. Clinical laboratories are now expected to perform 
calibration tests at regular intervals, traceable to an Isotope Dilution Mass Spectrometry 
(IDMS) reference measurement 8,10-11. 
Thus far, the methodological issues involved in measuring creatinine in other fluids than 
plasma, have received little attention, although the creatinine concentration in urine has 
an indispensable role in calculating the CCR. In this study we wanted to examine the 
variability between different techniques (Jaffe, enzymatic, liquid chromatography mass 
spectrometry) to measure creatinine in plasma, urine and peritoneal fluid (in patients on 
peritoneal dialysis) and the effects of various measurement techniques on outcome of 
eGFR equations and CCR in a real-life population with a wide range of renal functions. 
Methods
This cross-sectional study was conducted in the Isala Clinics Zwolle, the Netherlands, 
from June 2010 to January 2011. The laboratory facilities of the Isala clinics provide 
both primary and secondary health care services for a region with a population of 








































70  |  Chapter 5
All subjects older than 18 years who came to the clinical chemistry department to 
deliver a 24-hour urine combined with a PCr assessment, irrespective the reason for 24-
hour urinary collection, were informed about the study and were asked to participate. 
Moreover, patients from the peritoneal and hemodialysis departments were invited by 
letter before they came to the hospital for the periodic assessment of dialysis adequacy. 
This procedure includes the collection of a 24-hour urine (provided patients are not 
anuric), the drawing of blood samples to measure PCr and for PD patients the collection 
of 24-hour peritoneal dialysate. Moreover, 27 healthy volunteers, who were considered 
to have a normal renal function, working at the clinical chemistry department, the 
department of internal medicine or the diabetes centre participated in this study. All 
patients who decided to participate were asked to give an extra 12-16 ml blood for 
this study and to give permission to draw 4 samples from their 24-hour urine and 24-
hour dialysate (if  on peritoneal dialysis). 181 persons gave their informed consent to 
participate in this study. 
Details concerning medication, medical history, comorbidities, BMI, and ethnicity were 
not available due to the nature of our data collection methods. Based on the known 
population data in the Zwolle region, it can be safely assumed that the vast majority of 
this cohort has a Caucasian background. 
All plasma and urine creatinine measurement results, volumes from the 24-hour urines, 
together with screening data regarding demographic characteristics (sex, age) were 
imported in a database. No personal information was added to protect the anonymity 
of the patients. 
Ethical statement
The study protocol (clinical trials identifier number NCT01575392) has been approved 
by the Medical Ethics Committee of the Isala Clinics Zwolle. A signed informed consent 
form was obtained from all participants. 
Creatinine measurements and renal function measurements
Creatinine was measured in plasma, urine and peritoneal dialysis fluid using three 
different techniques: a Roche Modular P Creatinine Jaffe method, rate-blanked and 
compensated (1936131001V10), an enzymatic technique CREA Plus, (1193597600V12; 
Roche Mannheim, Germany), and as a reference technique the LCMS technique, 
verified with NIST SRM 967a (high performance liquid chromatographer 1100, 1200 
Agilent, Santa Clara, U.S.), Tandem Mass Spectrometer (Quattro Micro, Micromass 
(Manchester, England)) was used. The Jaffe and enzymatic assessments in blood were 
performed in lithium-heparin plasma (BD Vacutainer LH PSTTM II 367374. No additives 
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samples were stored frozen at -80º Celsius until the moment of examination and were 
measured in one batch.
CCR was assessed by calculating Ucreat×V/Pcreat, where Ucreat = creatinine concentration 
in urine, µmol/ml; V = urine volume, ml/min; and Pcreat = creatinine concentration in 
plasma in µmol/ml. Moreover, the GFR was estimated using the modification of diet 
in renal disease study equation (MDRD) using either Jaffe creatinine (MDRDJaffe) or 
enzymatic creatinine (MDRDenzymatic) respectively 
1-3. For the present analysis, all patients 
were assumed to be Caucasian.
Statistical analysis
Statistical analysis was conducted using SPSS 16.0 (Chicago IL, USA), Stata 12 
(StataCorp, Texas, USA). Q-Q plots and histograms were used to assess normality. 
Continuous variables are presented as mean (± standard deviation) for the normally 
distributed values and as median (interquartile range) for the non-normally distributed 
variables.
Scatterplots were created in order to assess the correlation between different laboratory 
techniques compared to the reference method (LCMS) for both creatinine measurements 
in plasma and urine. Scatterplots for PCr were only made for samples with a LCMS < 
200 µmol/L, since this is the range in which large differences may have important clinical 
consequences. 
Moreover, bias (mean difference between the CCR calculated when a Jaffe/enzymatic 
technique was used to measure creatinine in plasma and urine and when the LCMS 
was used to measure creatinine) and precision (standard deviation of the bias) were 
calculated for CCR as well as the MDRD. Bland-Altman plots were used to visualize the 
bias and precision of creatinine measurements in plasma and urine. 
A concordance correlation coefficient (Lin’s coefficient) was calculated in order to 
evaluate the reproducibility index of the different assays (Jaffe, enzymatic and LCMS) 
in plasma, urine and dialysate, as well as for the CCR and MDRD, when different assays 
to measure creatinine were used 12. The concordance correlation coefficient evaluates 
the agreement between two readings (from the same sample) by measuring the variation 
from the 45º line through the origin 12. 
Results
181 subjects participated in this study, 27 (15%) of these participants were healthy 
volunteers, 37 (20%) participants were on hemodialysis, 23 (13%) participants were on 
peritoneal dialysis, and 94 (52%) participants were patients, who for reasons unknown 
to the investigators, had to collect a 24-hour urine. Mean age was 58 years (SD 15; 23-88 
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The creatinine concentration in plasma samples using a Jaffe or an enzymatic technique 
was performed in 97% (n=175/181) of the participants; the LCMS technique was 
performed in 96% (n=174/181). The concentration of creatinine in the urine was measured 
in 79% (n=137/174) of the participants using a Jaffe and an enzymatic technique and 
in 80% (n=140/174) using the LCMS technique. In 20% of the patients urine data were 
absent because patients were anuric, or urine samples were lost. 
Table 1 shows the median values and interquartile ranges of the measured creatinine 
values in plasma, urine and dialysate for the non-dialysis and the dialysis population, 
respectively. As expected, the Jaffe technique gives higher creatinine measurements in 
plasma than when the enzymatic or LCMS technique are used. Moreover, enzymatic 
assays have a better concordance correlation coefficient, meaning that it had a better 
agreement with the LCMS technique compared to the Jaffe. Figure 1a shows the scatter 
plot of the Jaffe and enzymatic technique versus the LCMS. As expected, the creatinine 
values measured with the Jaffe technique were higher compared to the LCMS than when 
measured using an enzymatic technique. To illustrate the aforementioned more clearly, 
figure 1b and 1c were created showing the bias of both techniques compared to the 
LCMS. 


























































































Table 1. Creatinine measurements in patients not on dialysis and on dialysis. Data are depicted 
as median and interquartile range (IQR). Creatinine concentration is in µmol/L (plasma and 
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Figure 1a. Creatinine measurements in plasma. The black bullets represent creatinine values 
measured by the enzymatic technique. The open bullets represent creatinine values when a 
Jaffe technique was used. Only data of patients with plasma creatinine values <200 µmol/L are 
represented in this figure. LCMS: liquid chromatography mass spectrometry. 
  Figure 1b Figure 1c
The figures above represent the absolute bias of both the Jaffe (figure 1b) and the enzymatic (figure 
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In urine, the differences in creatinine measurements between Jaffe and enzymatic were 
less evident compared to plasma measurements, both the Jaffe and the enzymatic 
assay provided biased results for urine creatinine (table 2). The scatterplots (figure 
2a, 2b and 2c) show a very wide scatter for both Jaffe and enzymatic measurements 
when compared to LCMS, with a stronger tendency to under- than to overestimate. 
Concordance correlation coefficients were lower in urine measurements. Although 
concordance correlation coefficients were low, the enzymatic technique had a slightly 
better concordance correlation coefficient compared to the Jaffe assay in urine (table 1). 
In table 2, bias and precision are displayed in numbers for both the non-dialysis and 
the dialysis population. Measurements are less biased when the enzymatic technique 
is used, both for creatinine measurements in plasma and urine. The precision is more 
or less similar for plasma and urine measurements. This leads to substantial bias en 
imprecision in the CCR and the MDRD for especially the CCR and the MDRD when 
calculated using the Jaffe technique, and to a lesser extend for enzymatically measured 
creatinine values. 
Jaffe Enzymatic
Bias Precision Bias Precision 
Non-dialysis
Plasma 15.8 (µmol/L) 18.2 -1.96 (µmol/L) 12.6 
Urine -1.24 (mmol/L) 1.82 -0.75 (mmol/L) 1.88 
CCR -31.9 (ml/min) 30.1 -12.9 (ml/min) 29.0 
MDRD -11.1 (ml/min/1.73m2) 14.7 0.0 (ml/min/1.73m2) 9.5 
Dialysis
Plasma 24.6 (µmol/L) 58.5 4.8 (µmol/L) 59.1 
Urine -1.02 (mmol/L) 1.30 -0.75 (mmol/L) 1.32 
CCR -0.95 (ml/min) 1.59 -0.55 (ml/min) 1.08 
MDRD 0.16 (ml/min/1.73m2) 1.16 0.04 (ml/min/1.73m2) 0.95 
Table 2. Bias and precision of creatinine measurements for the non dialysis population. LCMS 
= Liquid Chromatography Mass Spectrometry, MDRD = Modification of Diet in Renal Disease 
study. Creatinine concentrations are in µmol/L (plasma and dialysate) or mmol/L (urine), 
CCR (creatinine clearance) is in ml/min; estimated glomerular filtration rate is ml/min/1.73m2 
(MDRD). Bias is the mean difference between plasma/urine/CCR/MDRDJaffe or plasma/urine/
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Figure 2a. Creatinine measurements in urine. The black bullets represent creatinine values 
measured by the enzymatic technique. The open bullets represent creatinine values when a Jaffe 
technique was used.
  Figure 2b Figure 2c
The figures above represent the absolute bias of both the Jaffe (figure 1b) and the enzymatic (figure 
1c) technique in urine.
The consequences of the different techniques to measure creatinine on CCR and the 
MDRD are shown in table 3. An underestimation of the CCR is observed both when 
Jaffe and enzymatic assays are used to measure creatinine in urine and plasma compared 
to the LCMS in the non-dialysis population. These differences are less obvious when the 
MDRD is used. Moreover, the reproducibility of the enzymatic assay was much better 
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Table 3. Creatinineclearance and eGFR in patients not on dialysis and on dialysis. Data are 
depicted as median and interquartile range (IQR). CCR: creatinineclearance rate, MDRD: the 
modification of diet in renal disease equation. 
Discussion
This study shows that both the enzymatic and the Jaffe assay provide biased and 
imprecise results for urine creatinine. Although both methods provided lower creatinine 
values compared with the LCMS technique, the Jaffe assay was most biased. Our study 
confirmed the well known bias of the techniques for the assessment of PCr, with the 
Jaffe technique being more biased than the enzymatic technique. As a result, CCR values 
were underestimated. Moreover, the Jaffe technique had lower reproducibility than the 
enzymatic technique. 
Due to interfering substances, a higher reading was expected for Jaffe PCr measurements 
6,13-14. Due to the high creatinine content in urine (mmol/L versus µmol/L in plasma), 
the urinary Jaffe measurement should have less interferences by other substances 
and therefore would show results more comparable to the enzymatic and LCMS 
measurements 15-17. Taking this into account, the observation of lower results in urinary 
measurements when using a Jaffe technique was unexpected and inexplicable. 
Such differences do have consequences. Firstly, normal ranges of CCR are mostly based 
on studies, in which Jaffe techniques have been used to measure creatinine. Based on the 
presented results, normal ranges might have to be reestablished when using an enzymatic 
technique as prime technique in a laboratory. MDRD differences are bothersome in 
some aspects, and the differences found emphasize once again the nature of the MDRD 
formula: it is an estimate, and when abnormal, should lead to further analysis, not be 
taken to represent the true value. 
Clinically, such differences in the MDRD has consequences, since variability in SCr 
measurements affects SCr based prediction equations such as the MDRD 5. CKD 
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may result in misclassification of patients 4,18. The variations in CCR due to the huge 
differences in urinary measurement results are more bothersome from a clinical point of 
view. However, the differences found with the different techniques do force a rethinking 
of this assumption. Furthermore, further research should be initiated both to explain 
these differences and to redefine normal and abnormal ranges for CCR. Although in 
subjects with end-stage renal disease differences are definitely less bothersome, also in 
this group the lack of precision remains a focus of attention.
 
Conclusions
Jaffe and enzymatic assays measuring creatinine in urine are biased and imprecise, 
leading to the underestimation of the CCR. In plasma samples the unreliable nature 
of Jaffe measurements compared to a reference method (LCMS) was shown again, at 
least in the (near)normal ranges. Using an enzymatic technique, results show a more 
consistent pattern, and are grossly comparable to the results using LCMS. 
Based on the urinary results and its consequences for calculating CCR, those ranges 
need to be redefined as well. However, in our opinion, first more research should be 
focused trying to explain these differences in urinary measurements before advocating 
changes in ranges. Based on our study results, accepting such a switch would have as a 
consequence redefining normal ranges. 
As it is, normal ranges for PCr have been redefined already. Still, the differences in PCr 
outcomes also have consequences for the MDRD formula outcomes. Calculating an 
eGFR using an enzymatic technique will show slightly higher results in (near)normal 
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Chapter 6
Chronic kidney disease and mortality risk among 
older patients with type 2 diabetes mellitus 
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Background and objectives An impaired glomerular filtration rate (GFR) and albuminuria 
are associated with increased mortality in patients with type 2 diabetes. In spite of 
increasing numbers of elderly patients with type 2 diabetes, this association is sparsely 
investigated in this patient group. Therefore, we wanted to analyze the association 
between a decreased estimated GFR (eGFR), albuminuria and mortality in elderly 
patients with type 2 diabetes mellitus. 
Methods From 1998-1999, 810 patients with type 2 diabetes ≥ 65 years participated 
in this prospective observational study. Mortality data were collected in 2009. With 
Cox proportional hazard modelling the association between eGFR, albuminuria and 
mortality was investigated. Analyses were performed in age strata: 65-75 (n=471), >75 
(n=339) years. 
Results An eGFR <45 and 45-60 ml/min/1.73m2 is associated with increased 
cardiovascular mortality in patients of 65-75 years, hazard ratio (HR): 3.29 (1.58-6.86) 
and 1.78 (1.09-2.90), respectively; in those >75 years increased cardiovascular mortality 
was observed when eGFR was <45 ml/min/1.73m2: 2.42 (1.47-3.69). Compared with 
patients of 65-75 years, an eGFR >60 ml/min/1.73m2 and normo-albuminuria, fully 
adjusted HRs for cardiovascular mortality were 2.26 (1.04-4.92) and 4.86 (2.33-10.15) 
for those aged 65-75 years, an eGFR of 45-60 ml/min/1.73m2 and normo-albuminuria or 
albuminuria, respectively; HRs were 1.33 (0.67-2.66) and 2.01 (1.02-3.94), respectively 
for those >75 years.
Conclusions An eGFR of 45-60 ml/min/1.73m2 in type 2 diabetes patients was associated 
with increased mortality in subjects aged 65-75 years but not in those >75 years. 
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Introduction
Chronic kidney disease (CKD) is an independent risk factor for cardiovascular 
morbidity and mortality as well as all-cause mortality 1-3. As a consequence, there has 
been increasing focus on the prevention and early detection of CKD. 
Some of the present CKD guidelines recommend follow-up and treatment when the 
estimated glomerular filtration rate (eGFR) falls below 60 ml/min/1.73m2 4. However, 
a substantial part of the elderly population has an eGFR <60 ml/min/1.73m2. The 
clinical significance of moderate reductions of eGFR in elderly people is still debated 
5-7. Some argue that, in the absence of other abnormalities, an age-related decrease in 
eGFR is physiological; others state that a reduction in eGFR in individuals >65 years) 
may reflect the high prevalence of kidney disease risk factors at older age8. In spite of 
the uncertainties regarding clinical significance, follow-up of renal function is indicated, 
since older patients can also have an underlying renal disease or factors adding to the 
progression of kidney disease. 
The number of older people with type 2 diabetes mellitus (T2DM) is increasing thanks 
to earlier diagnosis and better survival. Therefore complications, such as diabetic 
nephropathy occur more frequently 9 and screening for kidney disease has become a 
cornerstone of diabetes care 10. However, the association between eGFR, albuminuria 
and mortality has been sparsely investigated in older diabetic patients 11. Moreover, 
classic cardiovascular risk factors seem to have a diminished effect when assessed in 
patients >75 years 12-13. Therefore, we aimed to investigate the association between 
eGFR, albuminuria and mortality in older patients with T2DM, stratified according to 
age (65-75 years and >75 years). 
Methods
In 1998, the Zwolle Outpatient Diabetes project Integrating Available Care (ZODIAC) 
study was initiated in the Zwolle region, the Netherlands. The design and details of 
this study have been presented elsewhere 14. Briefly, the ZODIAC study is part of a 
shared care project, in which general practitioners are assisted by hospital-based nurses 
specialised in their care of patients with T2DM. At baseline, patients being treated by 
a specialist of internal medicine (20%) or patients with a very short life expectancy 
(including patients with active cancer) or insufficient cognitive abilities as judged by the 
general practitioner, were excluded. Ultimately, general practitioners excluded 5% of the 
patients treated in primary care for T2DM. 
Approximately 90% (n=1357) agreed to participate; four patients were excluded because 
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complete information on all confounders (n=810). The ZODIAC study was approved by 
the medical ethics committee, and all patients provided informed consent. 
Data collection
Baseline data were collected from 1998-1999 and consisted of a full medical history 
including assessment of macrovascular complications, medication use, diabetes duration 
and tobacco consumption. Macrovascular complications were defined as a history of 
angina pectoris, myocardial infarction, percutaneous transluminal coronary angioplasty, 
coronary artery bypass grafting, stroke or transient ischaemic attack. Laboratory and 
physical assessment data were collected annually and included glycated haemoglobin 
(HbA1c), non-fasting lipid profile, plasma creatinine (a kinetic colorimetric Jaffé method 
was used (Modular P Analyzer, Roche Almere, the Netherlands), albumin-to-creatinine 
ratio (ACR, assessed in a spot morning urine sample using immunonephelometry 
(Behring Nephelometer; Mannheim, Germany)), blood pressure (measured twice with a 
Welch Allyn sphygmomanometer), bodyweight and height. 
Renal function was estimated by the Modification of Diet in Renal Disease equation 
(MDRD) [15]. MDRD was categorized into 3 classes: <45, 45-60 and ≥60 ml/min/1.73m2. 
Albuminuria was defined as an ACR ≥2.5 mg/mmol in men and ≥3.5 mg/mmol in women. 
The overall cohort (n=810) was divided into a low (65-75 years, n=471) and a high age 
group (>75 years, n=339). 
Clinical endpoints
Two clinical endpoints were examined: all-cause and cardiovascular mortality. In 2009, 
the vital status and cause of death were retrieved from records maintained by the hospital 
and general practitioners. 
Statistical analyses
SPSS version 16.0 (SAS Insitute, Cary, NC, USA) and STATA version 11.0 (Stata Corp., 
College Station, TX, USA) were used for statistical analyses. 
A Cox proportional hazard model was used to investigate the association between 
eGFR, ACR and mortality with adjustment for selected confounders. The associations 
were investigated for the eGFR as a categorical variable as well as a continuous variable 
(using baseline MDRD values) and for albuminuria as a categorical variable. Hazard 
ratios (HRs) for covariates were calculated for changes in eGFR of 10 ml/min/1.73m2.
The following possible confounders were selected: age, gender, smoking (dichotomous), 
body mass index, systolic blood pressure, history of macrovascular complications 
(dichotomous), diabetes duration, HbA1c, use of carbasalate calcium, use of lipid 
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the eGFR was added and albuminuria was removed as a confounder when the association 
between (normo)albuminuria and mortality was tested.
Three different models were analyzed: model 1 (crude), model 2 (including all selected 
confounders) and model 3 in which all selected confounders were used, except variables 
that were already used in the MDRD (sex and age). The latter model was performed to 
reduce the phenomenon of multicollinearity and to evaluate the influence of omitting 
these variables on the association between renal function predicted by the MDRD, and 
mortality.
Cox regression analyses were performed to investigate the association of albuminuria 
with all-cause and cardiovascular mortality; these analyses were repeated in eGFR 
categories ≤ and >60 ml/min/1.73m2 with and without albuminuria. Since stratification 
by the level of ACR may be warranted in terms of association with mortality, we tested 
the interaction between the MDRD (as continuous and as categorical variable) and the 
ACR.
For Kaplan-Meier curves eGFR baseline values were categorised into three different 
groups: <45, 45-60 and >60 ml/min/1.73m2.
Results
Baseline characteristics of the population are shown in table 1. Patients >75 years had an 
eGFR <60 ml/min/1.73m2 (n=213; 63%) and albuminuria (n=176; 52%) more frequently 
than patients aged 65-75 years (n=195, 41% and n=209, 44%, respectively). 
274 patients (81%) in the high age group and 170 patients (36%) in the low age group 
died after a follow-up time of 10 years. In 27 patients (3%) the cause of death was 
unknown, 19 patients were lost to follow-up. The proportion of deaths attributable to 
cardiovascular causes was 43% in the high age group and 42% in the low age group.
Renal function estimates and plasma creatinine
Tables 2 and 3 (for table 3, please see the table appendix 1 in the supplementary data on 
the journal website http://ageing.oxfordjournals.org) present the hazard ratios (HRs) for 
cardiovascular and all-cause mortality for eGFR categories and (normo)albuminuria. 
The MDRD as a continuous variable was associated with both increased all-cause as 
well as cardiovascular mortality in all models of both age groups. After adjusting for 
confounders, the cardiovascular mortality risk increased by 64% [95% confidence interval 
(95% CI): 33-96%] and 47% [95% CI: 25-75%] for every 10 ml/min/1.73m2 decrease in 
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65-75 years >75 years
Characteristic n=471 n=339
Age (years) 71 [68, 73] 79 [77, 83]
Men 192 (41%) 122 (36%)
Body mass index (kg/m2) 29 (5) 27 (4)
Systolic blood pressure (mmHg) 159 (24) 156 (25)
Diastolic blood pressure (mmHg) 84 (11) 81 (11)
Current smoking 66 (14%) 32 (9%)
Cholesterol-HDL ratio 5.2 (1.5) 4.9 (1.6)
HbA1c (mmol/mol) 58 57 
Macrovascular complications present 175 (37%) 150 (44%)
Receiving antihypertensive treatment 263 (53%) 234 (62%)
Receiving carbasalate calcium 65 (14%) 61 (18%)
Receiving lipid lowering treatment 61 (13%) 15 (4%)
Duration of diabetes mellitus type 2 (years) 6 [3, 12] 8 [4, 13]













Albuminuria present 209 (44%) 176 (52%)
Table 1. Baseline characteristics
Patients with an eGFR <45 ml/min/1.73m2 in the high age group, had an increased risk 
for all-cause and cardiovascular mortality compared with the reference category (>60 
ml/min/1.73m2). Such a relationship was not observed for eGFR values between 45 en 
60 ml/min/1.73m2. In contrast in patients aged 65-75 years, cardiovascular mortality risk 
was increased in patients with eGFR values between 45-60 ml/min/1.73m2. The HRs of 
model 1 and 2 for all-cause mortality in this age group were not significant for patients 
with an eGFR <60 ml/min/1.73m2. However, the results of model 3 show that the risk 
of all-cause mortality was increased for patients with an eGFR value below 60 ml/
min/1.73m2 compared with higher levels. Figure 1 and 2 show the association between 
eGFR and cardiovascular mortality and all-cause mortality, respectively, in both the low 
(A) and the high (B) age group. 
Albuminuria
In both age groups, albuminuria was associated with all-cause and cardiovascular 
mortality (tables 2 and 3). Compared with participants aged 65-75 years with an eGFR 
>60 ml/min/1.73m2 and normo-albuminuria, the fully adjusted HRs for cardiovascular 
mortality were 2.26 (95% CI 1.04-4.92) for impaired eGFR (45-60 ml/min/1.73m2) and 
normo-albuminuria, and 4.86 (95% CI 2.33-10.15) for those with an eGFR of 45-60 ml/
min/1.73m2 and albuminuria. For participants aged >75 years, HRs were 1.33 (0.67-
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No interaction between the MDRD and ACR was present for both age groups (MDRD 
categorical: p-value 0.085 and 0.575; MDRD continuous p-value 0.767 and 0.386 for 
patients aged 65-75 respectively >75 years).
Figure 1. Kaplan Meier curves showing the association between estimated glomerular filtration 
rate and cardiovascular mortality for patients aged 65-75 years (A) and patients aged >75 years 
(B).
Figure 2. Kaplan Meier curves showing the association between estimated glomerular filtration 
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Discussion
In this study renal function loss was related to both increased all-cause and cardiovascular 
mortality. In patients >75 years, increased all-cause and cardiovascular mortality was 
only observed when the eGFR was <45 ml/min/1.73m2, this in contrast to elderly 
patients aged 65-75 years in which an increased risk for cardiovascular mortality was 
observed when renal function estimates dropped below 60 ml/min/1.73m2. Albuminuria 
was independently associated with all-cause and cardiovascular mortality irrespective of 
eGFR in both age groups. The fact that in model 3 the risk of all-cause mortality was 
increased for patients with an eGFR value <60 ml/min/1.73m2 compared with higher 
levels, shows that multi-collinearity occurs when age and sex are, next to its presence in 
the MDRD formula, also used as a confounder (such as in model 2).
Thus, age seems to be an important effect modifier in CKD. A meta-analysis in general 
population cohorts showed independent and joint associations of albuminuria and 
eGFR <60 ml/min/1.73m2 on cardiovascular and all-cause mortality 16. However, the 
number of patients >70 years was relatively small and associations were not evaluated in 
separate age cohorts. Other studies investigating the consequences of a reduced eGFR 
in patients >75 years in the general population have shown that if  normoalbuminuric, 
mortality risk is only increased when eGFR is <45 ml/min/1.73m2  17-19. Moreover, older 
patients had higher rates of death and lower rates of end-stage renal disease than younger 
patients at comparable levels of eGFR 20. From a cross-sectional study in older people, 
it appeared that an eGFR <45 ml/min/1.73m2 mainly identifies a smaller sub-group of 
people >75 years with significant comorbidity, impaired functional state and a high risk 
of potentially reversible consequences (e.g. anaemia) 21. 
Most of the above mentioned studies contained only few diabetes patients or patients 
>75 years. A study among diabetic patients >65 years showed that albuminuria and an 
eGFR <60 ml/min/1.73m2 were independent risk factors for mortality 2. However, the 
observed relationship might have been largely attributable to the proportion of patients 
with an eGFR <45 ml/min/1.73m2. Our results show that even in normo-albuminuric 
patients with T2DM, >75 years, an eGFR of 45-60 ml/min/1.73m2 is not associated with 
an increased risk for cardiovascular and all-cause mortality, in contrast to those aged 
65-75 years. Our results are confirmed by a recent meta-analysis in normo-albuminuric 
patients at high risk for CKD (n=106690, 40% had diabetes), whose risk for all-cause 
mortality was increased at eGFR levels <60 ml/min/1.73m2 3. However, in subjects ≥65 
years, significance was reached at a lower level (<45 ml/min/1.73m2), as opposed to 
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The attenuation of the association of mortality with certain eGFR stages in older patients 
as we observed; was not found for albuminuria. This is confirmatory with previous 
studies. An independent association between proteinuria and mortality has been shown 
in patients with and without diabetes. In the HUNT II study, the presence of micro-
albuminuria or high-normal ACR ratios was associated with increased cardiovascular 
mortality below the threshold of 75 ml/min/1.73m2 compared with those with normo-
albuminuria 18. A more recent study found in a largely male cohort that the ACR in 
diabetes patients >65 years was independently associated with mortality at all levels of 
eGFR 11; an observation that is in agreement with our study. In contrast to our study, a 
large study in primary care, investigating the association between dipstick proteinuria, 
eGFR and mortality in patients aged >75 years, the presence of dipstick proteinuria did 
not add to cardiovascular mortality risk. This is remarkable since one would expect that 
especially when a dipstick is used, the risk of cardiovascular mortality would have been 
higher 19. Also another study in older individuals referring patients with CKD stage 4 
did not find a statistically significant association between level of proteinuria and risk 
of death; 33% was >75 years) 22. An explanation for the discrepancy in the two last 
mentioned studies and our study results has not been found. 
The absence of an association of moderate reduction in eGFR with mortality at older 
age may have been caused by the fact that the MDRD was not developed for use in 
older patients. Moreover, creatinine is a poor marker of renal function in these patients 
leading to inaccuracy 23-24. Secondly, older patients have higher background mortality 
and a higher prevalence of comorbidity 25. Finally moderate reductions in eGFR may 
reflect a physiological decline in renal function with advancing age 26-27. Since albuminuria 
reflects another pathway of kidney damage than eGFR, this may explain we found 
no attenuation of the association between albuminuria and increased cardiovascular 
mortality 28-29. 
Strengths and limitations
Our study has some methodological aspects that need discussion. Firstly, our study cohort 
is rather small, especially the group with an eGFR <45 ml/min/1.73m2. Therefore the 
results should be interpreted with caution. Due to the small numbers no differentiation 
in micro- and macroalbuminuria was made since the number of patients in the separate 
groups would become too small. Secondly, we have used uncalibrated plasma creatinine 
measurements. This might have induced systematic errors in eGFR values. Fortunately, 
all creatinine measurements were performed in the same laboratory, so interlaboratory 
variation was excluded. Selection bias may have occurred, since patients with a short 
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the MDRD has not been validated in patients >70 years. Strengths are the prospective 
nature, the possibility to take into account many possible confounders with few missing 
data, and the long follow-up. 
In conclusion, patients >75 years with T2DM and an eGFR of 45-60 ml/min/1.73m2 
are not at increased risk for all-cause and cardiovascular mortality compared with their 
counterparts with an eGFR >60 ml/min/1.73m2. In contrast albuminuria at all levels 
of eGFR is strongly associated with increased all-cause and cardiovascular mortality, 
and therefore may have potential as a more discriminative risk stratification tool in the 
large group of older patients with moderate reductions in eGFR (45-60 ml/min/1.73m2). 
In this study, as in most studies of CKD in older individuals, patients with moderate 
decrements of renal function account for a large proportion of the older population 
with CKD, which suggests that the current staging system, taking into account eGFR 
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Background and objectives To describe the consequences of using age-related cut-
off  values for renal function on the burden for primary and secondary care in the 
Netherlands, when following the Dutch national transmural agreement (LTA) for 
‘Chronic renal impairment’, rather than the ‘Kidney disease outcome quality initiative’ 
(K/DOQI) guidelines.
Methods In this observational cross-sectional study, patients whose serum creatinine was 
examined in 2009 were identified from the laboratory registry of the Isala Clinics in 
Zwolle, The Netherlands. The glomerular filtration rate (GFR) was estimated using the 
abbreviated Modification of Diet in Renal Disease (MDRD) equation. Burden of care 
was defined as the necessity for referral or consultation in secondary care. The number 
of people that would have been referred using the K/DOQI guideline that refers all those 
with an eGFR <60 ml/min/1.73m2, was compared with a situation using age-related cut-
off  values in the referral policy. 
Results The study population contained 82,424 people; 45.3% were men; age range 
was 19-106 years; 38.7% were >65 years. 19% of the population (n = 15,637) had an 
eGFR <60 ml/min/1.73m2 and would have been referred had the K/DOQI guidelines 
been applied; 11,935 of those 15,637 were >65 years. The use of the LTA for ‘Chronic 
renal impairment’, that includes age as one of the criteria, would have resulted in the 
referral of 3,303/15,637 patients (2,011 of those 3,303 were >65 years), and resulted in 
consultation with a nephrologist for 5,748/15,637 patients (3,338/5,748 were >65 years). 
The majority of patients aged >65 years and with an eGFR <60 ml/min/1.73m2 (55%) 
could be treated in primary care without consultation of secondary care or referral.
Conclusion The categorization applied by the current LTA for ‘Chronic renal 
impairment’, whereby age-related cut-off  values are used in the referral policy, will result 
in more targeted referral to secondary care, especially in the elderly patient group, when 
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Introduction
In 2002 the Kidney Disease Outcome Quality Initiative (K/DOQI) guidelines were 
introduced to uniformly define and classify chronic kidney disease (CKD), to recognize 
patients with CKD in an early stage, and to improve the prognosis of this patient group 1. 
In these guidelines CKD is devised in 5 stages (table 1). The classification in stage 1 and 
2 is, apart from the estimated glomerular filtration rate (eGFR), especially based on the 
presence of persisting (micro-) albuminuria or erythrocyturia of glomerular origin 1. 
From stage 3 onwards, the classification is solely based on the GFR, as estimated by the 
Modification of Diet in Renal Disease formula (MDRD) 2-3.
Stage eGFR
1 >90 ml/min/1.73m2 and persisting (micro-) albuminuria or persisting and specific 
sediment abnormalities (dysmorphous erythrocytes and / or cell cylinders). 
2 60-90 ml/min/1.73m2 and persisting (micro-) albuminuria or persisting and specific 




Tabel 1 Stages of chronic kidney disease according to ´the Kidney Disease Outcomes Quality 
Initiative (K/DOQI-guidelines). The glomerular filtration rate is estimated by the Modification of 
Diet in Renal Disease (MDRD) formula. 
According to the K/DOQI guidelines approximately 10% of the Dutch population has 
CKD, of whom approximately 60% has an eGFR <60 ml/min/1.73m2 4. If  the eGFR 
is <60 ml/min/1.73m2 these guidelines recommend additional research to an eventual 
underlying renal disease. Moreover, the cardiovascular risk profile has to be examined 
as well as the risk for further renal function deterioration 1. Therefore, in some countries 
this threshold is an indication for referral to a nephrologist.
In 2009 a national guideline for CKD (‘de Landelijke Transmurale Afspraak (LTA) 
chronische nierschade’) was introduced in the Netherlands 5. The LTA gives advices for 
the management and referral of patients diagnosed with renal function loss. For patients 
with proteinuria or erythrocyturia of glomerular origin, referral is advised irrespective 
of the eGFR. When proteinuria or erythrocyturia are absent and an eGFR <60 ml/
min/1.73m2 is found, age becomes an important factor in the decision process for further 
diagnostics and / or referral (table 2). For patients younger than 65 years, consultation 
or referral to a nephrologist is advised when the eGFR is <60 ml/min/1.73m2, for those 
older than 65 years consultation or referral is only advised when the eGFR is <45 ml/
min/1.73m2. This classification is based on the fact that renal function loss in elderly is 
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an eGFR <60 ml/min/1.73m2. The median eGFR for a healthy 70-79 year old man or 
woman is 79 and 72 ml/min/1.73m2; the 5th percentile is 54 respectively 52 ml/min/1.73m2 
6-9. Not using an age criterion, would mistakenly result in a larger percentage of elderly 
being referred to a nephrologic centre only on the basis of an eGFR, while the eGFR 
is appropriate for their age. However, one should keep in mind that also in elderly with 
a reduced eGFR an underlying renal disease or factors adding to the progression of 
kidney disease might be present. 
In this study the consequences of using age-related cut-off  values for renal function 
on the burden for primary and secondary care in the Netherlands, following the Dutch 
national transmural agreement (LTA) for ‘chronic renal impairment’, rather than the 
‘Kidney Disease Outcome Quality Initiative’ (K/DOQI) guidelines will be evaluated.
Age categories according to the ‘LTA chronische nierschade’
eGFR ≤65 jaar (n=50550) >65 jaar (n=31874)
<30 ml/min/1.73m² 549 (1.1%) 2011 (6.2%)
30-45 ml/min/1.73m² 743 (1.4%) 3338 (10.5%)
45-60 ml/min/1.73m² 2410 (4.8%) 6586 (20.7%)
>60 ml/min/1.73m² 46848 (92.7%) 19939 (62.6%)
 Referral to nephrologist  Consultation nephrologist   Follow-up primary care
Tabel 2. Implications of the ‘Landelijke Transmurale Afspraak (LTA) chronische nierschade’ on 
referral patterns from primary care to a nephrologic centre. For each of the age cateogories (≤ 65 
and >65 years) the number of people per eGFR category is presented. Different colours indicate 
which patients can be followed in primary care ( ), which patient group needs referral to a 
nephrologist ( ), and in which patient group consultation of a nephrologist will be sufficient ( ). 
Methods
Study design and study population 
In this retrospective observational cross-sectional study all serum creatinine data, 
that had been analyzed in the Isala clinics in 2009, were identified. Ultimately, serum 
creatinine data of 224455 patients (from primary and secondary care) were collected in 
a database. The adherence region of the Isala Clinics encompasses 130 general practices, 
taking care for a population of approximately 375000 patients. No personal information 
was added to the database for patient anonymity reasons. Therefore, we did not have any 
information on specific medical indications for measuring serum creatinine, the presence 
or absence of albuminuria and erythrocyturia, ethnicity, medical history and medication 
use. 
Data regarding the demography of Zwolle and its adherence region were withdrawn from 
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to provide inside in the frequency of renal function measurements in the different age 
categories of the study population. 
All subjects <18 years (n=5142) were excluded. When serum creatinine had been assessed 
more than once in the indicated period, the two most recent values were added to the 
database (n=34756). The definitive database contained data from 82424 patients. No 
permission was required from the Medical Ethics Committee as our data only included 
laboratory result information, as obtained from a laboratory database. 
Serum creatinine measurements and the MDRD
All serum creatinine measurements were measured enzymatically using a modular P 
Analzer (creatinine plus assay, Roche Diagnostics, Mannheim, Germany). The GFR was 
estimated using the MDRD: 175* (serum creatinine (µmol/L)/88.4)-1.154 * age (years)-0.203) 
* factor (factor=1 for men; factor = 0.742 for women) 2-3.
Statistical analysis
Analyses were performed using SPSS 16.0 (SPSS Inc., Chicago, IL). Data regarding age 
distribution in the adherence region of the Isala clinics were presented per age category 
of five year, for men and women separately. Consequently, the number of renal function 
measurements per age category was calculated. Since we did not have any information 
on albuminuria and haematuria, the number of patients with K/DOQI stage 3-5 was 
assessed. Subsequently, the study population was classified according to the categories 
as applied in the LTA: eGFR <30, 30-45, 45-60 and ≥60 ml/min/1.73m2. Moreover, the 
prevalence of patients with an eGFR <60 ml/min/1.73m2 was assessed. Ultimately, the 
number of patients categorized in each eGFR category and the number of patients that 
would be referred to a nephrologist, when the K/DOQI guidelines or the LTA guidelines 
were applied, was evaluated. Finally we studied the effect of repeated serum creatinine 
measurements on the need for referral to a nephrology ward. In patiens having an extra 
serum creatinine assessment after 2-12 weeks or after more than 3 months we assessed in 
how many patients still an indication for referral existed after this period. 
Results
Serum creatinine data of 82424 patients were used; 45.3% were men, 38.7% was >65 
years, age ranged from 19-106 years. 
Figure 1a and 1b show the frequency of renal function measurements per age category 
in Zwolle and its adherence region. These figures demonstrate that renal function 
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A
B
Figure 1 A en B. Population structure (bars with scale on left vertical axis) depicter per age category 
(horizontal axis) in Zwolle and the adherence area of the Isala Clinics in 2009; the number of renal 
function measurements (line chart with scale on right vertical axis) per age category. Figure A: men; 
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In figure 2 the prevalence of people with a renal function <30, 30-45, 45-59 and ≥60 ml/
min/1.73m2 per age cohort is shown. In the group of patients aged >65 years, the number 
of subjects with an eGFR <60 ml/min/1.73m2 is almost linearly increasing, from 22.2% 
in the group aged 65-70 years to 58% in the group older than 85 years. 
Figure 2. Bars ranging from dark-grey to light-grey, represent the prevalence of patients with an 
estimated glomerular filtration rate of <30, 30-45, 46-60 and >60 ml/min/1.73m2, respectively, 
depicted per age category.
The implications of using age-related cut-off  values for renal function (as proposed in 
the LTA guidelines) on referral patterns, is shown in table 2. When every patient having 
an eGFR <60 ml/min/1.73m2, would be referred to secondary care, 19% (n=15637) of 
the total study population would have been referred. When the LTA guidelines using 
age-related criteria would be applied, only 4% (n=3303) of the total study population 
would have been referred. This is a difference of 12334 patients. For 3% (n=2410) of 
the patients aged ≤65 years, consultation of a nephrologists could take place instead of 
referral. In the population >65 years with an eGFR <60 ml/min/1.73m2 83% (9924 of 
the 11935) is not referred any longer; for 6586 of these subjects follow-up can take place 
in primary after a screening (blood pressure, weight, specific laboratory measurements 
(see LTA guidelines) 4) and in the remaining 3338 people consultation or referral to 
secondary care would have been advised. 
In the group of patients in whom renal function was reassessed after 2-12 months 
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months, 15% respectively 18% did not need consultation or referral any longer after the 
second serum creatinine measurement. 
Discussion
We assessed the consequences of the application of age-related cut-off  values following 
the LTA guidelines rather than the K/DOQI guidelines on the burden for primary and 
secondary care in a patient population with potential renal impairment. Using age-
related thresholds, as is stated in the LTA guidelines, leads to more directed referrals from 
primary to secondary care. Moreover, repeated measurements will result in a reduction 
of referrals to secondary care of approximately 16%. Especially in the patient group 
older than 65 years the number of referrals to secondary care will increase but to a lesser 
extent. 55% of the patients with an eGFR <60 ml/min/1.73m2 could be followed-up in 
primary care, in 28% of the patients consultation of a nephrologist may occur and in 
17% of the patients referral to a nephrologist is indicated. Because of this the workload 
in primary care will increase. Irrespective of age, an eGFR <60 ml/min/1.73m2 implies 
that certain advices and measures have to be evaluated in these patients 4. 
When the K/DOQI guidelines were published, automatic reporting of the MDRD 
became routine practice, and an eGFR <60 ml/min/1.73m2 was considered to be 
pathological, the number of patients needing referral was expected to increase 10-11. This 
hypothesis was confirmed in a Canadian population, in which the number of referrals 
to a nephrology ward increased with 70% 12. It mainly concerned middle-aged people, 
women, patients with diabetes mellitus and patients with hypertension. 
Renal function loss and age
Implicitly related to whether or not we should apply age-related thresholds in the referral 
policy of patients with CKD is the question, whether renal function in elderly should 
be considered physiological or pathological. This remains a point at issue worldwide. 
Approximately 56% of the population older than 75 years has a MDRD of 30-60 ml/
min/1.73m2 13-14. The clinical relevance hereof is unclear. Population studies have shown 
that the relative risk for mortality associated with CKD is lower for elderly people 15-16. 
One study demonstrated how mortality risk attributable to CKD varied with age 17: an 
eGFR of 50-59 ml/min/1.73m2 in the patient group aged 18-54 years was associated with 
a higher mortality. However, in the elderly patient group (>65 years) an eGFR >50 ml/
min/1.73m2 was not associated with increased mortality (HR 1.02 [95% CI 0.99-1.05]). 
The absence of an association with mortality in the elderly patient group with a moderate 
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using the MDRD in elderly patients, since the MDRD has not been validated in the age 
category >70 years. Moreover, serum creatinine is not a good indicator of renal function 
in elderly 18-19. However, it could also be true that differences in relative risk for mortality 
and eGFR indeed exist between different age categories 15.
In a representative primary care population of patients older than 75 years it has been 
demonstrated that when renal function decreases there is a moderate independent 
increase in total and cardiovascular mortality, especially in men and subjects with an 
eGFR <45 ml/min/1.73m2. Therefore, the identification and treatment of CKD in elderly 
should focus on the select group of patients with a severely decreased renal function 
(<45 ml/min/1.73m2) 20. 
Risk appraisal in elderly
It will be complicated to determine an exact threshold for increased cardiovascular risk 
exclusively associated with a reduced eGFR 21. It is plausible that this threshold is lower 
for the elderly population. Perhaps, an eGFR is insufficient as measure of outcome to 
determine cardiovascular morbidity and mortality in elderly. Possibly albuminuria is 
needed as marker of damage. In several studies a strong association has been shown 
between the degree of albuminuria and mortality risk 22-23. Recently it has become 
clear that in elderly patients with diabetes the albumin/creatinine ratio is independently 
associated with mortality in all eGFR categories and can be a good handle for risk 
stratification in a large group of patients with moderate reductions of eGFR. To be able 
to make definitive conclusions, research in well defined cohorts is essential.
Strengths and weaknesses
This study is a reflection of daily clinical practice, in which renal function is often 
assessed in elderly patients. Moreover, by using a calibrated serum creatinine the chance 
of under- or overestimation of the number of subjects with renal function loss is reduced 
24-25.
Since patients included in this study were at risk for CKD, this study is not a reflection 
of the general population; the prevalence of CKD in the study population will be higher 
than in the general population 9,26. To give an illustration: 42-44% of the patients aged 
over 85 years in the NBS had an eGFR <60 ml/min/1.73m2, compared with 58% in our 
cohort. 
The GFR was estimated using the MDRD. The MDRD is developed in a population 
with renal disease. Moreover, the MDRD has a reduced individual precision, resulting 
in a systematic underestimation in GFR values >60 ml/min/1.73m2. Therefore, a part 
of the study population might have been categorized in the wrong category. However, 








































102  |  Chapter 7
representation of daily clinical practice. Finally, the prevalence of CKD in this 
population is underestimated, since data on albuminuria and erythrocyturia are lacking. 
Conclusion
The use of age-related thresholds in the referral policy of patients with CKD, may 
result in more targeted referrals to secondary care. At the moment, a good definition 
of pathologic or physiologic moderate renal impairment in the elderly patient group is 
lacking. Perhaps that albuminuria should be adapted as an extra marker in the definition 
of significant renal function loss at older age. Until then, nomograms should be used in 
the elderly individual to evaluate whether there is stable renal impairment or progressive 
deterioration of renal function loss compared with subjects of the same age and sex. 
Repeated MDRD measurements in accordance with the LTA guidelines are important 
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Optimising drug prescribing and dispensing in subjects 
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improving drug safety in primary health care 
by low eGFR alerts
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Background and objectives Iatrogenic injury due to medication errors is known as adverse 
drug events (ADEs). Renal impairment is a risk factor for ADEs. The aim of this study 
was to assess the risk of medication errors in subjects with renal impairment, defined 
as an estimated glomerular filtration rate (eGFR) ≤40 ml/min/1.73m2, in a primary 
care setting. Moreover, the effectiveness of generating automatic eGFR ≤40-alerts and 
medications reviews involving community pharmacists was evaluated. 
Methods 22 community pharmacists and 65 general practitioners participated in this 
clinical survey. The total number of ambulatory subjects with an eGFR ≤ 40-alert 
during the study period of one year, the number of medication errors related to renal 
impairment, the type and number of proposed drug adjustments recommended by the 
community pharmacist and acceptance rate by the prescribing physicians. Classification 
of all medication errors on their potential to cause an adverse drug event (ADE) and the 
actual occurrence of ADEs (limited to those identified through hospital record review) 
one year after the introduction of the alerts were measured.
Results Creatinine measurements were performed in 25929 adults. An eGFR ≤40-alert 
was indicated for 5.3% (n=1369). This group had a median [IQR] age of 78 [69,84] years, 
and in 73% polypharmacy (≥5 drugs) was present. In 15% (n=211) of these subjects, a 
medication error was detected. The proportion of errors increased with age. Pharmacists 
recommended 342 medication adjustments; mainly concerning diuretics (22%) and 
antibiotics (21%). The physicians’ acceptance rate was 66%. Of all the medication errors, 
88% were regarded as potential ADEs, with most classified as significant or serious. 
At follow-up, the ADE risk (n=40) appeared highest when the proposed medication 
adjustments were not implemented (38% versus 6%).
Conclusions The introduction of automatic eGFR-alerts identified a considerable 
number of subjects who are at risk for ADEs due to renal impairment in an ambulatory 
setting. The nationwide implementation of this simple protocol could identify many 
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Introduction
Safe medication management is an important health care topic, as medication errors are 
a significant source of iatrogenic injury to patients 1-7. Injuries resulting from such errors 
are known as adverse drug events (ADEs). Various factors are associated with ADEs, 
including patient characteristics, lack of medication monitoring, and prescription 
errors 4-6,8. Studies on medication related hospital admissions estimate that 21-91% of 
admissions were potentially preventable 1,6,9,10. Important patient determinants for ADEs 
are increasing age, female gender, polypharmacy, noncompliance and co-morbidities 
such as cognitive dysfunction or renal impairment 1-4,7,8,10. 
Renal impairment is a well-known risk factor for ADEs, but often remains unrecognized 
by physicians and pharmacists 11-14. Even in high-risk patients such as elderly and those 
with diabetes, health care workers are not always sufficiently alert 15-17. Various studies 
reported considerable dosing difficulties and subsequent medication errors in patients 
with renal impairment 10,12,17-19. Therefore, intensified collaboration between health 
care workers (such as general practitioners (GPs), pharmacists, and nephrologists) is 
recommended with exchange of relevant patient information (medical history and co-
morbidities) and more effective use of routinely collected data from electronic patient 
records such as laboratory results relating to renal function) 2,6,20-23.
In this 1-year observational study, we aimed to evaluate the number of subjects at risk for 
medication errors due to renal impairment (defined as an estimated glomerular filtration 
rate (eGFR) ≤40 ml/min/1.73m2) and the effectiveness of providing automatically 
generated eGFR ≤40-alerts towards community pharmacists in a shared pharmaceutical 
care model. In addition, we classified all medication errors for their potential to cause 
ADEs and evaluated the actual number of ADEs in those with a medication error after 
a period of one year.
Materials and methods
Setting 
This study was conducted in Zwolle, which is a city in the north of the Netherlands 
with a population of more than 89,000 adults 24. All of the primary care pharmacies 
(n=11) and the general practices (n=24) participated in this study. Their characteristics 
are shown in table 1. Dutch patients are generally registered at one single pharmacy 
and GP practice, which promotes continuity of care and reliable information regarding 
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Clinics, a 1000+ bed teaching-hospital in Zwolle. All standard laboratory investigations 
requested in both primary and secondary care are performed in one laboratory, which 
uses a single electronic system for data handling.
Characteristics Pharmacists GPs
Participants





























Number (%) 11 (100) 24 (100)







Overall number of patients, n 114033 117147
Practice size, median [IQR] 10.000 [7000, 14000] 3426 [2691, 6586]
Prescription system, n (%)
Computer-based 11 (100) 24 (100)
Table 1   . Characteristics of participating pharmacists and general practitioners (GPs), and their 
practices. IQR=Interquartile Range; GP=general practitioner.
Design and case-finding
This prospective observational study was conducted between February 1st 2009 and 
January 31st 2010. During this period, all consecutive adults in whom a serum creatinine 
was measured in the ambulatory setting who had an eGFR at or below the cut-off  point 
of 40 ml/min/1.73m2 were identified, irrespective of the reason for laboratory testing. 
This threshold was based on guidelines advising dosage adjustment in renal impairment 
25,26 and also chosen from a practical point of view. A higher cut-off-point of 50-60 ml/
min/1.73m2 was expected to exceed an acceptable workload, and the generation of many 
alarms induces the risk of ignoring and overriding alerts. Each week the laboratory 
automatically generated a report for any ambulatory patients with an eGFR ≤40 ml/









































Optimising drug prescribing in renal impairment  |  109
Study protocol
A predefined protocol was followed after the pharmacist received a report on an 
eGFR ≤40 ml/min/1.73m2 (figure 1). First, the patients’ pharmacist checked the actual 
medication regimen for current errors related to renal impairment. Numbers and types 
of errors were registered. Medication errors were based on Dutch Pharmacists guidelines 
including ‘the National Formulary on drug prescribing in renal impairment’ and the 
‘National Shared Care Guidelines on Chronic Kidney Disease (CKD)’ 25,26. Second, 
the pharmacist alerted the prescribing physician (GP or clinician) on the low eGFR 
and, if  appropriate, an adjusted medication regimen was recommended. Pharmacists 
contacted prescribing physicians by telephone or (if  unreachable) by email. Finally, an 
alert warning for a low eGFR (eGFR ≤40-alert) was activated in the patient’s pharmacy 
record. This eGFR ≤40-alert then appeared with every future new prescription. After 
this first laboratory notification, follow-up eGFR results were also reported to the 
pharmacists. When an eGFR recovered well beyond the cut-off  value during follow-up 
(specified as an eGFR >50 ml/min/1.73m2), the eGFR ≤40-alert was removed from the 
pharmacy record.
Defining Risk Factors Associated with Renal and Cognitive Dysfunction
Figure 1 Flow chart summarizing study method and selection of study population. * from both 
primary and secondary care; # from hospital records (January 2011).
eGFR=estimated glomerular filtration rate (ml/min/1.73m2); ADE=adverse drug event; 
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The study was approved by the local medical ethics committee and conducted in 
accordance with the guidelines of the Declaration of Helsinki. All pharmacists and GPs 
informed their patients about the study through flyers, issued both at the pharmacies 
and at the GP practices. The patient folder and the Isala Clinics website also contained 
information about the stepwise eGFR ≤40-alert protocol, the sharing of laboratory 
data, and medication monitoring. The study had an opt-out policy, therefore, subjects 
who did not wish to participate in this pharmacovigilance study were excluded from 
the weekly reporting. It should be emphasized that the final decision about making any 
medication changes after an alert (and informing the patient) was considered to be the 
responsibility of the prescribing physician. 
Definitions and calculations
Serum creatinine was measured with an enzymatic essay (Modular, Roche, Mannheim, 
Germany) and eGFR was calculated with the enzymatic MDRD formula 27. The only 
medications included were those prescribed by health care professionals, and topical or 
over the counter (OTC) products were excluded. Actual medication use was assessed 
by documenting all current prescriptions according to the Anatomical Therapeutic 
Chemical (ATC) classification system 28 at the moment of the first eGFR ≤40-alert. 
Polypharmacy was defined as the chronic (>1 year) use of 5 or more drugs.
Data collection
For all identified subjects with an eGFR ≤ 40-alert, demographics and medication 
information were collected. Any medication adjustment recommendations were 
recorded, which included the patient’s medical record number, the pharmacist, the type 
and daily dose of the medication, and the prescribing physician (GP or clinician). The 
physician’s response to the pharmacist’s recommendation was also recorded. Finally, the 
amount of time the pharmacists spent on every eGFR ≤40-alert was documented.
Classification and tracking of (potential) adverse drug events
To evaluate the impact of eGFR ≤40-alerts two pharmacists (EP and KB) independently 
evaluated all medication errors on the potential to cause an ADE (defined as a potential 
ADE (pADE)). They received a database that was anonymized by an investigator not 
involved in the eGFR-alert processing (HJ). A methodology developed for classification 
of medication errors and (p)ADEs.29 They judged and classified the theoretical severity 
of the medication error, yielding a score of 0-4 (0=drug error without significant 
harm, 1=potentially significant, 2=potentially serious, 3=potentially life threatening, 
4=potentially fatal) (table 2). To reach a consensus, all discrepant ratings were discussed 
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classifications are listed in table 2. The best assessment of the number of ADEs proved to 
be from the documentation on ADEs in the hospital records.30 Therefore, one year after 
the end of the study, the hospital records of all subjects in whom a medication error was 
detected, were reviewed. This review was performed by two nephrologists (HJ and HB) 
who independently checked the occurrence of ADEs. ADEs were based on admission 
and discharge diagnosis in the patients’ medical records. The relationship of the ADE 
with the ‘suspected’ agent was double checked by evaluating whether the medication 
regimen at admission in the hospital record matched with the pharmacy record at the 
date of admission. After review of the hospital records HJ and HB discussed their 
findings for reaching consensus.
Score Potential severity Examples
0 Drug error without 
potential harm
Not applicable
1 Significant -Gastro-intestinal complaints
-Therapeutically ineffective dose according to eGFR
-Mild neurological effects (e.g. motoric dysfunction)
-Hepatic dysfunction
-Any significant event identified by patient which does not 
require change in therapy
2 Serious -Hypoglycemia
-Nephrotoxicity or increased risk nephrolithiasis
-Electrolyte disturbances (e.g. hyperpotassiemia)
-Altered mental status due to sedation 
-Myopathy or rhabdomyolysis
-Gastrointestinal bleed
3 Life threatening -Lactic acidosis
-Cardiac arrhythmia
-Decline in mental status with risk of falling
-Respiratory failure requiring intubation (e.g. bronchospasms)
4 Fatal Death
Table 2. Categories of potential adverse drug events according to severity
Data analysis 
The main outcome measures were the incidence of eGFR ≤40-alerts, the number 
and types of medication errors, and the number and types of medication adjustment 
proposals. Secondary outcome measures were the time required for pharmacists to 
process the eGFR ≤40-alerts, the adherence of physicians to the proposed adjustments, 
risk factors for medication errors, and the severity of medication errors. In addition, 
after one year of follow-up, we checked the incidence of ADEs in subjects in whom a 
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16.0 (SPSS Inc., Chicago, IL, USA). Data are presented as mean and standard deviation 
(SD) when normally distributed. Otherwise, median and interquartile range [IQR] were 
used. For normally distributed data, the differences in baseline characteristics were 
evaluated with the independent samples t-test. For nonparametric data Mann-Whitney 
U test was used. Differences in distribution were calculated using the chi-square tests. 
Results 
Incidence of eGFR ≤40-alert and characteristics of the study population 
During the study period 46781 creatinine measurements were performed in 25,929 
subjects. In 5.3% (n=1369) of cases, an eGFR ≤40-alert was indicated. One patient 
indicated no willingness to participate for privacy reasons, leaving 1368 subjects for 
analysis (figure 1). Their characteristics are summarized in table 3. Overall, 56% was 
female, the median age was 78 [69,84] years (distribution is shown in figure 2) and the 
median eGFR was 34 [27,38] ml/min/1.73m2. Overall, polypharmacy was present in 73% 
(n=993) with a mean number of medications per patient of 7 (range 0-21). An overview 
of the actual medication use in the study population (which reflects comorbidities) 
according to the ATC classification is given in Appendix A. 
Variable
Number of subjects, n (%) 1368 (100)
Demographics







eGFR (ml/min/1.73m2), median [IQR] 
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2    Optimising drug prescribing and dispensing in subjects at risk for drug errors due to renal impairment:  
improving drug safety in primary healthcare by low eGFR alerts.
Figure 2 Age distribution of study population and risk of medication error per age category.
Number and type of medication errors 
Overall, 342 medication errors were detected in 211 patients with an eGFR ≤40-alert 
(15% of the study population) (figure 1). The proportion of errors increased with 
increasing age (figure 2). The types of medication most commonly associated with errors 
were diuretics (22%), antibiotics (21%), and anti-gout medications (15%) (figure 3).The 
majority of these medications (77%) were prescribed by GPs. An overview of the type of 
medication errors that were identified by the pharmacists is given in figure 4.
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2    Optimising drug prescribing and dispensing in subjects at risk for drug errors due to renal impairment:  
improving drug safety in primary healthcare by low eGFR alerts.
Figure 4 Type of medication errors identified by the pharmacists.
Physicians’ compliance with medication adjustment recommendations
Figure 5 gives an overview of the frequency and types of medication adjustment 
recommendations. The most common recommendations were ‘change dosage’ (55%), 
followed by ‘stop medication (24%). In 31% (n=105) the proposal concerned a new 
prescription. Physicians complied with the recommendation in 66% (n=226) of cases. In 
28% (n=96) of cases, the pharmacists’ advice was rejected and the medication regimen 
remained unchanged. The main reasons for rejection included already increased alertness 
with intensive monitoring by the prescribing physician (often being an internist or 
nephrologist) and an inadequate response to lower dosages in the past. The majority of 
rejected recommendations included diuretics and renin-angiotensin-aldosterone system 
(RAAS) blockers like ACE inhibitors and ARB drugs. In some cases, the recovery of 
renal function was expected or underestimation of renal function was presumed, both 
of which were generally checked with a 24-hour creatinine clearance. Overall, acutely 
reduced eGFR did not account for an important subset of the eGFR ≤40 alerts towards 
the community pharmacists (n=3). Notably, in 22 of the 96 cases, the medication was 
soon changed anyway, due to a further decrease in the eGFR or the occurrence of 
an ADE. Therefore, from the latter it seems plausible that with the eGFR ≤40-alert 
the physician’s awareness of the risk for an ADE was triggered. Data on rejection or 
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- 36 -
Defining Risk Factors Associated with Renal and Cognitive Dysfunction
Figure 5 Type and frequency of recommended medication adjustments by community pharmacists. 
Potential risk factors for medication errors in patients with eGFR≤40 alerts
Compared with the subjects without medication errors (n=1157), subjects for whom 
medication adjustments were recommended (n=211) were more often female (59% versus 
41%, p=0.04) and had a lower eGFR (median 34 [28,38] versus 29 [2,34] ml/min/1.73m2, 
p<0.001, respectively). Notably, the latter had higher rates of polypharmacy (70 versus 
89%, p<0.001, mean number of medications 6.6 (3.8) versus 8.2 (3.5), p<0.001). 
Effectiveness: potential ADEs and occurrence of ADEs after follow up
Overall, 88% (n=299) of the medication errors were regarded as relevant pADEs 
(score>0). These were mainly judged to be either significant or serious. An overview of 
the number and potential severity of pADEs in the study population is given in figure 1. 
Overall, 40 ADEs were identified in hospital records within one year after the study period 
in the group of subjects with medication errors, including two life-threatening ADEs 
(bradycardia due to digoxin intoxication and acute kidney injury with lactic acidosis 
associated with persistent metformin use). The number and severity of ADEs are shown 
in figure 1. Importantly, the ADE risk was higher in subjects whose medication regimen 
remained unchanged (n=60) as compared with subjects whose medication regimen was 
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Effectiveness: workload and time investment of the pharmacists
After receiving an eGFR ≤40-alert, the pharmacist needed an average of 11 minutes 
(range 5-13 minutes) to check an individual’s medication regimen for errors. When 
taking into account the time needed for consultation with the prescribing physician, 
pharmacists required an average of 20 minutes to process one eGFR ≤40-alert triggering 
a medication adjustment. All pharmacists judged the time investment as feasible, 
particularly considering the fact that each pharmacy received an average of only one 
alert per week. Retrospectively we evaluated the feasibility of different thresholds for 
kidney function alerts by calculating the number of low eGFR-alerts that would have 
been generated during the study period using different cut-offs for renal impairment 
(<30, <50 and <60 ml/min/1.73m2, respectively, see Appendix B). 
Overall, 904 eGFR ≤40-alerts were activated in the records of the participating 
pharmacies at the end of the study period, as 16% (n=214) of the population died and 
in 250 subjects, the most recent eGFR was at least twice >50 ml/min/1.73m2. Therefore, 
on average, every primary care pharmacy had 82 patients with an activated eGFR 
≤40-alert. If  we translate this to a standard Dutch GP practice (±2300 patients), simple 
laboratory data sharing identified approximately 23 patients per practice who need drug 
adjustment(s) or extra alertness in medication management. 
Discussion 
The main findings of this study were that an eGFR ≤40-alert was indicated in 5.3% 
of the adult population of a Dutch city in whom a creatinine measurement was 
performed in an ambulatory setting and that in these subjects 342 medication errors 
(mainly involving antibiotics and diuretics) were detected during the year following the 
introduction of an automatic eGFR ≤40-alert system. The majority of the medication 
errors was regarded as relevant pADEs, necessitating medication adjustments as 
recommended by pharmacists. Physicians complied in 66% of cases. ADE risk increases 
with age, polypharmacy, and in instances when the proposed medication adjustments 
were initially rejected. Overall, automatically generated low eGFR-alerts in primary care 
seemed effective, easy to implement, and, importantly, improve both the pharmacists’ 
and the physicians’ awareness of medication safety. 
Comparison with other studies
Despite the fact that medications are usually both prescribed and dispensed in the primary 
care setting, most studies on (p)ADEs have been hospital-based.3,9,10 We aimed to study 
the incidence of (p)ADEs in a shared pharmaceutical care model with a central role for 
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pharmacist drug proposal rates (0.7-1.9%) than the 15% we found.31-33 These studies 
were performed in a general population, while we selected a high-risk population of 
subjects with renal impairment. In line with our results, primary and ambulatory care 
studies evaluating pharmacists’ drug proposals in vulnerable subgroups like the elderly 
or subjects with cardiovascular risk factors also reported higher rates.12,17,34,35 Two recent 
studies, also concerning subjects with renal impairment, identified problems related to 
inappropriate prescribing in over 20% of patients.18,36
Patients with renal impairment are especially vulnerable to medication errors.12,13,18 
Various strategies to improve drug safety in these patients have been studied, such as 
educational wards rounds, immediate clinician-pharmacist feedback, or dose adjustment 
according to renal function at hospital discharge.12,18,37-42 However, despite the fact that 
most prescribing takes place in the primary health care setting, the majority of the 
strategies implemented so far have been tailored to hospital settings and are therefore not 
suitable for primary care. Others have demonstrated the effectiveness of ‘computerized 
physician order entry’ and ‘clinical decision support’ in reducing medication errors in 
case of renal impairment.39-41 However, computerized drug prescribing alerts do not 
always guarantee a reduction of prescribing errors,43 partly because such alerts are 
often overridden or ignored by prescribing physicians.41,44-46 This phenomenon is also 
reflected in our data, as in 28% of cases pharmacist recommendations were rejected by 
the prescribing physician.
A central role for community pharmacists in improving medication safety in primary 
care has been recognized. Many pharmacists are gradually extending their role as 
integral members of the medical team around the patient, thereby taking an important 
position in a shared care environment.21,47,48 This has not only been induced by legislative 
issues,21,25 but also recommended in various guidelines and studies to counteract problems 
associated with multiple medication prescribers.20,26,32,48 This is important in view of our 
ageing population in which complex drug therapy will only increase, polypharmacy 
is common and renal impairment widespread.49,50 A recent review showed notable 
differences in ADE prevalence rates by age groups increasing from 5% for adults up to 
16% for the elderly.7 Therefore, in complex cases (as with renal impairment) the close 
collaboration between community pharmacists and physicians is essential to prevent 
ADEs. 
The alert method we have investigated here could be a simple solution to address this. 
Our strategy included three steps to reduce medication errors in patients with renal 
impairment. First, automatic laboratory alerts were generated, second these alerts were 
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discussed recommended changes with physicians. Several studies investigated the impact 
of the above steps. The introduction of automatically generated laboratory alerts had 
varied effects on the prescribing physician.41,51,52 Authors suggested that such passive 
alerts did not have enough of an impact. There is limited data on the effect of extending 
the alerts so that the community pharmacist was also involved.. Other studies showed 
that when the pharmacy data were linked with the laboratory renal data, the medication 
dosage could be beneficially adjusted..12,42,53 We aimed to optimize medication safety 
in cases of renal impairment by combining the aforementioned steps and tailored our 
strategy for application in the primary care setting.
 
Implications for clinical practice
The estimated prevalence of both moderate (30-59 ml/min/1.73m2) and severe (15-29 ml/
min/1.73m2) renal insufficiency in the adult American and Dutch population is 4.5% and 
5.3% respectively.26,54 Therefore, the number of subjects potentially susceptible to related 
medication errors is substantial. If  we compile our pADE-rate towards nationwide 
figures (based on 12,500,000 adults in the Netherlands), our type of data sharing could 
intercept more than 40,000 potential ADEs related to renal impairment each year. 
This would undoubtedly increase health care safety with already available data and 
(hopefully) decrease the costs of ADE related morbidities. Drug safety management 
might be further improved by extending patient data exchange towards other important 
parameters, such as medication allergies, platelet counts, electrolyte concentrations, 
INR, liver enzymes, and plasma drug levels.
Strengths and weaknesses of the study
Some limitations of this study have to be noted. First, our study design does not 
allow determining individual health care effects, nor overall cost-benefits. This would 
necessitate a more complex study design as was for example used in the population-
based randomized controlled renal drug alert effectiveness trial of Bhardwaja et al., or a 
‘before and after’ design 36. However, participating GPs and pharmacists indicated that 
the protocol improved their awareness of medication errors related to renal function 
impairment. Second, data on the incidence of ADEs before start of the study project 
were not available in our region; therefore a possible change in ADE incidence as a 
result of our interventions cannot be determined. Besides, the incidence of ADEs is 
likely underestimated due to underreporting, missed recognition, and lack of recording 
in daily clinical practice. Our study also has several strengths. First, our intervention can 
be easily implemented in various health care settings. We simply extended the availability 
of laboratory renal data which were not shared formerly. Second, physicians valued the 
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of the pharmacists’ was fairly good (67%), as compared with previous studies (24-
82%)17,32,34,37,51 and our prescription ratio between GPs and hospital-based physicians 
(77:23%) reflects the normal distribution of prescriptions in the Netherlands (82:18%)55. 
However, to improve the overall efficiency of the eGFR-alerts, also variables influencing 
physicians’ (non-) adherence towards pharmacists’ recommendations (like type and 
duration of medication use) should be further studied. Third, the time investment was 
acceptable and costs were low. Finally, we chose for a safe, but also feasible threshold 
for renal function alerts. However, as thresholds for dosage adjustment vary between 
different guidelines, a higher cut-off  of ≤50 or 60 ml/min/1.73m2, or drug specific 
thresholds could be discussed.25,26,36,56 Besides, as the Cockcroft-Gault (CG) formula 
is often used in pharmacokinetic studies and for drug dosing recommendations, the 
implications of the use of renal function estimates like the MDRD equations for drug 
dosing, is under debate. Several studies have compared drug dosing recommendations 
based on the CG with those based on the MDRD57-59. In summary, the accuracy of the 
MDRD seems comparable to the CG 57-59. Based on these studies, in our opinion, the 
MDRD is a reasonable alternative to the CG for drug dosing. This is of importance 
especially since there is an increasing trend of clinical laboratories reporting the MDRD 
along with serum creatinine, which is also recommended by national and international 
organizations 26,60.
Some guidelines advise a higher cut-off  point for dose adjustments (creatinine clearance 
50-60 ml/min),11,61 but this was expected to result in an amount of alerts exceeding an 
acceptable workload. Moreover, as the MDRD tends to underestimate true GFR, we 
presumably already included subjects with true GFR >40 ml/min.62 
Conclusions and policy implications
The introduction of automatic renal function alerts in the ambulatory care setting, 
with the involvement of both GPs and community pharmacists, revealed that a 
considerable part of the population is at risk for ADEs due to impaired renal function. 
Extending the availability of renal laboratory data to community pharmacists resulted 
in their presenting the prescribing physicians with a considerable number of medication 
adjustment recommendations. We feel that nationwide implementation of this simple 
protocol could potentially identify many pADEs and substantially reduce the risks of 
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SUPPLEMENTAL DATA
ATC CLASSIFICATION Number (%)
A ALIMENTARY TRACT AND METABOLISM 1764 (19.1)
A01 STOMATOLOGICAL PREPARATIONS 4 
A02 DRUGS FOR ACID RELATED DISORDERS 556 
A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 27 
A04 ANTIEMETICS AND ANTINAUSEANTS 15 
A05 BILE AND LIVER THERAPY 7
A06 LAXATIVES 194 
A07 ANTIDIARRHEALS, ANTIINFLAMMATORY/ANTIINFECTIVE 30
A09 DIGESTIVES, INCL. ENZYMES 6
A10 DRUGS USED IN DIABETES 558
A11 VITAMINS 179
A12 MINERAL SUPPLEMENTS 185
A15 APPETITE STIMULANTS 1 
A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS 2 
B BLOOD AND BLOOD FORMING ORGANS 1107 (11.9)
B01 ANTITHROMBOTIC AGENTS 902
B02 ANTIHEMORRHAGICS 2
B03 ANTIANEMIC PREPARATIONS 203
C CARDIOVASCULAR SYSTEM 4064 (43.8)
C01 CARDIAC THERAPY 400 
C02 ANTIHYPERTENSIVES 28 
C03 DIURETICS 1145 
C04 PERIPHERAL VASODILATORS 1 
C07 BETA BLOCKING AGENTS 767 
C08 CALCIUM CHANNEL BLOCKERS 316 
C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM 830 
C10 LIPID MODIFYING AGENTS 577
D DERMATOLOGICALS 3 (0.03)
G GENITO URINARY SYSTEM AND SEX HORMONES 147 (1.6)
H SYSTEMIC HORMONAL PREPARATIONS 254 (2.8)
J ANTIINFECTIVES FOR SYSTEMIC USE 165 (1.9)
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 100 (1.0)
M MUSCULO-SKELETAL SYSTEM 312 (3.4)
N NERVOUS SYSTEM 846 (9.2)
P ANTIPARASITIC PRODUCTS, INSECTICIDES,REPELLENTS 6 (0.06)
R RESPIRATORY SYSTEM 417 (4.6)
S SENSORY ORGANS 6 (0.06)
V VARIOUS 36 (0.5)
OVERALL                                                                                                                            9227 (100)
Appendix A. Overview of drug use according to the Anatomic Therapeutical Chemical (ATC) 
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Chapter 9
Discussion, recommendations and future perspectives
eGFR threshold (ml/min/1.73m2 Number of patients Change in workload (%)
<30 647 -47% 
<40 (current study design) 1369 reference 
<50 2696 +196%
<60 5041 +368%
Appendix B    The calculated number of patients in the study setting and the change in amount of 
patients (workload) when applying different thresholds for eGFR-alerts.
Appendix C. Technical details of automatic laboratory alerts.
In the management database system of our laboratory the relationship and indexes of different 
types of data are embedded. We defined a query in this database to select our study population. 
This query included: test code (eGFR), ambulatory laboratory requests (excluding clinical eGFR 
data), and data were filtered on age ≥18, eGFR ≤45 and zip codes of the city of Zwolle. The 
query was run periodically (weekly). A module matching the patients’ unique Citizens Service 
Number (CSN) with the patient’s pharmacy code was developed for this project, which enabled us 
to address the eGFR-alerts to the right community pharmacy. The fact that in The Netherlands 
patients are generally registered at one single community pharmacy (en thus have a one personal 
pharmacy code) facilitates this method.
Chapter 9
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The studies in this thesis were aimed at assessing the degree of (un)reliability of the 
formulas that are most frequently used for estimating the glomerular filtration rate 
(GFR). Differences between formulas were evaluated, and the influence of variations in 
creatinine assays on the outcomes of these formulas as well as the creatinine clearance 
(CCR) were studied. Furthermore, the aim was to study the effect of using different 
formulas on clinical decision making and referral policy. Finally a new medication alert 
system warning to prevent medication errors in patients with CKD was evaluated.
The introduction and consequences of the use of formulas to estimate renal function
At first formulas estimating renal function were developed to reflect CCR, the best used 
of which was and is the Cockcroft Gault formula. When methods were developed to 
specifically and reliably measure the glomerular filtration rates (GFR), formulas were 
developed to estimate GFR as well. The role of both types of formula (estimating CCR 
and estimating GFR) in clinical decision making is still under discussion. 
One also has to consider the fact that the definition of renal function varies. When 
basing the conclusion of renal function only on serum creatinine, pitfalls are manifold. 
A 24-year old male bodybuilder and a frail old lady will have completely different renal 
functions, even when their serum creatinine will be the same, e.g. 100 µmol/L. 
When assessing renal function by measuring creatinine both in serum and in urine, one 
has to realize that creatinine is excreted both in the glomeruli and in the tubuli (and 
a small amount is lost in the gut), with a rather wide variation in tubular excretion 
(estimated at 10 to 40% of the amount excreted through the glomeruli).
When measuring GFR with tracer elements, results are translated towards a standardized 
body surface area of 1.73m², thus not representing the true GFR of the tested individual. 
This routine recalculation quite often results in a lower GFR outcome, since adults tend 
to have a higher BSA than 1.73m².
These differences have consequences, which add to the unreliability of the estimate 
formulas. When looking at renally cleared medication and indications and dosages 
adjusted according to renal function, there are quite some definitions of decreased renal 
function. In former times, cut-off  points were formulated in relation to serum creatinine, 
irrespective of the technique of creatinine measurements. In more recent years, eGFR 
has predominantly been used. since formal studies assessing circulating medication levels 
with varying dosages at different renal functions are relatively scarce, these estimates are 
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Attention points
Despite the ambition to see estimates as being reliable enough to reflect renal function, 
there still remain doubts 1. A major issue is that these formulas were often derived from 
information gathered in highly selected patient cohorts and nonetheless are applied in 
heterogeneous patient populations, quite often as a screening tool to gain an impression 
of the actual renal function, since serum creatinine as a separate entity knows its pitfalls 
as sole assessment of renal function.
Over time, different formulas to estimate GFR have been developed in different 
populations, the most important being: the modification of diet in renal disease formula 
(MDRD) and the chronic kidney disease epidemiology collaboration equation (CKD-
EPI) 2-3. The remodeling of especially the MDRD formula by its creators indicates, that 
these formulas apparently do perform reasonably well in a grid scale and for the total 
group, but are much less precise in estimating the GFR in an individual 4-5. 
Facts and fallacies in relation with a decreased renal function
The need to know a more exact renal function also in screening circumstances is driven by 
various reasons, explanations, and assumptions. In general, a decreased renal function, 
and especially renal function loss combined with proven renal damage, is associated by 
many with an increased risk of cardiovascular (CV) disease and end stage renal disease 
6-8. Furthermore, many medications are cleared through the kidney, and being unaware 
of the degree of renal function decrease may result in potentially major or even lethal 
side effects through overdosing 9-10.
As for the first point regarding the association with adverse CV and renal outcome, 
literature shows a definitely mixed picture. In younger persons with overt renal disease 
and renal function loss, this seems to hold true. Whether applying the same rules to 
elderly people with a decreased renal function but no signs of renal disease, is very 
doubtful 11-13. Other means to assess, assume or suspect renal disease are needed besides 
the information on renal function per se, whether measured by proven techniques or by 
estimation formulas. 
As for the second point (medication use), renal function assessment definitely is of major 
importance; especially in the elderly, as for drug dosing. It does not matter whether the 
impaired renal function is associated with decreased function with age or with renal 
damage by disease: countering medication dosing mistakes remains the predominant 
issue. 
When putting into a model the separate variables of the MDRD-4 formula, the 
combination of the separate variables actually leads to a better estimation of 
(cardiovascular) mortality, than the formula itself  14. Those factors are part of the 
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with an interest in nephrology: knowing age and sex, measuring serum creatinine, so one 
might question the need to use an estimation formula for other purposes than estimating 
renal function. 
Therefore, with all the second thoughts regarding the use of estimation formulas, the 
eGFR should always be seen as an alert signal, and an abnormal outcome should be 
seen in the light of the clinical observations with possible implications for the person, 
for whom the formula is used. One always needs to know whether there are (other) signs 
of renal damage, whether renal function is stable or not, and what the implications are, 
when a certain GFR estimate is used for clinical decision making. As an example: when 
in subjects with diabetes metformin is used as an oral glucose lowering drug and the 
eGFR falls below 30 ml/min/1.73m2, metformin will have to be discontinued as primary 
treatment according to current guidelines; this in turn might result to the need to start 
insulin, a major change in treatment with many practical consequences. Under such 
circumstances it would be worthwhile to actually measure a CCR in the old-fashioned 
way, and to use this information not only as leading in decision making regarding 
medication doses, but also as a reference when assessing renal function thereafter. 
When at a certain time point eGFR shows an outcome of 34 ml/min/1.73m2, but a CCR 
performed at the same time results in an outcome of 55 ml/min, this allows for the 
mental calculation of a correction factor, at least as long as renal function does not 
change too dramatically in time.
Renal function prediction equations
In chapter 2 and 3 of this thesis, the implications of using different eGFR equations on 
CKD staging were evaluated in a population of patients with diabetes mellitus. Chapter 
2 focused on the differences in performance of the MDRD and the CKD-EPI formula, 
as well as the consequences of their use on chronic kidney disease staging. Both the 
MDRD formula and the CKD-EPI formula were found to have a substantial bias and 
imprecision compared with the measured 24 hr CCR. The two scatterplots (see figures 
1a and 1b) illustrate the substantial variability between an eGFR calculated with a 
formula and CCR, both in patients with renal impairment as well as in patients with 
a ‘normal’ renal function. Unfortunately, due to the absence of mortality data in the 
cohort studied in chapter 2, it is unclear whether the patients who were down-/upstaged 
when using the CKD-EPI also had a higher or lower mortality risk, respectively. A 
large meta-analysis of data from general population cohorts showed that the CKD-EPI 
equation categorized the risk for mortality more accurate than the MDRD equation 15. 
However, we should remain reticent to embrace the CKD-EPI only because it produces 
better risk profiles, since some inherent limitations of the MDRD remain essentially 
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The fact that the CCR was used in chapter 2 makes the interpretation of these data 
complex. As already mentioned, the CCR is not a true reflection of GFR and measures 
both the glomerular function as well as the tubular secretion of creatinine, leading to an 
overestimate of 10-40% compared with the inulin clearance. Of course, the fact that the 
absolute difference between the measured GFR and the CCR in the population studied 
was unknown, complicated the interpretation of bias and accuracy. Although no firm 
conclusion can be drawn based on the results of chapter 2, it does raise questions about 
the role of the eGFR as a screening tool in clinical practice. The bias and imprecision of 
the MDRD has also been observed in studies that did have a measured GFR (mGFR). 
The accuracy of the MDRD in this study deteriorated with declining mGFR and thus 
led to misclassifications of chronic kidney disease. This makes the eGFR a tool with 
multiple limitations for diagnosing CKD in individuals 4. 
Figure 1a. shows the correlation between the CCR (ml/min) and the CKD-EPI (ml/min/1.73m2).
Figure 1b. shows the correlation between the CCR (ml/min) and the MDRD (ml/min/1.73m2).
Chapter 3 more specifically evaluated the impact of differences in body weight. 
Worldwide, the prevalence of obesity as well as the complications associated with 
obesity, such as diabetes, hypertension and renal function loss, are increasing 17-18. Also 
in patients with overweight and obesity, the use of renal function prediction equations 
led to interpretation difficulties due to bias 19. When compared with the CCR as a 
reference value, the CG turned out to be the best predictor of renal function compared 
with the MDRD and the CKD-EPI formulas. Our findings are in contrast with the 
conclusions of a large French study that evaluated the influence of body size on the 
predictive ability of eGFR equations. Froissart et al showed that the MDRD formula 
was less biased, more precise and more accurate than the CG formula in all patients 
20. Our and Froissart’s study differed in some important aspects: we have used CCR as 
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of GFR. Moreover, in our study the MDRD and CKD-EPI formulas calculated eGFR 
in ml/min/1.73m2, whereas CG and CCR were not BSA-corrected. In contrast, the 
French investigators have used BSA corrected values for all equations and the actual 
GFR measurement. We must acknowledge that our analysis was biased in favor of the 
CG formula. Indeed, when we adjusted the data of our patient cohort to the actual BSA 
of the participants, the performance of both the MDRD equation and the CKD-EPI 
equation improved. However, we question the use of an indexed CG, since weight is one 
of the clinical variables included in the CG equation. A correction for BSA will thus 
result in a double adjustment for weight. Such a double adjustment may influence the 
performance of the equation in this study. 
An important point to be stressed when using formulas to estimate renal function in 
a population with overweight is the correction for a standard BSA of 1.73m2, whereas 
the average Dutch adult has a body surface of approximately 2.1 m2. By definition, this 
means that in general an eGFR outcome will be lower than the actual renal function 
in the average adult. The correction for a standard BSA of 1.73m2 occurs both in the 
MDRD and the CKD-EPI, in spite of the fact that body mass indices (and thus the 
BSA) are increasing in most populations during the last decades 21. This also implies for 
example, that with a comparatively large BSA and calculating medication dosages based 
on GFR estimate formulas corrected for 1.73m², medication dose might be too low to be 
sufficiently effective in an individual. Therefore, from a clinical point of view, correcting 
eGFR for actual BSA could help to achieve more adequate medication dosages in quite 
a few patients.
It is still unclear which estimate is best to approach the real glomerular function in 
overweight and obese patients. All current formulas have substantial bias in this 
population. Future research should be performed to evaluate which technique to estimate 
renal function gives the best prediction regarding mortality, morbidity or progressive 
renal function loss.
So far, all formulas to estimate renal function have their specific limitations when 
estimating renal function. The fact that the reliability of renal function estimates in 
populations with different characteristics from the original study population poses 
restrictions with regard to their general applicability, was already acknowledged in the 
Kidney Disease Outcomes Quality Initiative guidelines 22. This has also been stressed 
in a cohort of patients with DM. This cross-sectional study of patients with normo- or 
microalbuminuria who had their renal function measured annually during 8 years by 
means of a iohexol plasma clearance showed that both the MDRD and the CKD-EPI 
did neither provide reliable estimates of GFR at baseline nor of the changes over time 
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as antihypertensive therapy, and the deterioration of GFR over time associated with 
renal disease progression) 5. 
Although the CKD-EPI was developed to overcome the problem of imprecision and 
systematic underestimation of the MDRD in patients with normal to high normal serum 
creatinine (SCr) levels, our study indicated that the MDRD and CKD-EPI formulas 
proved to be equally imprecise in estimating the GFR in patients with diabetes or obesity, 
a fact which has also been stressed in literature previously 5,23-25. Therefore, changing 
from one equation to the other will not result in a clinically relevant improvement of the 
reliability of the estimate for an individual subject. 
Evaluating the results of the performance of renal function prediction equations in this 
thesis as well the plethora of literature discussing this subject, one may conclude that 
it is and will be very hard to create a renal function prediction equation that functions 
accurately, and – thus – reliably, in any patient population with all differences in race, 
sex, age, posture, and renal function. 
Kidney function and ageing
Although there are still many uncertainties regarding the use of renal function prediction 
equations in clinical practice, most clinical laboratories report an eGFR every time SCr is 
measured. Often these reported eGFR values are seen as reliable outcome measures to be 
accepted at face value, although they should rather be interpreted as a signal for further 
thought and - when indicated - action. The obligation of clinical chemistry laboratories 
to report an eGFR every time SCr is assessed, may be interpreted as a disguised screening 
tool for CKD 1,26. Although the ambition to identify renal function loss in an early stage 
is valuable, a substantial number of patients will be erroneously classified as having a 
disease, needing additional diagnostics. In the end, an early identification of a disease 
is only meaningful when adequate treatment or early intervention elicited by this early 
identification results in lower morbidity and mortality rates or a reduced risk for the 
development of ESRD or other complications related to renal function loss 1. 
In this respect, an important group of patients to be mentioned is the large group of 
elderly individuals, since a substantial part of individuals with stage 3 CKD (eGFR 
30-60 ml/min/1.73m2) is older than 65 years 27. It is subject to debate whether this 
population is at increased risk to progress to a higher CKD stage, in the absence of other 
features of kidney damage (especially the presence of albuminuria). As is shown in this 
thesis in chapter 6, the oldest elderly population (>75 years) with type 2 diabetes mellitus 
seems to be one of the target populations that will be erroneously classified as having a 
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the moderate reductions in eGFR observed in that population were not associated with 
an increased (cardiovascular) mortality risk, this in contrast to the population aged 65-
75 years. In contrast, albuminuria irrespective of eGFR proved to be an independent 
marker of mortality in both the group aged 65-75 years as well as those older than 75 
years. 
Studies analyzing mortality risk of CKD according to a measured GFR level do not 
exist. Using an eGFR may be considered as a limitation since creatinine based equations 
lack precision around the value of 60 ml/min/1.73m2. However, the aforementioned 
attenuation of the association between mortality and eGFR in elderly that was found in 
this thesis confirms the findings of previous studies 11-12,28-30. Also, data as presented by the 
Chronic Kidney Disease Consortium, including more than 2 million participants from 
46 different cohorts (both general and high-risk cohorts) with a follow-up time of 5.8 
years, show the same attenuation of the association. In this cohort 7.3% was older than 
75 years. There was a significant age interaction; mortality risk always started to increase 
in the eGFR range 60-75 ml/min/1.73m2. However, in those aged 75 years or older it 
reached statistical significance at an eGFR of 56 ml/min/1.73m2 or lower (HR 1.35 [95% 
CI 1.23-1.48]) 11. Although significance is reached, the relevance is questionable; isn’t it 
biological age we are looking at and isn’t it time to start using age related cut-off  values 
(such as in the LTA) in international guidelines or even better gender as well as age-
related thresholds?  
Although causality cannot be proven from the observational study such as performed 
in this thesis, the results of this study do raise questions about the need for referral to 
specialist nephrological care of the (oldest) elderly patient population with a modest 
decrease in renal function. Prospective studies are needed in order to be able to make 
valid recommendations both for valid cut-off  points, for additional discriminating 
diagnostics, and – in case of true and clinically significant renal function loss - appropriate 
treatment in elderly patients. 
The ageing kidney and referral mechanisms in elderly
Another argument supporting other referral criteria for the elderly population is the 
biological variability in GFR 21,31-33. As was observed in the Nijmegen Biomedical Study, 
eGFR decreases with age 31,33. Also in a study of Poggio et al, evaluating GFR reference 
values, it was shown in a population of 1057 living kidney donors whose renal function 
was measured using 125I-Iothalamate, that the 5th percentile at 60 years was 64 and 60 
ml/min/1.73m2 for men and women respectively. GFR decreased 8 ml/min/1.73m2 per 10 
years. From this results one may expect the value of the 5th percentile in healthy subjects 
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Ignoring this age-related decrease, without taking into account other markers of kidney 
damage (such as albuminuria) will lead to an astronomically high number of patients 
that would need to be referred to a nephrologist based on an eGFR value <60 ml/
min/1.73m2 (as suggested in the K/DOQI guidelines), as is demonstrated in this thesis 
in chapter 7. In an observational cross-sectional study of 82424 patients, the impact of 
the introduction of age-related cut-off  values for estimated glomerular filtration rate 
(eGFR) on consultation and referral patterns from primary care to nephrologists were 
analyzed. 19% (n=15637) of this population had an eGFR <60 ml/min/1.73m2. If  age 
related cut-off  values would have been used, 3303 patients would have been referred, 
and for 5748 patients the nephrologist would have been consulted. For the majority of 
patients (55%) follow-up could take place in primary care. Using age-related thresholds, 
as is advocated in the LTA guidelines, will lead to more relevant and focused referrals 
from primary to secondary care, resulting in the referral of only the selection of patients 
with complex renal problems or those that need nephrological care in a predialysis phase. 
Of course, using the MDRD formula in chapter 7, which has not been validated in 
an elderly population, this may have introduced some misclassifications. However, also 
in clinical practice decisions are frequently made based on this eGFR in the elderly 
population. The fact that the Dutch national transmural agreement (LTA) for ‘Chronic 
renal impairment’ applies age-related cut-off  values, is a first step in a more differentiated 
approach of the elderly patient with eGFR loss 35. An additional step in the approach of 
the elderly patient could be the addition of albuminuria as a risk stratification marker 
in classification schemes, in order to identify those elderly patients with a reduced 
eGFR having clinically relevant CKD (see also the addendum). After all, the impact of 
proteinuria on cardiovascular morbidity and mortality risk has been largely confirmed 
by data from previous trials and could therefore be a good differentiator for risk 
stratification in the rather large group of patients with moderate reductions of eGFR 
6,8,29,36.
Creatinine
Creatinine is by far the most frequently used measure to assess renal function. However, 
there are many limitations related to using creatinine as a marker of renal function: 
variations in the production, variations in the (tubular) secretion, the variability between 
the techniques to measure creatinine, as well as the presence of exogenous creatinine 
sources (see table introduction) 37-38. All these variables may have an effect on serum 
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The method of creatinine measurement is rather important, since its accuracy to 
reflect true creatinine concentrations will have impact on the accuracy of all renal 
function estimating equations. Rather small differences in creatinine measurements 
have substantial influence on the estimated glomerular filtration rate (eGFR) 39-42. 
Since significant interlaboratory variations in creatinine measurements were observed 
worldwide, it was internationally confirmed that calibration traceability to higher-order 
reference methods was needed to realize comparable biochemical measurement results. 
Since the development of NIST SRM 967 in 2006, in vitro diagnostic manufacturers 
of creatinine assays in Europe are legally obliged to make their products traceable, 
regardless of the method applied 43-47. 
Improving the accuracy of SCr measurements (both Jaffe and enzymatic) as included 
in the various equations estimating the GFR should be seen as imperative in order to 
diminish at least the impact of the variability of this factor, when striving to improve 
the reliability of the formulas to estimate GFR. However, a study from 2008 showed 
that despite the European IVD directive, an unacceptable inter-laboratory variation 
was observed, which was mainly due to calibration differences. Especially the between 
laboratory variation of Jaffe-based methods did not decrease, notwithstanding the 
interventions made 44.
In chapter 4 of this thesis the implications of the variability in SCr measurements (using a 
Jaffe or an enzymatic technique) between laboratories after this global restandardization 
was evaluated in a theoretical model as well as the impact thereof on the MDRD and 
CKD staging in the Netherlands. It was reconfirmed that especially the Jaffe method is 
inaccurate with a high non-specificity bias, which most probably occurs as a result of 
analytical interferences of field methods by plasma proteins. Although the enzymatic 
technique to measure serum creatinine has interference with various substances as well 
(see table introduction), the specificity remains better than the specificity of the Jaffe 
method 48. This finding is supported by data from a multicentre study evaluating IDMS-
traceable enzymatic creatinine assays 49. The high non-specificity of especially the Jaffe 
method results in inaccurate estimates of the GFR when using equations, with the most 
important clinically relevant impact when patients are inaccurately downgraded to a 
more severe CKD category. Applying an enzymatic technique on the other hand, more 
often resulted in change to a less severe CKD stage, which is less relevant in routine 
clinical practice than downgrading to a more severe CKD stage, although undeserved 
staging to a less severe CKD stage also may have consequences. 
It has also been shown in other studies that due to plasma pseudo-creatinine chromogens 
true SCr concentrations are overestimated, even when an eventual calibration error is 
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inaccurate and less precise than enzymatic assays. Enzymatic techniques measure SCr 
with substantially less variability than Jaffe techniques as compared with IDMS reference 
values. This leads to more reliable estimation of GFR and CKD staging. Therefore, it 
can only be concluded that to improve reliability of renal function estimates, using the 
Jaffe assays to measure creatinine in clinical practice should be discarded and replaced 
by the enzymatic technique.
In chapter 5 the variability in creatinine measurements using a Jaffe, an enzymatic and 
an LCMS assay in urine are evaluated, as well as the implications thereof on the CCR. 
Quite remarkably, an unexpected and inexplicable tendency of the Jaffe assay towards 
lower results in urinary measurement was found. Although the enzymatic assay showed 
a more consistent pattern compared with the Jaffe method, the reliability of the urinary 
measurements appeared not optimal with the use of an enzymatic technique as well. 
Since the CCR has an important role when other renal function estimates either show 
a questionable result or need confirmation, in pre-dialysis, to assess the adequacy of 
hemo- and peritoneal dialysis, and to examine the urinary excretion of biomarkers to 
correct for sampling errors. These differences in urinary measurements are bothersome. 
Further research should take place to explain these differences; furthermore, redefining 
the normal and abnormal ranges for CCR could be the consequence of the presented 
findings. 
Cystatin C
Since creatinine based equations suffer from the limitations associated with using 
serum creatinine as a marker of renal function, an alternative biomarker cystatin C 
has been introduced. Cystatin C is less sensitive for differences in muscle mass or diet. 
Formulas estimating GFR based on cystatin C have shown variable results regarding 
their accuracy in GFR estimation in different populations 51-54. Since a standardized 
calibration has become available for cystatin C, a new GFR prediction equation has 
been introduced, combining serum creatinine and cystatin C: the CKD-EPI mix 54-57. 
Whether measurement of cystatin C levels and incorporating this information in the 
eGFR formula will improve patient care is still unknown, and not studied for this thesis. 
Further studies in more specific patient groups have to follow in order to determine the 
position of this new biomarker. 
Medication safety
A theme inextricably related to renal function is medication safety. Renal function loss 
often alters the pharmacokinetics of medication and therefore makes patients prone for 









































Discussion  |  137
inadequate, and more vulnerable to adverse drug events 9-10,58-59. The results presented 
in chapter 8, showed that the use of GFR estimates in clinical practice may be used as 
a tool to select high-risk populations in order to optimize patient safety. Moreover, it 
illustrates that the number of subjects at increased risk for adverse drug events (ADEs) 
due to renal impairment is substantial 60. The elderly population, whose renal function 
is often impaired and whose constituents often are on 5 or more different medications 
(polypharmacy), especially benefited from this intervention. By means of a relatively 
simple intervention, the issuance of eGFR alerts, community pharmacists were able 
to provide valuable medication adjustment recommendations to prescribing physicians. 
The implementation of this simple protocol nationwide in the Netherlands might 
possibly lead to the early recognition of more than 40,000 potential ADEs because of 
renal function loss annually. This probably will lead to a (cost) reduction of morbidities 
caused by ADE as well as increase health care safety. 
In our ageing population in which polypharmacy and renal impairment are common, 
there are strong arguments to promote more effective use of patients records such as 
renal function data between health care workers (general practitioners, nephrologists 
and pharmacists) in order to allow monitoring of safe drug therapy 22,61-64. This is also 
recommended in different guidelines and studies to counteract problems created by 
multiple drug prescribers. As GP’s are key players in drug therapy (accounting for over 
80% of drug prescriptions in the Netherlands), links on information with regard to renal 
function between community pharmacists and GPs supported by proper and accorded 
protocols are essential to reduce or even prevent drug errors.
One must conclude that despite the efforts over the last 15 year, the accuracy of the 
eGFR formulas for the individual remains an issue. It is doubtful that a more precise 
formula will be developed soon, at least when based on easily available personalized 
information.
The outcome of the formula calculation should therefore be considered an indicator, not 
as a true value. An abnormal value (maybe sometimes even a normal value) should only 
be seen as the starting point for further clinical thinking and assessment, and not as an 
infallible guide. Especially in elderly people, moderate renal function decrease without 
signs of renal damage and within the range of their age, should be seen as part and parcel 
of their life and age, and conveys to us a completely different message than in younger 
people. Insufficiently treating possible risk factors for CV disease and progression of 
renal damage is one thing, but treating a substantial part of the general population 
undeservedly just because of an estimate not interpreted within a well defined context is 
another. “Prevent or slow down harm and disease” has always to be weighed against “do 
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Conclusions
•	 To date, all measures that are available to estimate renal function in daily practice 
are extremely inaccurate. 
•	 The CKD-EPI formula that was developed to overcome the problem of imprecision 
and underestimation of GFR in patients with normal to high SCr levels by the 
MDRD, was shown to be as imprecise as the MDRD in estimating renal function 
in a cohort of patients with diabetes mellitus and a preserved renal function. 
•	 In an overweight and obese population, the CG formula surprisingly seemed 
to be the best predictor of renal function when compared with the MDRD and 
the CKD-EPI. When making clinical decisions, limitations of renal function 
prediction equations should always be kept in mind. 
•	 An eGFR of 45-60 ml/min/1.73m2 in patients with diabetes mellitus type 2 is 
associated with increased mortality in patients aged 65-75 years, but not in those 
>75 years. Albuminuria is associated with increased mortality in all patients >65 
years. Mortality risk related to renal function thus varies with age. Therefore, the 
age related cut-off  values as applied in the Dutch ‘Landelijke Transmurale afspraak 
chronische nierschade’, will aid to prevent unnecessary referral to secondary care, 
especially of elderly patients with moderate renal function loss. Moreover, we 
suggest albuminuria to be added as a marker of renal damage in order to identify 
elderly people with relevant renal function loss and – thus - CKD. 
•	 Accurate and precise measurements of SCr are required to improve the reliability 
of the eGFR formulas as support for reliable clinical decision making. Enzymatic 
techniques measure SCr with substantially less variability than Jaffe techniques 
as compared with IDMS reference values. This leads to less unreliable estimation 
of GFR and CKD staging. To allow improvement of reliability of eGFR, 
specific enzymatic techniques to measure SCr are preferable over unspecific Jaffe 
techniques. 
•	 Both the Jaffe and the enzymatic assay provide biased results for urine creatinine, 
leading to an underestimation of the CCR. More research should be focused 
trying to explain these differences in urinary measurements before advocating 
changes in ranges. 
•	 Extending the availability of renal function data towards community pharmacists 
can be an effective intervention to improve drug safety. An intensified collaboration 
between community pharmacists and prescribing physicians resulted in a 
considerable amount of drug adjustments aiming to maximize therapeutic efficacy 
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Recommendations and future perspectives
In this thesis the pitfalls of using creatinine based renal function estimating equations 
are sketched. Based on the conclusions of this thesis the following recommendations 
can be made:
1. It should be severely questioned whether serum creatinine-based equations 
estimating glomerular function should be used as the only tool to identify and 
monitor progression of renal function (loss), especially in patients at risk for 
renal function loss, such as patients with diabetes mellitus. A better performing 
and more reliable formula is needed in this population. Whether cystatin-based 
equations could be used, should be further investigated in future research. Until 
that time one should be very well aware that the GFR is estimated by these 
formulas, and – thus – an abnormal result should be the trigger for further 
analysis, not be considered a reliable outcome to be accepted at face value. 
In the meantime we should consider whether we should not stop estimating the 
GFR by means of formulas and start measuring GFR by appropriate techniques 
such as iohexol or look for other exogenous biomarkers of glomerular filtration 
that are purely filtered by the glomerulus, at least in those subjects suspected of 
a decrease in renal function or progressive renal function loss. 
2. Once a decreased renal function is found, the outcomes should be interpreted in 
the light of the personal characteristics and diet of the patient and one should 
keep in mind the many flaws of these formulas. A 24-hour CCR should be 
considered when an abnormal eGFR is found. 
3. Especially in patients with over- or underweight, but also in non-obese 
populations, indexation of GFR for BSA may induce relevant differences. 
When the (estimated) GFR is used for clinical decision making (drug dosing 
etc.) as well as in the follow-up of renal function, a measured GFR would be 
preferable in these patient categories. Future research should occur in a large 
cohort of healthy adults with a wide range of body sizes in order to determine 
whether BSA indexation should be abandoned or can be maintained. 
4. Accurate and precise measurements of creatinine are required for a reliable 
estimation of GFR as support for clinical decision making. Enzymatic 
techniques measure serum creatinine with substantially less variability than Jaffe 
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the Netherlands (and preferably worldwide) should abandon the Jaffe assay to 
measure creatinine. Creatinine measurements in urine remain a point of concern. 
Before proposing a redefinition of the normal ranges regarding the CCR, more 
research should be done to explain the differences in urinary measurements. 
5. As long as it is unclear when renal function loss in elderly patients is significant, 
every time a moderately decreased renal function is found in patients >65 years, 
we should evaluate whether there is a stable moderately decreased renal function 
or progressive loss of renal function, by comparing them to eGFR values of 
peers of the same age and sex. Furthermore, other indices pointing towards 
possible damage should be considered, such as the presence of persistent (micro)
albuminuria. 
6. The differentiation of the LTA in age related cut-off  values has been a first step 
to prevent excessive referral rates of elderly people with moderate renal function 
loss to a nephrologist. Even better would be a situation in which laboratories 
present every time a serum creatinine is measured and an eGFR is calculated in 
patients >65 year, the median eGFR value (with 5th and 95th percentile) based on 
the nomograms like those of the Nijmegen biomedical study. Further research 
should focus on a method to better identify patients who are at greatest risk 
of CKD that without intervention would progress to end stage / symptomatic 
renal disease. 
7. Increased collaboration with community pharmacists improves health care 
safety and awareness of medication errors related to renal function impairment 
in primary care, thereby substantially reducing iatrogenic complications in 
subjects with impaired renal function. Extending the availability of laboratory 
renal data which were not formerly shared is relatively straightforward with 
minimal expense. Therefore, the nationwide implementation of this relative 
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A clear definition and classification system, to raise awareness for chronic kidney 
disease (CKD) and to recognize CKD adequately worldwide, was developed in 2002; 
the so-called Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines. The 
(estimated) glomerular filtration rate ((e)GFR) and the presence of albuminuria / 
proteinuria became the two most important components of this classification scheme. 
Care pathways for patients with various CKD stages have been developed. Since these 
pathways also involve assessment and (sometimes major) treatment decisions, a proper 
estimation of GFR is pivotal for good patient care. 
Currently, various equations estimating the GFR are used. Before the introduction 
of these equations, the serum creatinine concentration (SCr) was used as an estimate 
of renal function in clinical practice. However, a major drawback of using SCr as an 
estimate of the GFR, is the hyperbolic relation between SCr and GFR. In research 
settings the inulin clearance (which is considered to be the gold standard) and other 
isotopic methods are frequently used to measure the GFR. However, these methods are 
cumbersome and costly, and therefore not applicable in daily practice. Less costly and 
complex is the 24-hour creatinine clearance (CCR), which for its accuracy is dependent 
on the accuracy of the 24-hour urine collection. In principle, CCR will be higher than 
GFR, since, in general, creatinine will also be secreted at a tubular level besides the 
glomerular loss.
As already mentioned before, several renal function prediction equations have been 
developed over time: the Cockcroft-Gault equation (CG; 1976), and the more recently 
developed Modification of Diet in Renal Disease equation (MDRD; 1999), the 
Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI; 2009). All 
these GFR prediction equations contain SCr as a variable. Therefore, using accurate 
SCr measurements is essential, since systematic errors cause unreliable renal function 
estimates leading to incorrect drug dose adjustments, misclassifications in CKD staging 
and incomparability of patient data. 
Apart from the variability in creatinine measurements, there are still many open ends 
when using eGFR estimating equations in daily (clinical) practice; the use of the equations 
may give biased results when used in populations that differ from the population these 
equations originally were developed in. Moreover, we need more insight in the differences 
between the various equations, the use of threshold values of eGFR in relation to age, 
the implications of variations in creatinine assays on the predictions equations, and the 
role of eGFR on pharmacovigilance. 
This thesis focused on the different aspects of the various equations estimating renal 
function. First: the performance of the two currently most frequently used equations 
estimating the glomerular filtration rate (GFR) and the impact thereof on chronic kidney 
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obese population, third: the influence of using different techniques to measure creatinine 
on renal function estimating equations, fourth: the variability between creatinine assays 
in urine and the influence hereof when calculating the CCR, the association between 
renal function and mortality at different ages, and fifth: staging chronic kidney disease 
(CKD) while applying age-related cut-off  levels and the consequences thereof on referrals 
to the nephrology department, as well as how a medication alert system warning for a 
decreased renal function may improve medication safety. 
In chapter 2 the performance of the Modification of Diet in Renal Disease formula 
(MDRD) was compared with the more recently developed Chronic Kidney Disease 
Epidemiology Collaboration Equation (CKD-EPI) in a group of 916 diabetic patients 
whose SCr and 24-hour CCR had been measured in the Maxima Medical Centre in 
Eindhoven, the Netherlands. Age ranged from 18-92 years and the CCR ranged from 11 
to 250 ml/min/1.73m2. The MDRD and CKD-EPI were found to be equally imprecise 
when compared to the CCR: 26.3 [25.1-27.6] and 25.6 [24.5-26.9] ml/min/1.73m2, 
respectively. With regard to consequences in staging of CKD, 17.1% of the women was 
staged in a lower CKD category when compared to the MDRD. A larger percentage of 
diabetes patients <65 years was diagnosed as having CKD stage 3-5 when the MDRD 
was used. The classification of renal impairment in patients with diabetes can be 
simplified by using equations estimating the GFR, as long as one realizes oneself  that 
the precision of both the MDRD and the CKD-EPI is low. Compared to the MDRD, 
the CKD-EPI gives higher estimates of GFR in young patients with diabetes, leading to 
a lower prevalence estimate of CKD on population level. Moreover, the performance of 
the CKD-EPI equation in diabetic patients has to be determined in a study in which a 
gold standard to measure renal function is used as a comparator. 
Both the MDRD, the CKD-EPI (both estimating the GFR) and the CG (estimating 
the CCR) have been developed in populations with specific patient characteristics. No 
clear advices exist regarding which formula is best used for optimal estimation of kidney 
function in overweight and obese patients, since it is uncertain whether these equations 
give accurate estimates of renal function in these populations. All these equations 
correct for body weight, each on its own way. The Cockcroft-Gault formula (CG) 
uses weight as a variable because it is a crude estimate of muscle mass and therefore 
also of creatinine production. The MDRD and the CKD-EPI have been indexed for 
a body surface of 1.73m2 (the mean body surface of a non-overweight person). In 
chapter 3 data of the same cohort as evaluated in chapter 2 were used. The influence of 
overweight and obesity on the performance of the CG, the MDRD, and the CKD-EPI 
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of patients that is misclassified as having chronic kidney disease. The renal function 
estimates were classified in weight categories: body mass index (BMI) <25 kg/m2; BMI 
25-30 kg/m2 (overweight); BMI >30kg/m2 (obese).The CG had the greatest accuracy in 
the overweight and obese patient group (76.9 en 76.8% were correctly classified; versus 
45.8% (MDRD) and 34% (CKD-EPI) in the overweight group and 1.9% (MDRD) and 
34% (CKD-EPI) in the obesity group. All renal function prediction equations are biased 
when used in overweight or obese diabetic populations, at least in those with a preserved 
renal function. Therefore, when using renal function prediction equations in clinical 
practice, their disadvantages should be kept in mind when making decisions based on 
the outcomes of these equations. 
Many of the currently used equations to estimate GFR use SCr. In the Netherlands 
two techniques are used to measure creatinine: the Jaffe and the enzymatic technique. 
However, both techniques do show varying results when measuring the creatinine 
concentration, which in turn will affect the equation outcomes that are used to estimate 
the GFR. In chapter 4 the problem of non-equivalence in SCr measurements across 
Dutch laboratories and the consequences thereof on CKD staging were explored. 
Data collected in 2009 by the annual national external quality assessment (EQA) 
organization for clinical chemistry laboratories (Stichting Kwaliteitsbewaking Medische 
Laboratorium diagnostiek, SKML) were used. The Jaffe technique overestimated the 
SCr when compared to a reference method (21%, 12% and 10% for SCr target values 
of 52, 73 and 94 µmol/L); the enzymatic technique gave more accurate measurements 
of creatinine (0%, -1% and -2% for SCr target values of 52, 73 and 94 µmol/L). When 
these Jaffe SCr values were used to estimate GFR, they gave an underestimation of renal 
function in 1-79% of the patients. When the enzymatic technique was used, only 2-4% of 
the patients were reclassified according to the CKD classification system. Thus, SCr as 
measured by a Jaffe technique leads to a substantial overestimation and stages patients 
in a lower CKD category than when an enzymatic technique is used compared to a 
reference method. Therefore, it is strongly advisable to use specific enzymatic techniques 
in clinical practice in order to generate more reliable GFR estimates.
Thus far, methodological issues involved in measuring creatinine in other fluids than 
plasma, have received little attention, although the creatinine concentration in urine has 
an indispensable role in calculating the CCR. Chapter 5 examines the variability between 
the Jaffe, enzymatic and liquid chromatography mass spectrometry in plasma, urine and 
peritoneal fluid and the effects thereof on the eGFR and CCR in a population of 181 
patients, including a spectrum from healthy subjects to dialysis patients, from the Isala 
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group were -1.24 (1.82) and -0.75 (1.88) mmol/L for the Jaffe and enzymatic technique 
compared to LCMS, respectively. Bias (precision) for the CCR in the non-dialysis group 
were -31.9 (30) and -12.9 (29) ml/min for the Jaffe and enzymatic technique compared to 
LCMS, respectively. The enzymatic assay showed a more consistent pattern for creatinine 
measurements compared to the Jaffe method. However, the reliability of the urinary 
measurements appeared not optimal with the use of an enzymatic technique. These 
differences in urinary measurements are bothersome, since the CCR is important in 
clinical practice in pre-dialysis, to assess the adequacy of hemo- and peritoneal dialysis, 
and to examine the urinary excretion of biomarkers to correct for sampling errors. 
Further research should take place to explain the differences in urinary measurements 
before advocating changing the ranges of the CCR. 
CKD is a risk factor for (cardiovascular) morbidity and mortality. Therefore, this is 
an additional reason to detect CKD in an early stage. In elderly patients it is unclear 
whether moderate renal impairment is a physiological process (without major clinical 
consequences) or whether it is associated with increased (cardiovascular) morbidity and 
mortality. In chapter 6 we evaluated whether an association exists between a decreased 
eGFR (eGFR <45 and 45-60 ml/min/1.73m2), albuminuria and mortality in patients 
with type 2 diabetes stratified according to age (65-75; >75 years). Information on 
810 patients with diabetes mellitus type 2 was derived from the database of the Zwolle 
Outpatient Diabetes project Integrating Available Care (ZODIAC) study, a study which 
was initiated in the Zwolle region, the Netherlands in 1997. Patients had been followed 
for 9.8 years and were divided in three groups based on their eGFR: <45, 45-60, >60 ml/
min/1.73m2. A moderately decreased renal function (eGFR 45-60ml/min/1.73m2) was 
not associated with an increased all-cause and cardiovascular mortality risk in those 
older than 75 years, provided there was no albuminuria. Albuminuria, irrespective of 
eGFR proved to be an independent marker of mortality in this elderly population and 
therefore is potentially useful as a more discriminative risk stratification tool in the 
large group of older patients with moderate reduction in eGFR. Although an eGFR 
of 45-60 ml/min/1.73m2 is not associated with increased mortality in those >75 years, 
patients still may have an underlying cause and risk factors adding to progression of 
renal function. Moreover, irrespective the age, an eGFR <60 ml/min/1.73m2 implies that 
certain lifestyle advices may have to be given and measures to be taken (see LTA chronic 
renal impairment).
In 2002 the Kidney Disease Outcome Quality Initiative (KDOQI) guidelines were 
developed to define and classify CKD uniformly and to recognize patients with CKD in 
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as well as the presence of albuminuria and renal haematuria became components of 
the classification scheme of CKD. The KDOQI guidelines state that an eGFR <60 ml/
min/1.73m2 requires referral to a nephrologist for additional diagnostics, irrespective the 
age. However, a substantial part of the elderly have moderate (probably physiological) 
renal function loss with increasing age, without having an underlying (renal) disease 
or increased risk of mortality. Therefore, in the Dutch national guidelines (LTA) age-
related cut-off  values have been adapted. Chapter 7 describes a cross-sectional analysis, 
examining the impact of the introduction of age-related cut-off  values on consultation 
and referral patterns from general practitioners to nephrologists in a population of 
82,424 patients. Median eGFR was 79 (65, 93), age ranged from 1-106 years; 31898 
(39%) was >65 years All these patients had their SCr examined in 2009 in the Isala 
Clinics. When the KDIGO guidelines were used 19% (15,637 patients) would have been 
referred to secondary care. When applying age-related cut-off  values, 3303 patients 
would have been referred, in 5748 patients peer consultation by a nephrologist would 
have occurred and 6586 patients would not have been referred or consulted about at all. 
The use of these age-related cut-off  values in referral policy will result in fewer as well 
as at the same time more targeted referrals to nephrology departments, especially in the 
elderly patient group. However, fewer referrals to secondary care will also result in an 
increased number of patients that need to be monitored and treated in primary care. We 
suggest that the addition of albuminuria as a marker of renal damage may be of value 
for optimal risk stratification and targeted referral of elderly. 
Iatrogenic injury due to medication errors is known as an adverse drug event (ADEs). 
Renal impairment is a risk factor for ADEs. When renal impairment is diagnosed, often 
the dosing of medications has to be adapted. Adaptations can only be done when the 
doctor and pharmacist are aware of the renal function of the patients. In Chapter 8 the 
problem of medication errors in a community based population was assessed from a 
preventive perspective. It was investigated how many people were at risk for medication 
errors due to renal impairment and whether intensification of the cooperation between 
pharmacist and primary (community pharmacists and general practitioners) and 
secondary health care workers (clinical chemists and nephrologists) resulted in a decrease 
of the number of medication errors. This prospective observational study was conducted 
in the Zwolle region. Every time a decreased renal function (as assessed by MDRD and 
defined as an eGFR ≤40 ml/min/1.73m2) was found, the laboratory sent a signal to the 
community pharmacist. The renal function of 25,929 persons was tested during this 
shared-care project. 1368 (5.3%) subjects were identified with an increased risk for an 
eventual adverse drug event (ADE), since they had an eGFR ≤40 ml/min/1.73m2. In 
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Chapter 11
Nederlandse samenvatting 
adverse drug event, most classified as significant or serious. The proportion of errors 
increased with age. Pharmacists recommended 342 medication adjustments, and in 66%, 
the dosage advice of the pharmacists was adopted by the doctor. Higher age, female sex 
and polypharmacy (defined as use of 5 or more medications) were identified as potential 
risk factors for renal function-associated medication errors. This study showed that an 
intensified collaboration between community pharmacists and prescribing physicians 
results in a considerable amount of drug dose adjustments and lead to improved 
medication safety in patients with renal impairment. Moreover, awareness for this 
problem was raised in health care workers. The results underline the potentially valuable 
role of community pharmacists in medication monitoring and provide evidence that 
exchange of medical patient information is relevant to safer drug therapy. 
Based on the results of this thesis the following conclusions are warranted:
•	 The accuracy of the eGFR formulas for the individual remains doubtful, and 
outcomes of these equations should be used as an indicator, not as a true value. 
•	 The Jaffe method for measuring creatinine should be abandoned. 
•	 In elderly people, moderate renal function decrease without signs of renal 
damage, should be seen as part and parcel of their life and age. 
•	 Extending the availability of renal function data towards community 
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De nieren hebben een belangrijke functie in het menselijk lichaam. De nieren zuiveren het 
bloed en hebben een belangrijke rol in de vochthuishouding. Als de nieren beschadigd 
raken, leidt dit tot nierfunctieverlies, ziekte en een verhoogde kans op overlijden. Nieren 
kunnen beschadigd raken door verschillende ziekten (zoals suikerziekte), maar ook 
door factoren als een verhoogde bloeddruk, roken en overgewicht. Door gezond te 
leven kan de kans op nierziekten worden verkleind, omdat je dan minder kans hebt deze 
risicofactoren te ontwikkelen. Vaak wordt nierschade pas in een laat stadium opgemerkt 
omdat een verminderde nierwerking vaak pas klachten geeft als er nog maar plusminus 
30-45% van de oorspronkelijke nierfunctie over is. 
Nierschade kan worden opgespoord door middel van bloedonderzoek (het meten van 
de creatinine concentratie, een afbraakproduct van creatininefosfaat afkomstig uit 
spierweefsel dat met een vrij constante snelheid wordt geproduceerd) en urineonderzoek 
(het meten van de hoeveelheid eiwit; als er eiwit in de urine zit betekent dit dat er sprake 
is van schade aan de nierfilters). Er is sprake van nierschade als de creatinine concentratie 
in het bloed verhoogd is of als er eiwit in de urine zit (albuminurie). Een andere manier 
om een indruk van de nierfunctie te krijgen is het meten van de creatinineklaring. Bij 
deze klaring wordt niet zozeer gekeken hoe hoog de concentratie creatinine in het 
bloed is (deze is naast de nierfunctie ook afhankelijk van onder andere de hoeveelheid 
spierweefsel dat iemand heeft), maar naar hoe goed de nieren in staat zijn om het 
creatinine vanuit het bloed in de urine te krijgen. Daarnaast kan de klaring ook worden 
gemeten met stoffen als inuline en radioactief  gelabelde stoffen als 125I-iothalamaat en 
51Chroom-EDTA, maar deze worden in de dagelijkse praktijk eigenlijk niet gebruikt, 
maar wel bij wetenschappelijk onderzoek. 
Huisartsen hebben een belangrijke rol in het opsporen van nierschade en risicofactoren 
voor hart- en vaatziekten. In 2002 werd er een classificatiesysteem ontwikkeld met als doel 
chronische nierschade in een vroeger stadium te herkennen. In plaats van de tot dan toe 
gebruikte creatinine bepaling in het bloed (die onvoldoende betrouwbaar was gebleken 
om een goede schatting van de nierfunctie te maken), werden er nu formules gebruikt 
om de nierfunctie te schatten. In deze schattingsformules worden naast het creatinine 
ook leeftijd, geslacht en ras (alle bepalende factoren voor de hoeveelheid spierweefsel 
die iemand gemiddeld heeft) meegenomen. De meest frequent gebruikte formules zijn de 
Cockcroft-Gault (CG) formule (uit 1976), de MDRD formule (uit 1999), en de CKD-
EPI formule (uit 2009). De beperking van het gebruik van deze formules is echter dat 
ze in specifieke patiëntengroepen zijn ontwikkeld, waardoor het maar de vraag is of ze 
toegepast kunnen worden in patiëntengroepen die hiervan afwijken.
In 2002 werd het classificatiesysteem van chronische nierschade gepresenteerd in een 
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aanwezig zijn van albuminurie, berust dit classificatie systeem op een schatting van de 
nierfunctie met een formule. Het gebruik en de keuze van de formule voor het schatten 
van de nierfunctie heeft belangrijke gevolgen voor het classificeren van de chronische 
nierschade en daarmee ook voor het verwijs-/ en behandelbeleid van patiënten. 
Nierfunctiebepalingen worden veel gebruikt in de dagelijkse praktijk. Ondanks de 
bovengenoemde beperkingen van schattingsformules worden ze voor uiteenlopende 
patiëntengroepen gebruikt en worden er op basis van deze schattingen veel beslissingen 
genomen. 
Stadium Beschrijving
1 eGFR ≥ 90 ml/min/1,73m2 én persisterende (micro)albuminurie of persisterende en 
specifieke sedimentsafwijkingen ((afwijkende) rode bloedcellen in de urine)
2 eGFR 60-89 ml/min/1,73m2 én persisterende (micro)albuminurie of persisterende en 
specifieke sedimentsafwijkingen ((afwijkende) rode bloedcellen in de urine)
3 eGFR 30-59 ml/min/1,73m2 
4 15-29 ml/min/1,73m2 
5 <15 ml/min/1,73m2 of dialyse
Tabel 1. Classificatie systeem van chronische nierschade 
Doelstellingen en samenvatting van dit proefschrift
In dit proefschrift kijken we kritisch naar het gebruik van deze nierfunctie 
schattingsformules: 1) hoe nauwkeurig en precies zijn deze formules, 2) welke invloed 
hebben deze formules op het (juist) vaststellen van nierschade, 3) maakt het voor de 
betrouwbaarheid van de uitkomst van formules uit welke techniek wordt gebruikt 
om de creatinine concentratie in het bloed te meten, 4) is een verminderde GFR even 
bedreigend voor zowel jonge als oude mensen, 5) wat is het effect van het hanteren van 
leeftijdsgebonden afkapwaardes voor de eGFR op het aantal diagnoses ‘nierschade’ en 
dus op het doorverwijzen van het aantal patiënten naar nefrologen (medisch specialisten 
in nierziekten), 6) kunnen deze formules, wanneer de samenwerking tussen apothekers 
en artsen wordt geïntensiveerd, helpen om de medicatieveiligheid voor mensen met 
nierschade te verbeteren?
In hoofdstuk 2 worden de MDRD en de CKD-EPI formules met elkaar vergeleken 
in een groep patiënten met suikerziekte. Beide schattingsformules hadden een brede 
foutmarge en waren niet erg precies. Deze foutmarge heeft belangrijke gevolgen voor het 
classificeren van nierschade; 17,1% van de vrouwen werd door de CKD-EPI in een lagere 
nierschade stadium ingedeeld in vergelijking met de MDRD en dus als ‘chronisch (nier)
ziek’ beschouwd. Het voordeel van schattingsformules is dat het berekenen en indelen 
van nierschade bij deze mensen eenvoudiger is. Uit onze studie blijkt dat zorgverleners 
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Zoals eerder genoemd zijn de verschillende schattingsformules in geselecteerde groepen 
mensen ontwikkeld. Daarom zijn deze formules soms moeilijk te vertalen naar specifieke 
patiëntgroepen (zoals mensen met suikerziekte, overgewicht of ouderen). 
Overgewicht is een toenemend probleem in Nederland. De MDRD en de CKD-EPI 
zijn echter ontwikkeld in een groep mensen met een normale lengte en een normaal 
gewicht. In de CG formule wordt gewicht (als grove schatting van de spiermassa, en 
dus creatinine productie) als variabele meegenomen in de formule, wat spaak loopt als 
iemand veel overgewicht (vetmassa) heeft. In hoofdstuk 3 hebben wij daarom de invloed 
van overgewicht op 3 nierfunctie schattingsformules (de CG, MDRD en CKD-EPI) 
vergeleken. In deze studie hebben wij gebruik gemaakt van onderzoeksgegevens van 916 
patiënten met suikerziekte. Uitkomsten van de schattingsformules werden vergeleken 
met de creatinineklaring in verschillende gewichtsgroepen: 1) normaal (body mass index 
(BMI) <25 kg/m2; een index die de verhouding tussen lengte en gewicht bij personen 
weergeeft en wordt gebruikt om een indicatie te krijgen of er sprake is van over- dan wel 
ondergewicht), 2) overgewicht (BMI 25-30 kg/m2) en 3) ernstig overgewicht ofwel obesitas 
(BMI>30 kg/m2). In het algemeen was er voor alle schattingsformules een aanzienlijke 
foutmarge bij zowel de mensen met overgewicht als obesitas. In verhouding was de CG 
het nauwkeurigste in de overgewicht en de obese patiëntengroep (76,9% en 76,8% werden 
correct geclassificeerd respectievelijk; versus 45,8% (MDRD) and 34% (CKD-EPI) in de 
overgewicht groep and 51,9% (MDRD) en 34% (CKD-EPI) in de obesitas groep. In de 
dagelijkse praktijk moet dus steeds weer rekening worden gehouden met de beperkingen 
van nierfunctieschattende formules in de groep patiënten met overgewicht. 
Veel van de gebruikte formules om de nierfunctie te schatten doen dit met behulp van de 
creatinine concentratie in het bloed. Deze creatinine concentratie kan je op verschillende 
manieren in het laboratorium bepalen. In Nederland zijn er twee technieken die veel 
worden gebruikt, de zogenaamde ‘Jaffé techniek’ en de ‘enzymatische techniek’. Echter, 
er is veel variabiliteit tussen deze twee technieken om serum creatinine te bepalen. Dit 
heeft gevolgen voor de betrouwbaarheid en de uitkomsten van nierfunctieschattende 
formules, als ook voor de classificatie van chronische nierschade. In hoofdstuk 4 is 
nagegaan wat de consequenties zijn van de variabiliteit in serum creatinine bepalingen in 
de Nederlandse laboratoria voor het classificeren van chronische nierschade in een grote 
patiëntengroep. Zoals verwacht overschatte de Jaffé techniek de serum creatinine waarde 
ten opzichte van de gouden standaard (de meest nauwkeurige maat om creatinine te 
meten), de liquid chromatography mass spectrometry (LCMS). De enzymatische 
techniek daarentegen evenaarde nagenoeg de gouden standaard. Wanneer met de Jaffé 
creatinine waardes een schatting werd gemaakt van de GFR, leidde dit bij 1-79% van 
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ernstiger) categorie in de chronische nierschade classificatie terecht kwamen. Bij de 
enzymatische techniek gebeurde dit slechts bij 2-4% van de patiënten. Daarom is het 
ten zeerste aan te bevelen om de Jaffé techniek niet meer te gebruiken voor het bepalen / 
schatten van de nierfunctie, en heeft het de sterke voorkeur dat laboratoria overgaan op 
het gebruik van een enzymatische techniek voor het bepalen van het serum creatinine. 
Naast de formules die worden gebruikt om de nierfunctie te schatten, wordt ook 
nog steeds de creatinineklaring gebruikt om een indruk van de nierfunctie te krijgen. 
De creatinineklaring wordt o.a. gebruikt om het juiste moment voor het starten van 
nierfunctievervangende behandeling (dialyse) te bepalen of wanneer de uitkomsten van 
nierfunctie schattingsformules onzeker zijn. In hoofdstuk 5 is gekeken naar de variabiliteit 
van de creatininebepaling in urine wanneer een Jaffé dan wel een enzymatische techniek 
wordt gebruikt, ten opzichte van de gouden standaard. De creatinine concentratie is 
bepaald in bloed (plasma), urine en dialyse vloeistof in een groep van 181 patiënten. 
Lagere creatinine concentraties in urine ten opzichte van de gouden standaard werden 
gemeten wanneer de Jaffé werd gebruikt en in iets mindere mate als de enzymatische 
techniek werd gebruikt. Omdat de Jaffé bepalingen in het plasma ook de verwachte 
onnauwkeurigheid lieten zien, leidde dit tot onderschatting van de creatinineklaring. 
Alvorens over te gaan tot het aanpassen van de normaalwaarden van de 24-uur 
creatinineklaring, zal er eerst meer onderzoek moeten plaatsvinden om de gevonden 
verschillen te verklaren. 
Chronische nierschade is een risicofactor voor het ontwikkelen van hart- en vaatziekten, 
het overlijden aan hart- en vaatziekte, en verhoogd ook de totale sterftekans van een 
patiënt. Daarom probeert men de afgelopen jaren om chronische nierschade in een zo 
vroeg mogelijk stadium op te sporen. Bij ouderen is onduidelijk of achteruitgang van 
de nierfunctie een proces passend bij het ouder worden is, of dat het als ziekte moet 
worden beschouwd. In hoofdstuk 6 werd daarom onderzocht of er een verband is tussen 
de geschatte nierfunctie, albuminurie en sterfte bij mensen met ouderdomssuiker(ziekte) 
in verschillende leeftijdsgroepen (65-75; >75 jaar). Dit werd onderzocht in een groep 
patiënten die voor hun suikerziekte onder behandeling waren bij de huisarts. Een groep 
van 810 patiënten met suikerziekte werden 9,8 jaar gevolgd. Mensen werden op basis 
van hun nierfunctie ingedeeld in drie groepen: <45 ml/min/1,73m2 (ernstige nierschade), 
45-60 ml/min/1,73m2 (matige nierschade), >60 ml/min/1,73m2 (geen nierschade). Een 
nierfunctie <60 ml/min/1,73m2 was in de groep 65-75 jaar geassocieerd met meer sterfte 
aan hart- en vaatziekten. Echter, bij mensen ouder dan 75 jaar werd pas meer sterfte aan 
hart- en vaatziekten gezien bij een nierfunctie <45 ml/min/1,73m2, mits er geen sprake 
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toegenomen sterfte. Bij ouderen moet er dus steeds worden nagegaan of er sprake is van 
een matige maar stabiele nierschade, of dat er sprake is van een gestage achteruitgang 
van de nierfunctie met aanwezigheid van albuminurie. 
In 2002 werd een richtlijn (‘the Kidney disease outcomes quality initiative (K-DOQI)-
richtlijn) opgesteld waarin een classificatiesysteem wordt voorgesteld met als doel om 
patiënten met nierschade in een vroeg stadium te herkennen en zo de prognose van deze 
groep te verbeteren (tabel 1). 
Patiënten < 65 jaar
Normo/micro-albuminurie Macro-albuminurie
eGFR > 60 ml/min/1,73m2
eGFR 45-60 ml/min/1,73m2
eGFR 30-45 ml/min/1,73m2
eGFR < 30 ml/min/1,73m2
Patiënten > 65 jaar
Normo/micro-albuminurie Macro-albuminurie
eGFR > 60 ml/min/1,73m2
eGFR 45-60 ml/min/1,73m2
eGFR 30-45 ml/min/1,73m2
eGFR < 30 ml/min/1,73m2
  Begeleiding in de eerste lijn
  Consultatie nefroloog en eventueel gezamenlijke behandeling
  Verwijzing naar de tweede lijn
Tabel 2. Indicaties voor beleid in de eerste lijn, tweede lijn en gezamenlijke behandeling.
Afhankelijk van in welk stadium van nierschade een patiënt valt, worden er adviezen 
gegeven ten aanzien van verdere diagnostiek of verwijzing. Bij ouderen is er regelmatig 
sprake van een iets verminderde, maar stabiele nierfunctie. In de Nederlandse richtlijnen 
(de landelijke transmurale afspraak chronische nierschade) is er daarom voor gekozen 
om naast de schatting van de nierfunctie en de albuminurie, ook de leeftijd (≤ of >65 
jaar) in ogenschouw te nemen in de besluitvorming tot verdere diagnostiek en verwijzing. 
In hoofdstuk 7 hebben wij de impact van deze leeftijdsgebonden afkapwaardes op het 
verwijsbeleid naar het ziekenhuis van de LTA (tabel 2) vergeleken met de afkapwaardes 
uit de K-DOQI richtlijnen (tabel 1). 
Deze studie werd gedaan in een onderzoeksgroep van 82424 patiënten uit de regio Zwolle. 
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van de populatie worden verwezen voor verder (poliklinisch) onderzoek in ziekenhuis. 
Bij het gebruik van leeftijdsgebonden afkappunten zouden 3303 patiënten zijn verwezen 
en 5748 mensen een ziekenhuisspecialist nierziekten hebben geconsulteerd. Het gebruik 
van leeftijdsgebonden afkappunten zal dus leiden tot meer gerichte verwijzingen naar de 
afdeling nierziekten in met name de groep ouderen en waarschijnlijk leiden tot minder 
zorgkosten. 
De nieren spelen een belangrijke rol in het verwerken van medicatie en het verwijderen 
van hun afvalproducten. Als de nierfunctie gestoord is, kan medicatiegebruik sneller 
leiden tot bijwerkingen, en daarnaast worden de nieren extra gevoelig voor bepaalde 
medicijnen als ze slechter werken. Daarom moet bij veel medicijnen de dosering worden 
aangepast aan de nierfunctie en moet een apotheker de medicatielijst van mensen met 
nierschade extra in de gaten houden. Aanpassingen kunnen alleen worden gedaan als 
arts en apotheker op de hoogte zijn van de nierfunctie van de patiënt en dit is lang 
niet altijd het geval. Daarom is in hoofdstuk 8 geëvalueerd hoeveel mensen risico liepen 
op medicatiefouten door nierfunctiestoornissen, en of het intensiever samenwerken 
tussen apotheker, (huis)arts en klinisch chemici resulteerde in een afname van het aantal 
medicatiefouten. 
Dit onderzoek vond plaats in Zwolle van februari 2009 tot maart 2010. Elke keer dat 
er een verminderde nierfunctie werd vastgesteld in het laboratorium, is er vanuit het 
laboratorium een signaal naar de apotheek gestuurd. In totaal is van 25929 personen 
de nierfunctie getest. Hiervan had 1368 (5,3%) een verminderde nierfunctie. Bij deze 
mensen werd door de apothekers gecontroleerd of de dosering van de gebruikte 
medicatie de juiste was. Bij 15% van de studiepopulatie waren aanpassingen nodig in 
het medicatiegebruik vanwege de nierfunctie. Dit werd telefonisch besproken met de 
voorschrijvend arts. In 66% zijn de door de apotheek voorgestelde wijzingen in de 
dosering van de medicijnen overgenomen door de arts. Hoge leeftijd, het vrouw zijn 
en polypharmacie (gedefinieerd als het gebruik van 5 of meer medicijnen) werden 
aangewezen als mogelijke risicofactoren voor nierfunctie gerelateerde medicatie fouten. 
Deze studie laat zien dat een intensievere samenwerking tussen apothekers, klinisch 
chemici en (huis)artsen resulteert in een aanzienlijke hoeveelheid aanpassingen in de 
dosering van medicijnen en leidt tot een verbeterde medicatie veiligheid bij patiënten met 
nierfunctiestoornissen. Bovendien, is er meer bewustzijn gekweekt bij gezondheidszorg 
medewerkers ten aanzien van nierfunctie en medicatiegebruik. Apothekers vonden 
het systeem nuttig en de tijdsinvestering van medicatiecontroles de moeite waard. De 
resultaten onderstrepen de mogelijk waardevolle rol van apothekers bij het monitoren 
van de medicatie en bieden bewijs dat uitwisseling van medische patiënten informatie 
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Conclusies
Alle formules die worden gebruikt om nierfunctie te schatten zijn onnauwkeurig 
in populaties die afwijken van de populatie waarin deze formules zijn ontwikkeld. 
Om te komen tot een zo nauwkeurig mogelijke schatting van de nierfunctie, moeten 
enzymatische technieken worden gebruikt om de creatinine concentratie in het bloed 
te meten. Het blijft onduidelijk welke techniek het meest betrouwbaar is voor het 
bepalen van de creatinine concentratie in urine. Bij patiënten met suikerziekte >75 jaar 
is een matig gestoorde nierfunctie (eGFR 45-60 ml/min/1,73m2) niet geassocieerd met 
een verhoogde kans op sterfte, mits er geen sprake is van albuminurie. Het hanteren 
van leeftijdsgebonden afkappunten in de richtlijn chronische nierschade zoals die in 
Nederland wordt gebruikt lijkt dan ook gerechtvaardigd en leidt tot minder onnodig 
verwijzen van oudere patiënten naar het ziekenhuis voor aanvullend onderzoek. 
Een intensievere samenwerking tussen apothekers en artsen bestaande uit een 
alarmeringssysteem waarbij een verminderde nierfunctie door apothekers kan worden 
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Dankwoord
Onderzoek doen is een teamprestatie. Alleen lukt het je niet. Op deze plaats wil ik graag 
iedereen bedanken die, ieder op eigen wijze, heeft bijgedragen aan het tot stand komen 
van dit proefschrift. Allereerst de patiënten en hulpverleners die belangeloos hebben 
meegewerkt. Daarnaast wil ik een aantal mensen speciaal bedanken. 
Prof. Dr. H.J.G. Bilo, beste Henk, dank voor alles! Er zijn veel mooie herinneringen 
tijdens het hele traject om aan terug te denken bij het schrijven van dit dankwoord. 
Jouw niet aflatende enthousiasme en gave om mensen te motiveren en inspireren, de 
mogelijkheden die jij creeërt en de vrijheid die je een ieder geeft om onderzoeksactiviteiten 
te ontplooien maken het een plezier om bij het Diabetes Kenniscentrum onderzoek te 
doen. 
Prof. Dr. J.F.M. Wetzels, beste Jack, onze samenwerking is grotendeels via de mail 
gelopen. Ik ben erg blij dat jij bij mijn promotietraject betrokken bent geweest. Ik heb 
jouw positief  kritische begeleiding en prikkelende gezichtspunten altijd zeer gewaardeerd. 
Jouw terzake doende, scherpe en snelle commentaar heb ik als zeer waardevol ervaren.
Dr. N. Kleefstra, beste Nanno, een onderzoeker pur sang, dat is zoals ik je zou willen 
typeren. Jij hebt het belangrijkste aandeel gehad in de dagelijkse begeleiding tijdens mijn 
promotietraject. Van jouw prikkelende opmerkingen tijdens de vele sparmomenten die 
we hebben gehad heb ik veel geleerd. Daarnaast wil ik je heel hartelijk danken voor het 
idee en het snelle tot stand komen van ´de eerste editie´ van mijn boekje.  
Klaas Groenier, beste Klaas, in de author instructions van het tijdschrift Diabetologia 
kwam ik het volgende advies van Edwin Gale waarbij ik toch een beetje aan jou moest 
denken: ‘If you are lucky enough to find a statistician who can communicate with the non-
numerate and is of the opposite sex, you should consider a proposal of marriage.’ Heel 
dankbaar ben ik voor de oplossingen die jij steeds weer wist aan te dragen voor mijn 
statistische problemen en jouw talent om het in begrijpelijke taal glashelder te kunnen 
uitleggen. 
De onderzoeksgroep van het Diabetes Kenniscentrum, de een als medeauteur, de ander 
als onderzoekscollega, een leuke groep inspirerende energieke mensen waarmee ik veel 
onvergetelijke en leuke momenten heb beleefd. Dank ook voor de steun en betrokkenheid 
die ik van jullie heb ervaren. Daarnaast zijn ook de ´niet-onderzoekers´ belangrijk 
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De collega’s van het klinisch chemisch laboratorium in Zwolle en de medewerkers 
van het peritoneaal en haemodialyse centrum van de Isala Klinieken in Zwolle wil ik 
bedanken voor hun medewerking bij de dataverzameling voor dit proefschrift en het 
kritisch meedenken op een ieders expertisegebied. 
Hans van Hateren, beste Hans, vanaf het begin van mijn promotietraject hebben wij de 
kamer op het Kenniscentrum gedeeld. Naast een hele prettige samenwerking als collega 
onderzoekers, was er altijd ook plaats voor gezelligheid en goede grappen. Fijn dat jij mij 
30 april terzijde staat als paranimf. 
Judith Drion, lieve Juud, heel erg blij ben ik dat jij als zus naast mij staat bij mijn 
verdediging. Heel dankbaar ben ik je voor het ontwerpen van de kaft van ‘mijn boekje’. 
Lieve pap en mam. Dank voor jullie onvoorwaardelijke steun, de basis die jullie mij 
gaven en de vrijheid die jullie hebben gegeven om mijn eigen keuzes te maken. Pap, heel 
blij ben ik dat jij ´de eerste versie´ van het boekje hebt kunnen zien. 
Lieve Sicco, Erna en Ella. Dank ook voor jullie steun en toeverlaat en de interesse die 
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